Jazz Pharmaceuticals (JAZZ) 10-K 28 Feb 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2023	Feb. 21, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-33500
Entity Registrant Name	Jazz Pharmaceuticals plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1032470
Entity Address, Address Line One	Fifth Floor, Waterloo Exchange
Entity Address, Address Line Two	Waterloo Road
Entity Address, City or Town	Dublin 4
Entity Address, Country	IE
Entity Address, Postal Zip Code	D04 E5W7
Country Region	353
City Area Code	1
Local Phone Number	634-7800
Title of 12(b) Security	Ordinary shares, nominal value $0.0001 per share
Trading Symbol	JAZZ
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction	false
Entity Shell Company	false
Entity Public Float			$ 7,659,805,500
Entity Common Stock, Shares Outstanding		62,345,283
Documents Incorporated by Reference	Certain information required by Part III, Items 10-14 of this Form 10‑K is incorporated by reference to the registrant’s definitive Proxy Statement for the 2024 Annual General Meeting of Shareholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A. If such Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Form 10‑K, such information will be included in an amendment to this Form 10‑K to be filed within such 120-day period.
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Central Index Key	0001232524

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2023
Auditor Information [Abstract]
Auditor Name	KPMG
Auditor Location	Dublin, Ireland
Auditor Firm ID	1116

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,506,310	$ 881,482
Investments	120,000	0
Accounts receivable, net of allowances of $21,136 and $17,843 at December 31, 2023 and 2022, respectively	705,794	651,493
Inventories	597,039	714,061
Prepaid expenses	185,476	91,912
Other current assets	320,809	267,192
Total current assets	3,435,428	2,606,140
Property, plant and equipment, net	169,646	228,050
Operating lease assets	65,340	73,326
Intangible assets, net	5,418,039	5,794,437
Goodwill	1,753,130	1,692,662
Deferred tax assets, net	477,834	376,247
Deferred financing costs	6,478	9,254
Other non-current assets	67,464	55,139
Total assets	11,393,359	10,835,255
Current liabilities:
Accounts payable	102,750	90,758
Accrued liabilities	793,914	803,255
Current portion of long-term debt	604,954	31,000
Income taxes payable	35,074	7,717
Deferred revenue	0	463
Total current liabilities	1,536,692	933,193
Long-term debt, less current portion	5,107,988	5,693,341
Operating lease liabilities, less current portion	59,225	71,838
Deferred tax liabilities, net	847,706	944,337
Other non-current liabilities	104,751	106,812
Commitments and contingencies (Note 14)
Shareholders’ equity:
Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 62,255 and 63,214 shares issued and outstanding at December 31, 2023 and 2022, respectively	6	6
Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2023 and 2022	55	55
Capital redemption reserve	473	472
Additional paid-in capital	3,699,954	3,477,124
Accumulated other comprehensive loss	(842,147)	(1,125,509)
Retained earnings	878,656	733,586
Total shareholders’ equity	3,736,997	3,085,734
Total liabilities and shareholders’ equity	$ 11,393,359	$ 10,835,255

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) shares in Thousands, $ in Thousands	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 € / shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2022 € / shares
Current assets:
Accounts receivable, allowances | $	$ 21,136		$ 17,843
Shareholders’ equity:
Ordinary shares, nominal value (in dollars per share) | $ / shares	$ 0.0001		$ 0.0001
Ordinary shares, authorized (in shares)	300,000		300,000
Ordinary shares, issued (in shares)	62,255		63,214
Ordinary shares, outstanding (in shares)	62,255		63,214
Non-voting euro deferred shares, par value (in euros per share) | € / shares		€ 0.01		€ 0.01
Non-voting euro deferred shares, authorized (in shares)	4,000		4,000
Non-voting euro deferred shares, issued (in shares)	4,000		4,000
Non-voting euro deferred shares, outstanding (in shares)	4,000		4,000

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 3,834,204	$ 3,659,374	$ 3,094,238
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	435,577	540,517	440,760
Selling, general and administrative	1,343,105	1,416,967	1,451,683
Research and development	849,658	590,453	505,748
Intangible asset amortization	608,284	599,169	525,769
Acquired in-process research and development	19,000	444,148	0
Intangible asset impairment charge	0	133,648	0
Total operating expenses	3,255,624	3,724,902	2,923,960
Income (loss) from operations	578,580	(65,528)	170,278
Interest expense, net	(289,438)	(288,242)	(278,766)
Foreign exchange gain (loss)	8,787	(19,014)	(4,350)
Income (loss) before income tax expense (benefit) and equity in loss of investees	297,929	(372,784)	(112,838)
Income tax expense (benefit)	(119,912)	(158,645)	216,116
Equity in loss of investees	3,009	9,921	714
Net income (loss)	$ 414,832	$ (224,060)	$ (329,668)
Net income (loss) per ordinary share:
Basic (in dollars per share)	$ 6.55	$ (3.58)	$ (5.52)
Diluted (in dollars per share)	$ 6.10	$ (3.58)	$ (5.52)
Weighted-average ordinary shares used in per share calculations - basic (in shares)	63,291	62,539	59,694
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	72,066	62,539	59,694
Product sales, net
Revenues:
Total revenues	$ 3,736,943	$ 3,641,429	$ 3,079,001
Royalties and contract revenues
Revenues:
Total revenues	$ 97,261	$ 17,945	$ 15,237

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 414,832	$ (224,060)	$ (329,668)
Other comprehensive income (loss):
Foreign currency translation adjustments	283,127	(725,277)	(268,347)
Loss on fair value hedging activities reclassified from accumulated other comprehensive income (loss) to foreign exchange gain (loss), net of income tax benefit of $—, $43, and $—, respectively	0	128	0
Unrealized gain (loss) on cash flow hedging activities, net of income tax expense (benefit) of $1,215, $— and ($2), respectively	3,658	0	(14)
(Gain) loss on cash flow hedging activities reclassified from accumulated other comprehensive income (loss) to interest expense, net of income tax expense (benefit) of $1,137, $— and ($355)	(3,423)	0	2,482
Unrealized loss on fair value hedging activities, net of income tax benefit of $—, $— and $43, respectively	0	0	(129)
Other comprehensive income (loss)	283,362	(725,149)	(266,008)
Total comprehensive income (loss)	$ 698,194	$ (949,209)	$ (595,676)

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Tax benefit effect on fair value hedging activities	$ 0	$ 43	$ 0
Income tax expense (benefit) on unrealized loss on hedging activities	1,215	0	(2)
Tax expense (benefit) effect on fair value hedging activities reclassified	1,137	0	(355)
Tax benefit effect on fair value hedging activities	$ 0	$ 0	$ 43

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Share Options	Ordinary Shares	Non-voting Euro Deferred	Capital Redemption Reserve	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-in Capital Share Options	Accumulated Other Comprehensive Loss	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020				56,171	4,000
Beginning balance at Dec. 31, 2020	$ 3,659,745			$ 6	$ 55	$ 472	$ 2,633,670			$ (134,352)	$ 1,159,894
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in connection with the acquisition of GW Pharmaceuticals plc (in shares)				3,798
Issuance of ordinary shares arising from the acquisition of GW and share-based payment - pre-combination service	608,456		$ 3,555				608,456		$ 3,555
Issuance of ordinary shares in conjunction with exercise of share options (in shares)				1,042
Issuance of ordinary shares in conjunction with exercise of share options	119,058						119,058
Issuance of ordinary shares under employee stock purchase plan (in shares)				157
Issuance of ordinary shares under employee stock purchase plan	16,203						16,203
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)				465
Shares withheld for payment of employee's withholding tax liability	(35,602)						(35,602)
Share-based compensation	189,452						189,452
Other comprehensive (loss) income	(266,008)									(266,008)
Net (loss) income	(329,668)										(329,668)
Ending balance (in shares) at Dec. 31, 2021				61,633	4,000
Ending balance at Dec. 31, 2021	$ 3,965,191	$ (206,050)		$ 6	$ 55	472	3,534,792	$ (333,524)		(400,360)	830,226	$ 127,474
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Accounting standards update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)				832
Issuance of ordinary shares in conjunction with exercise of share options	$ 82,897						82,897
Issuance of ordinary shares under employee stock purchase plan (in shares)				139
Issuance of ordinary shares under employee stock purchase plan	15,123						15,123
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)				610
Shares withheld for payment of employee's withholding tax liability	(45,443)						(45,443)
Share-based compensation	223,279						223,279
Shares repurchased	(54)										(54)
Other comprehensive (loss) income	(725,149)									(725,149)
Net (loss) income	$ (224,060)										(224,060)
Ending balance (in shares) at Dec. 31, 2022	63,214			63,214	4,000
Ending balance at Dec. 31, 2022	$ 3,085,734			$ 6	$ 55	472	3,477,124			(1,125,509)	733,586
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of ordinary shares in conjunction with exercise of share options (in shares)	251			280
Issuance of ordinary shares in conjunction with exercise of share options	$ 30,189						30,189
Issuance of ordinary shares under employee stock purchase plan (in shares)				156
Issuance of ordinary shares under employee stock purchase plan	16,270						16,270
Issuance of ordinary shares in conjunction with vesting of restricted stock units (in shares)				735
Issuance of ordinary shares in conjunction with vesting of restricted stock units	0
Shares withheld for payment of employee's withholding tax liability	(50,952)						(50,952)
Share-based compensation	227,323						227,323
Shares repurchased (in shares)				(2,130)
Shares repurchased	(269,761)					1					(269,762)
Other comprehensive (loss) income	283,362									283,362
Net (loss) income	$ 414,832										414,832
Ending balance (in shares) at Dec. 31, 2023	62,255			62,255	4,000
Ending balance at Dec. 31, 2023	$ 3,736,997			$ 6	$ 55	$ 473	$ 3,699,954			$ (842,147)	$ 878,656

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net income (loss)	$ 414,832	$ (224,060)	$ (329,668)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Intangible asset amortization	608,284	599,169	525,769
Share-based compensation	226,841	221,996	189,006
Acquisition accounting inventory fair value step-up adjustment	151,446	273,392	223,085
Impairment of property, plant and equipment	61,014	0	0
Depreciation	30,412	30,302	26,714
Non-cash interest expense	22,378	37,973	92,655
Acquired in-process research and development	19,000	444,148	0
Provision for losses on accounts receivable and inventory	11,113	14,537	19,668
Deferred tax expense (benefit)	(260,217)	(292,251)	69,198
Intangible asset impairment charge	0	133,648	0
Loss on disposal of a business	0	37,704	0
Other non-cash transactions	11,343	(14,486)	10,032
Changes in assets and liabilities:
Accounts receivable	(51,883)	(90,135)	(92,735)
Inventories	(13,420)	(49,642)	(48,861)
Prepaid expenses and other current assets	(126,179)	35,788	(83,320)
Operating lease assets	14,948	14,769	15,583
Other non-current assets	(15,884)	(24,038)	817
Accounts payable	9,603	(11,225)	57,021
Accrued liabilities	(23,245)	165,991	142,355
Income taxes payable	25,220	(1,692)	(15,524)
Deferred revenue	(463)	(2,093)	(2,305)
Operating lease liabilities, less current portion	(16,965)	(16,422)	(16,037)
Other non-current liabilities	(6,171)	(11,396)	(4,946)
Net cash provided by operating activities	1,092,007	1,271,977	778,507
Investing activities
Proceeds from maturity of investments	270,000	60,000	1,095,000
Acquired in-process research and development	(19,000)	(444,148)	0
Purchases of property, plant and equipment	(23,962)	(29,046)	(27,641)
Acquisition of investments	(390,100)	(61,036)	(26,819)
Proceeds from sale of a business	0	53,000	0
Acquisition of intangible assets	0	(25,000)	(17,891)
Acquisition of a business, net of cash acquired	0	0	(6,234,792)
Net cash used in investing activities	(163,062)	(446,230)	(5,212,143)
Financing activities
Proceeds from employee equity incentive and purchase plans	46,459	98,020	135,261
Repayments of long-term debt	(31,000)	(582,014)	(1,101,788)
Payment of employee withholding taxes related to share-based awards	(50,952)	(45,443)	(35,602)
Share repurchases	(269,761)	(54)	0
Net proceeds from issuance of borrowings under credit agreement	0	0	3,719,930
Net proceeds from issuance of Senior Secured Notes, due 2029	0	0	1,471,533
Payments for repurchase of Exchangeable Senior Notes, due 2021	0	0	(218,812)
Net cash (used in) provided by financing activities	(305,254)	(529,491)	3,970,522
Effect of exchange rates on cash and cash equivalents	1,137	(6,222)	(3,207)
Net increase (decrease) in cash and cash equivalents	624,828	290,034	(466,321)
Cash and cash equivalents, at beginning of period	881,482	591,448	1,057,769
Cash and cash equivalents, at end of period	1,506,310	881,482	591,448
Supplemental disclosure of cash flow information:
Cash paid for interest	333,112	270,671	138,271
Cash paid for income taxes, net of refunds	$ 177,880	$ 94,681	$ 271,217

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we strive to identify new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Our lead marketed products, listed below, are approved in countries around the world to improve patient care. Neuroscience • Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution , a product approved by the U.S. Food and Drug Administration, or FDA, in July 2020 and launched in the U.S. in November 2020 for the treatment of cataplexy or excessive daytime sleepiness, or EDS, in patients seven years of age and older with narcolepsy, and also approved by FDA in August 2021 for the treatment of idiopathic hypersomnia, or IH, in adults and launched in the U.S. in November 2021. Xywav contains 92% less sodium than Xyrem®; • Xyrem (sodium oxybate) oral solution , a product approved by FDA and distributed in the U.S. for the treatment of cataplexy or EDS in patients seven years of age or older with narcolepsy; Jazz also markets Xyrem in Canada for the treatment of cataplexy in patients with narcolepsy. Xyrem is also approved and distributed in the European Union, or EU (EU market authorizations include Northern Ireland), Great Britain and other markets through a licensing agreement; and • Epidiolex® (cannabidiol) oral solution , a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals plc, or GW, and currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, or LGS, Dravet syndrome, or DS, or tuberous sclerosis complex, or TSC, in patients one year of age or older; in the EU and Great Britain (where it is marketed as Epidyolex®) and other markets, it is approved for adjunctive treatment of seizures associated with LGS or DS, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of seizures associated with TSC in patients 2 years of age and older. Oncology • Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) , a product approved by FDA in June 2021 and launched in the U.S. in July 2021 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who have developed hypersensitivity to E. coli -derived asparaginase. In September 2023, the European Commission granted marketing authorization for this therapy under the trade name Enrylaze; and • Zepzelca® (lurbinectedin) , a product approved by FDA in June 2020 under FDA's accelerated approval pathway and launched in the U.S. in July 2020 for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy; in Canada, Zepzelca received conditional approval in September 2021 for the treatment of adults with Stage III or metastatic SCLC, who have progressed on or after platinum-containing therapy. Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” "the Company", “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this report, all references to “ordinary shares” refer to Jazz Pharmaceuticals plc’s ordinary shares.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, and include the accounts of Jazz Pharmaceuticals plc and our subsidiaries. Intercompany transactions and balances have been eliminated. Our consolidated financial statements include the results of operations of businesses we have acquired from the date of each acquisition for the applicable reporting periods. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Adoption of New Accounting Standards In October 2021, the Financial Accounting Standards Board issued ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, or ASU 2021-08, which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 was effective for the Company from January 1, 2023 and adoption did not have a material impact on our consolidated financial statements. We will apply to future business combinations, if any. Significant Risks and Uncertainties Historically, our business was substantially dependent on Xyrem and while we expect that our business will continue to meaningfully depend on oxybate revenues from both Xywav and Xyrem, there is no guarantee that oxybate revenues will remain at current levels, or that oxybate revenues will otherwise grow in future periods. In this regard, our ability to maintain or increase oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties including, without limitation, those related to the launch of Xywav for the treatment of IH in adults and adoption in that indication; competition from the recent introduction of two authorized generic, or AG, versions of high-sodium oxybate and new products, such as Avadel’s Lumryz, for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, as well as potential future competition from additional AG versions of high-sodium oxybate and from generic versions of high-sodium oxybate and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav and Xyrem; increased rebates required to maintain access to our products; challenges to our intellectual property around Xywav and/or Xyrem, including from pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients . A significant decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds, which would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business. In addition to risks related specifically to Xywav and Xyrem, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: ongoing clinical research activity and related outcomes, obtaining regulatory approval of our late-stage product candidates; effectively commercializing our approved or acquired products such as Epidiolex, Rylaze and Zepzelca; obtaining and maintaining adequate coverage and reimbursement for our products; contracting and rebates to pharmacy benefit managers and similar organizations that reduce our net revenue; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; regulatory concerns with controlled substances generally and the potential for abuse; future legislation, action by the U.S. Federal Government authorizing the sale, distribution, use, and insurance reimbursement of non-FDA approved cannabinoid products; delays or problems in the supply of our products, loss of single source suppliers or failure to comply with manufacturing regulations; delays or problems with third parties that are part of our manufacturing and supply chain; identifying, acquiring or in-licensing additional products or product candidates; our ability to realize the anticipated benefits of acquired or in-licensed products or product candidates, such as Epidiolex and Zanidatamab, at the expected levels, with the expected costs and within the expected timeframe; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations. Concentrations of Risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet. We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of December 31, 2023 and 2022, we had foreign exchange forward contracts with notional amounts totaling $511.7 million and $505.0 million, respectively. As of December 31, 2023 and 2022, the outstanding foreign exchange forward contracts had a net asset fair value of $17.4 million. As of December 31, 2023, we had interest rate swap contracts with notional amounts totaling $500.0 million. These outstanding interest rate swap contracts had a net asset fair value of $0.4 million as of December 31, 2023. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant. We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and as of December 31, 2023, allowances on receivables were not material. As of December 31, 2023, five customers accounted for 79% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 41% of gross accounts receivable, ASD Specialty Healthcare LLC, which accounted for 13% of gross accounts receivable and McKesson Corporation and affiliates, or McKesson, which accounted for 11% of gross accounts receivable. As of December 31, 2022, five customers accounted for 87% of gross accounts receivable, including ESSDS, which accounted for 55% of gross accounts receivable, Cardinal Health Inc, which accounted for 10% of gross accounts receivable and McKesson, which accounted for 9% of gross accounts receivable. We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier. Business Acquisitions Our consolidated financial statements include the results of operations of an acquired business from the date of acquisition. We account for acquired businesses using the acquisition method of accounting. The acquisition method of accounting for acquired businesses requires, among other things, that assets acquired, liabilities assumed and any noncontrolling interests in the acquired business be recognized at their estimated fair values as of the acquisition date, with limited exceptions, and that the fair value of acquired in-process research and development, or IPR&D, be recorded on the balance sheet. Also, transaction costs are expensed as incurred. Any excess of the acquisition consideration over the assigned values of the net assets acquired is recorded as goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in earnings. Cash Equivalents and Investments We consider all highly liquid investments, readily convertible to cash, that mature within three months or less from date of purchase to be cash equivalents. Investments consist of time deposits with initial maturities of greater than three months. Collectively, cash equivalents and investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses, net of tax, are recorded in accumulated other comprehensive loss in shareholders’ equity. We use the specific-identification method for calculating realized gains and losses on securities sold. Realized gains and losses and declines in value judged to be other than temporary on investments are included in interest expense, net in the consolidated statements of income (loss). Derivative Instruments and Hedging Activities We record the fair value of derivative instruments as either assets or liabilities on the consolidated balance sheets. Changes in the fair value of derivative instruments are recorded each period in current earnings or other comprehensive income (loss), depending on whether a derivative instrument is designated as part of a hedging transaction and, if it is, the type of hedging transaction. For a derivative to qualify as a hedge at inception and throughout the hedged period, we formally document the nature and relationships between the hedging instruments and hedged item. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Gains or losses on cash flow hedges are reclassified from other comprehensive income (loss) to earnings when the hedged transaction occurs. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting and any related unrealized gain or loss on the derivative instrument is recognized in current earnings. We designate cross-currency interest rate swaps as fair value hedges to hedge foreign currency risks related to our borrowings denominated in currencies other than the U.S. dollar. Fair value hedge amounts included in the assessment of hedge effectiveness are recognized in foreign exchange gain (loss) within the consolidated statements of income (loss), along with the offsetting gains and losses of the related hedged item. We have elected to exclude the total forward points or currency basis from the assessment of hedge effectiveness and account for them as excluded components. The initial fair value of the excluded component is amortized to foreign exchange gain (loss) and the difference between changes in fair value of the excluded component and the amount recorded in earnings is recorded in other comprehensive income (loss). Derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current e arnings. Inventories Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales. We capitalize inventory costs associated with our products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. We had no pre-approval inventory on our consolidated balance sheet as of December 31, 2023 or 2022. Our inventory production process for our cannabinoid products includes the cultivation of botanical raw material. Because of the duration of the cultivation process, a portion of our inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are as follows: Buildings 40 years Manufacturing equipment and machinery 4-20 years Computer software and equipment 3-7 years Furniture and fixtures 5 years Leasehold improvements are amortized over the shorter of the noncancelable term of our leases or their economic useful lives. Maintenance and repairs are expensed as incurred. Leases We determine if an arrangement is a lease at inception. Leases are classified at lease commencement as either operating leases or finance leases. Operating leases are included in operating lease assets, accrued liabilities, and operating lease liabilities on our consolidated balance sheets. Finance lease assets are included in property, plant and equipment, net, and finance lease liabilities are included in accrued liabilities and other non-current liabilities in our consolidated balance sheets. Lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. In determining the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The lease asset also includes any lease payments made, reduced by lease incentives and increased by initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease expense is recognized as depreciation expense of property, plant and equipment and interest expense on finance lease liabilities. We have lease agreements with lease and non-lease components, which are generally accounted for separately. For vehicle leases we account for the lease and non-lease components as a single lease component. We have elected the short-term lease exemption and, therefore, do not recognize a lease asset or corresponding liability for lease arrangements with an original term of 12 months or less. Rent expense under short-term leases is recognized on a straight-line basis over the lease term. Goodwill Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. We have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. In performing the annual impairment test, the fair value of the reporting unit is compared to its corresponding carrying value, including goodwill. If the carrying value exceeds the fair value of the reporting unit an impairment loss will be recognized for the amount by which the reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount of goodwill. We test goodwill for impairment annually in October and when events or changes in circumstances indicate that the carrying value may not be recoverable. Acquired In-Process Research and Development The initial costs of rights to IPR&D projects acquired in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a finite-lived intangible asset, or discontinued, at which point the intangible asset will be written off. Development costs incurred after an acquisition are expensed as incurred. Intangible Assets Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives, which range from seven Revenue Recognition Our revenue comprises product sales, net and royalty and contract revenues. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Product Sales, Net Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient. Reserves for Variable Consideration Revenues from sales of products are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established and which relate to returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government rebates, government chargebacks, coupon programs and rebates under managed care plans and commercial payor contracts. Calculating certain of these reserves involves estimates and judgments and we determine their expected value based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs’ regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and channel inventory data. These reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. We reassess our reserves for variable consideration at each reporting date. Historically, adjustments to estimates for these reserves have not been material. Reserves for returns, specialty distributor fees, wholesaler fees, government rebates, coupon programs and rebates under managed care plans and commercial payor contracts are included within current liabilities in our consolidated balance sheets. Reserves for government chargebacks and prompt payment discounts are shown as a reduction in accounts receivable. Royalties and Contract Revenues We enter into out-licensing agreements under which we license certain rights to our products or product candidates to third parties. If a licensing arrangement includes multiple goods or services, we consider whether the license is distinct. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If the license to our intellectual property is determined not to be distinct, it is combined with other goods or services into a combined performance obligation. We consider whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting date and, if necessary, adjust the measure of performance and related revenue recognition. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or that of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. For arrangements that include sales-based royalties and milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties and sales-based milestones relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty or sales-based milestone has been allocated has been satisfied (or partially satisfied). Cost of Product Sales Cost of product sales includes manufacturing and distribution costs, the cost of drug substance, royalties due to third parties on product sales, product liability and cargo insurance, FDA user fees, freight, shipping, handling and storage costs and salaries and related costs of employees involved with production. Excluded from cost of product sales shown on the consolidated statements of income (loss) is amortization of acquired developed technology of $608.3 million, $599.2 million and $525.8 million in 2023, 2022 and 2021, respectively. Research and Development Research and development expenses consist primarily of costs related to clinical studies and outside services, personnel expenses, milestone expenses and other research and development costs, including milestone payments incurred prior to regulatory approval of products. Clinical study and outside services costs relate primarily to services performed by clinical research organizations, clinical studies performed at clinical sites, materials and supplies, and other third party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other research and development expenses primarily include overhead allocations consisting of various support and facilities-related costs. Research and development costs are expensed as incurred. For product candidates that have not been approved by FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the trial. Advertising Expenses We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $92.2 million, $108.8 million and $161.5 million in 2023, 2022 and 2021, respectively. Income Taxes We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amount and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to the amount that is more-likely-than-not to be realized. We recognize the benefits of a tax position if it is more-likely-than-not of being sustained. A recognized tax benefit is then measured as the largest amount of tax benefit that is greater than fifty percent likely of being realized upon settlement. Interest and penalties related to income taxes are included in the income tax expense and classified with the related liability on the consolidated balance sheets. Foreign Currency Our functional and reporting currency is the U.S. dollar. The assets and liabilities of our subsidiaries that have a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date with the results of operations of subsidiaries translated at the weighted average exchange rate for the reporting period. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive income (loss) in shareholders’ equity. Transactions in foreign currencies are translated into the functional currency of the relevant subsidiary at the weighted average exchange rate for the reporting period. Any monetary assets and liabilities arising from these transactions are translated into the relevant functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange gain (loss) in our consolidated statements of income (loss). Deferred Financing Costs Deferred financing costs are reported at cost, less accumulated amortization and are presented in the consolidated balance sheets as a direct deduction from the carrying value of the associated debt, with the exception of deferred financing costs associated with revolving-debt arrangements which are presented as assets. The related amortization expense is included in interest expense, net in our consolidated statements of income (loss). Contingencies From time to time, we may become involved in claims and other legal matters arising in the ordinary course of business. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. Legal fees and other expenses related to litigation are expensed as incurred and included in selling, general and administrative expenses. Share-Based Compensation We account for compensation cost for all share-based awards at fair value on the date of grant. The fair value is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method. The estimation of share-based awards that will ultimately vest requires judgment, and, to the extent actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We primarily consider historical experience when estimating expected forfeitures. Performance-Based Restricted Stock Unit Awards Performance-based restricted stock units, or PRSUs, awarded to employees vest upon the achievement of certain performance criteria at the end of a specified performance period, subject to a relative total shareholder return, or TSR, modifier. The estimated fair value of these PRSUs is based on a Monte Carlo simulation model. Compensation expense for PRSUs is recognized from the date the Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the performance criteria until the date results are determined. Variable Interest Entity In the year ended December 31, 2021, we invested in a cell of a protected cell company, or the protected cell, as part of our directors’ and officers’ liability risk financing strategy. Based on our control and the structure of the protected cell, we concluded that Jazz is the primary beneficiary of the protected cell and is required to consolidate the protected cell. The insurance premium payable to the protected cell for the years ended December 31, 2022 and 2021 and the protected cell’s assets and liabilities as of December 31, 2023 and 2022 were immaterial. No premium was payable for the year ended December 31, 2023. Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures”, which requires enhanced disclosures about significant segment expenses. The amendments are effective retrospectively to all prior periods presented in the financial statements, for fiscal years beginning after December 15, 2023. We are currently evaluating the impact of adopting this new accounting guidance. In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) - Improvements to Income Tax Disclosures”, which requires additional enhanced tax disclosures. The amendments are effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of ad

Collaborations, Disposition and

Collaborations, Disposition and Business Combination	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations, Disposition and Business Combination	Collaborations, Disposition and Business Combination License Agreements In November 2023, we entered into an exclusive licensing and collaboration agreement with Autifony Therapeutics Limited, or Autifony, to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Under the terms of the agreement, we made an upfront payment of $18.0 million to Autifony, which was recorded as acquired IPR&D expense in our consolidated statements of income (loss) for the year ended December 31, 2023. Autifony is eligible to receive development and commercial milestone payments of up to $752.5 million and, if a product is approved, a tiered, mid-single-digit percentage royalty on net sales of that product. In October 2022, we entered into an exclusive licensing and collaboration agreement with Zymeworks Inc., or Zymeworks, providing us the right to acquire development and commercialization rights to Zymeworks' zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks. In December 2022, we exercised the option to continue with the exclusive development and commercialization rights to zanidatamab. Zanidatamab is a bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. Under the terms of the agreement, Zymeworks received an upfront payment of $50.0 million, and, following our decision to continue the collaboration after the readout of the top-line clinical data from HERIZON-BTC-01, a second, one-time payment of $325.0 million. We recorded the $375.0 million as acquired IPR&D expense in our consolidated statements of income (loss) for the year ended December 31, 2022. Zymeworks is also eligible to receive regulatory and commercial milestone payments of up to $1.4 billion, for total potential payments of $1.76 billion. Pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on our net sales. In May 2022, we entered into a licensing agreement with Sumitomo Pharma Co., Ltd, or Sumitomo, to acquire exclusive development and commercialization rights in the U.S., Europe and other territories for DSP-0187, now referred to as JZP441. JZP441 is a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, IH and other sleep disorders. Under the terms of the agreement, we made an upfront payment of $50.0 million to Sumitomo, which was recorded as acquired IPR&D expense in our consolidated statements of income (loss) for the year ended December 31, 2022. Sumitomo is eligible to receive development, regulatory and commercial milestone payments of up to $1.09 billion and, if JZP441 is approved, a tiered, low double-digit royalty on Jazz's net sales of JZP441. In April 2022, we entered into a licen sing and collaboration agreement with Werewolf Therapeutics, Inc., or Werewolf, to acquire exclusive global development and commercialization rights t o Werewolf's investigational WTX-613, now referred to as JZP898. JZP898 is a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule. We made an upfront payment of $15.0 million to Werewolf in 2022, which was recorded as acquired IPR&D expense in our consolidated statements of income (loss) for the year ended December 31, 2022, and a milestone payment of $5.0 million in September 2023 which was recorded within research and development expense in our consolidated statements of income (loss) for the year ended December 31, 2023. Werewolf is eligible to receive further development, regulatory and commercial milestone payments of up to $1.26 billion and, if JZP898 is approved, a tiered, mid-single-digit percentage royalty on net sales of JZP898. Sunosi Disposition In March 2022, we entered into a definitive agreement to divest Sunosi to Axsome Therapeutics, Inc., or Axsome. In May 2022, we completed the U.S. divestiture and in November 2022, the ex-U.S. divestiture was completed. Under the terms of the sale agreement, Axsome received the rights to Sunosi in all of the existing territories available to us. We received an upfront payment of $53.0 million, and have the right to receive a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in current indications and a mid-single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications. Upon closing, we recognized a loss on disposal of $40.8 million within selling, general and administrative expenses We determined that the disposal of Sunosi did not qualify for reporting as a discontinued operation since it did not represent a strategic shift that has or will have a major effect on our operations and financial results. GW Acquisition On May 5, 2021, or the Closing Date, we acquired the entire issued share capital of GW. As a result, GW became an indirect wholly owned subsidiary of the Company. We acquired GW with the objective of broadening our neuroscience portfolio, further diversifying our revenue and driving sustainable, long-term value creation opportunities. GW was a global leader in discovering, developing, manufacturing and commercializing novel, regulatory approved therapeutics from its proprietary cannabinoid research to address a broad range of diseases. The aggregate consideration for the GW Acquisition was $7.2 billion as follows (all amounts in thousands except American Depositary Shares, or ADS, and per GW ADS amounts): GW ADS outstanding May 5, 2021 31,556,200 Cash consideration per GW ADS $ 200 Total cash consideration to GW ADS holders $ 6,311,240 Cash consideration to GW share option holders (inclusive of payroll taxes) 267,450 Total cash consideration 6,578,690 Equity consideration to GW ADS holders (1) 608,456 Consideration related to replacement share option pre-combination service 3,555 Total equity consideration 612,011 Total purchase consideration $ 7,190,701 ________________________ (1) 3.8 million ordinary shares were issued to GW ADS holders. The closing price of the ordinary shares on May 4, 2021 ($160.20) was used to determine the fair value of this equity consideration because the closing of the transaction on May 5, 2021 occurred prior to the opening of regular trading. In April 2021, we closed an offering of $1.5 billion in aggregate principal amount of 4.375% senior secured notes, due 2029, or the Secured Notes. In May 2021, we entered into a credit agreement, or the Credit Agreement, that provides for (i) a seven-year $3.1 billion term loan B facility, or the Dollar Term Loan, (ii) a seven-year €625.0 million term loan B facility, or the Euro Term Loan and, together with the Dollar Term Loan, collectively known as the Term Loan and (iii) a five-year $500.0 million revolving credit facility, or the Revolving Credit Facility. We financed the cash portion of the GW Acquisition consideration through a combination of cash on hand and borrowings under the Term Loan and the Secured Notes. For further information on the Term Loan and the Secured Notes, please see Note 12. The GW Acquisition was accounted for as a business combination using the acquisition method under which assets and liabilities of GW were recorded at their respective estimated fair values as of the Closing Date and added to the assets and liabilities of the Company, including an amount for goodwill representing the difference between the acquisition consideration and the estimated fair value of the identifiable net assets. The results of operations of GW have been included in our consolidated financial statements since the Closing Date. In 2021, we incurred $81.9 million in acquisition-related costs related to the GW Acquisition, which primarily consisted of banking, legal, accounting and valuation-related expenses. These expenses were recorded in selling, general and administrative expense in the accompanying consolidated statements of income (loss). In 2021, our consolidated statements of income (loss) included revenues of $476.4 million and a net loss of $704.6 million from the acquired GW business, as measured from the Closing Date. The following table summarizes the fair values of assets acquired and liabilities assumed at the Closing Date (in thousands): Fair Values of Assets Acquired and Liabilities Assumed Cash and cash equivalents $ 343,898 Accounts receivable 76,355 Inventory 1,206,290 Prepaid expenses and other current assets 72,758 Property, plant and equipment 154,407 Acquired developed technologies 5,480,000 In-process research and development 160,000 Total acquired identifiable intangible assets 5,640,000 Goodwill 933,234 Deferred tax liabilities, net (1,069,076) Accrued liabilities (131,971) Other assets/liabilities (35,194) Total purchase consideration $ 7,190,701 Inventory Inventories acquired included raw materials, work in progress and finished goods. Inventories were recorded at their estimated fair values. The inventory was valued at estimated selling price less the estimated costs to be incurred to complete (in the case of work in progress) and sell the inventory, the associated margins on these activities and holding costs. A step-up in value of inventory of $1,062.6 million was recorded in connection with the GW Acquisition. The step-up expense will be recorded in cost of product sales on our consolidated statements of income (loss) as the inventory is sold to customers from the Closing Date. Intangible assets The fair value of acquired intangible assets was $5,640.0 million. The intangible assets included acquired developed technologies, primarily related to Epidiolex, and IPR&D. The fair value of the Epidiolex acquired developed technology asset was determined by applying the income approach, which recognizes that the fair value of an asset is premised upon the expected receipt of future economic benefits such as earnings and cash inflows based on current sales projections and estimated direct costs, using a discount rate of 9.4% that reflects the return requirements of the market. This intangible asset is being amortized over an estimated useful life of 12 years. We acquired a nabiximols IPR&D asset Some of the more significant assumptions inherent in the development of intangible asset fair values include: the amount and timing of projected future cash flows (including revenue, cost of sales, research and development cost and sales and marketing expenses); probability of success; the discount rate selected to measure inherent risk of future cash flows; and the assessment of the asset’s life cycle and the competitive trends impacting the asset, among other factors. Deferred tax liabilities, net The net deferred tax liability relates to the difference between the financial statement carrying amount and the tax basis of acquired intangible assets and inventory, partially offset by acquired net operating loss carryforwards and other temporary differences. Other tangible assets and liabilities Other tangible assets and liabilities were valued at their respective carrying amounts as management believes that these amounts approximated their acquisition-date fair values. Goodwill Goodwill represents the excess of the total purchase consideration over the estimated fair value of net assets acquired and was recorded in the consolidated balance sheet as of the Closing Date. The goodwill was primarily attributable to the establishment of the deferred tax liability for the acquired intangible assets and inventory. We do not expect any portion of this goodwill to be deductible for income tax purposes.

Cash and Available-for-Sale Sec

Cash and Available-for-Sale Securities	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Cash and Available-for-Sale Securities	Cash and Available-for-Sale Securities Cash, cash equivalents and investments consisted of the following (in thousands): December 31, 2023 Amortized Gross Gross Estimated Cash and Investments Cash $ 437,724 $ — $ — $ 437,724 $ 437,724 $ — Time deposits 420,000 — — 420,000 300,000 120,000 Money market funds 768,586 — — 768,586 768,586 — Totals $ 1,626,310 $ — $ — $ 1,626,310 $ 1,506,310 $ 120,000 December 31, 2022 Amortized Gross Gross Estimated Cash and Investments Cash $ 334,018 $ — $ — $ 334,018 $ 334,018 $ — Time deposits 30,000 — — 30,000 30,000 — Money market funds 517,464 — — 517,464 517,464 — Totals $ 881,482 $ — $ — $ 881,482 $ 881,482 $ — Cash equivalents and investments are considered available-for-sale securities. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the consolidated statements of income (loss). Our investment balances represent time deposits with original maturities of greater than three months and less than one year. Interest income from available-for-sale securities was $65.1 million, $11.5 million and $1.8 million in 2023, 2022 and 2021, respectively.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The following table summarizes, by major security type, our available-for-sale securities and derivative contracts that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands): December 31, 2023 December 31, 2022 Quoted Significant Total Quoted Significant Total Assets: Available-for-sale securities: Time deposits $ — $ 420,000 $ 420,000 $ — $ 30,000 $ 30,000 Money market funds 768,586 — 768,586 517,464 — 517,464 Interest rate contracts — 3,784 3,784 — — — Foreign exchange forward contracts — 18,035 18,035 — 17,356 17,356 Totals $ 768,586 $ 441,819 $ 1,210,405 $ 517,464 $ 47,356 $ 564,820 Liabilities: Interest rate contracts $ — $ 3,410 $ 3,410 $ — $ — $ — Foreign exchange forward contracts — 681 681 — — — Totals $ — $ 4,091 $ 4,091 $ — $ — $ — As of December 31, 2023 and 2022, our available-for-sale securities included money market funds and time deposits and their carrying values were approximately equal to their fair values. Money market funds were measured using quoted prices in active markets, which represent Level 1 inputs and time deposits were measured at fair value using Level 2 inputs. Level 2 inputs are obtained from various third party data providers and represent quoted prices for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived from or corroborated by other observable market data. Our derivative assets and liabilities include interest rate and foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the fair value hierarchy. There were no transfers between the different levels of the fair value hierarchy in 2023 or in 2022. As of December 31, 2023 and 2022, the carrying amount of investments measured using the measurement alternative for equity investments without a readily determinable fair value was $4.7 million and $5.5 million, respectively. The carrying amount, which is recorded within other non-current assets, is based on the latest observable transaction price. As of December 31, 2023, the estimated fair values of the 1.50% exchangeable senior notes due 2024, or 2024 Notes and the 2.00% exchangeable senior notes due 2026, or 2026 Notes, which we refer to collectively as the Exchangeable Senior Notes, were approximately $559.0 million and $1.0 billion, respectively. As of December 31, 2023, the estimated fair value of the Secured Notes and the Dollar Term Loan were approximately $1.4 billion and $2.7 billion , respectively. The fair values of each of these debt facilities was estimated using quoted market prices obtained from brokers (Level 2).

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities We are exposed to certain risks arising from operating internationally, including fluctuations in foreign exchange rates primarily related to the translation of sterling and euro-denominated net monetary liabilities, including intercompany balances, held by subsidiaries with a U.S. dollar functional currency and fluctuations in interest rates on our outstanding term loan borrowings. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. We enter into foreign exchange forward contracts, with durations of up to 12 months, designed to limit the exposure to fluctuations in foreign exchange rates related to the translation of certain non-U.S. dollar denominated liabilities, including intercompany balances. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of December 31, 2023 and 2022 , the notional amount of foreign exchange contracts where hedge accounting was not applied was $511.7 million and $505.0 million, respectively. The foreign exchange gain (loss) in our consolidated statements of income (loss) included the following gains and losses associated with foreign exchange contracts not designated as hedging instruments (in thousands): Year Ended December 31, Foreign Exchange Forward Contracts: 2023 2022 2021 Gain (loss) recognized in foreign exchange gain (loss) $ 13,543 $ (58,755) $ (19,585) To achieve a desired mix of floating and fixed interest rates on our variable rate debt, we entered into interest rate swap agreements in April 2023 which are effective until April 2026. These agreements hedge contractual term loan interest rates. As of December 31, 2023, the interest rate swap agreements had a notional amount of $500.0 million. As a result of these agreements, the interest rate on a portion of our term loan borrowings is fixed at 3.9086%, plus the borrowing spread, until April 30, 2026. Our previous interest rate swap was entered into in March 2017. In May 2021, we repaid the term loan to which these interest rate swap agreements related, at which point the interest rate swap contracts were de-designated as cash flow hedges. These interest rate swap agreements matured in July 2021. The impact on accumulated other comprehensive income (loss) and earnings from derivative instruments that qualified as cash flow hedges was as follows (in thousands): Year Ended December 31, Interest Rate Contracts: 2023 2022 2021 Gain (loss) recognized in accumulated other comprehensive income (loss), net of tax $ 3,658 $ — $ (14) (Gain) loss reclassified from accumulated other comprehensive income (loss) to interest expense, net of tax (3,423) — 2,482 Assuming no change in the U.S dollar Secured Overnight Financing Rate, or Term SOFR based interest rates from market rates as of December 31, 2023, $2.8 million of gains, net of tax, recognized in accumulated other comprehensive income (loss) will be reclassified to earnings over the next 12 months. In order to hedge our exposure to foreign currency exchange risk associated with our Euro Term Loan, we entered into a cross-currency interest rate swap contract in May 2021, which matured in March 2022, and was de-designated as a fair value hedge. The terms of this contract converted the principal repayments and interest payments on the Euro Term Loan into U.S. dollars. The carrying amount of the Euro Term Loan and the fair value of the cross-currency interest rate swap contract were remeasured on a monthly basis, with changes in the euro to U.S. dollar foreign exchange rates recognized within foreign exchange gain (loss) in the consolidated statements of income (loss). The impact on accumulated other comprehensive income (loss) and earnings from the cross-currency interest rate swap contract was as follows (in thousands): Year Ended December 31, Cross-Currency Interest Rate Contract: 2022 2021 Loss recognized in accumulated other comprehensive income (loss), net of tax $ — $ (375) Loss reclassified from accumulated other comprehensive income (loss) to foreign exchange loss, net of tax 128 246 Loss recognized in foreign exchange loss 2,646 35,885 The cash flow effects of our derivative contracts are included within net cash provided by operating activities in the consolidated statements of cash flows, except for the settlement of notional amounts of the cross-currency swap, which were included in net cash used in financing activities. The following tables summarize the fair value of outstanding derivatives (in thousands): December 31, 2023 Asset Derivatives Liability Derivatives Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments: Interest rate contracts Other current assets $ 3,784 Accrued liabilities $ — Other non-current assets — Other non-current liabilities 3,410 Derivatives not designated as hedging instruments: Foreign exchange forward contracts Other current assets 18,035 Accrued liabilities 681 Total fair value of derivative instruments $ 21,819 $ 4,091 December 31, 2022 Asset Derivatives Liability Derivatives Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives not designated as hedging instruments: Foreign exchange forward contracts Other current assets $ 17,356 Accrued liabilities $ — Total fair value of derivative instruments $ 17,356 $ — Although we do not offset derivative assets and liabilities within our consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. These provisions were not applicable as of December 31, 2022 since all derivatives were in an asset position. The following table summarizes the potential effect on our consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions as of December 31, 2023 (in thousands): December 31, 2023 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 21,819 $ — $ 21,819 $ (4,091) $ — $ 17,728 Derivative liabilities (4,091) — (4,091) 4,091 — —

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in thousands): December 31, 2023 2022 Raw materials $ 25,595 $ 20,786 Work in process 431,732 517,670 Finished goods 139,712 175,605 Total inventories $ 597,039 $ 714,061 As of December 31, 2023 and 2022, inventories included $328.0 million and $457.6 million, respectively, related to the purchase accounting inventory fair value step-up on inventory acquired in the GW Acquisition.

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2023
Other Current Assets [Abstract]
Other Current Assets	Other Current Assets Other current assets consisted of the following (in thousands): December 31, 2023 2022 Deferred charge for income taxes on intercompany profit $ 171,507 $ 176,057 Other 149,302 91,135 Total other current assets $ 320,809 $ 267,192

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consisted of the following (in thousands): December 31, 2023 2022 Manufacturing equipment and machinery $ 82,897 $ 73,580 Land and buildings 70,912 68,935 Leasehold improvements 67,722 64,776 Computer software 38,134 34,116 Construction-in-progress 18,661 67,385 Computer equipment 15,398 16,424 Furniture and fixtures 9,273 10,481 Subtotal 302,997 335,697 Less accumulated depreciation and amortization (133,351) (107,647) Property, plant and equipment, net $ 169,646 $ 228,050 Depreciation and amortization expense on property, plant and equipment amounted to $30.4 million, $30.3 million and $26.7 million for the years ended December 31, 2023, 2022 and 2021, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The gross carrying amount of goodwill was as follows (in thousands): Balance at December 31, 2022 $ 1,692,662 Foreign exchange 60,468 Balance at December 31, 2023 $ 1,753,130 The gross carrying amounts and net book values of our intangible assets were as follows (in thousands): December 31, 2023 December 31, 2022 Remaining Gross Accumulated Net Book Gross Accumulated Net Book Acquired developed technologies 8.8 $ 7,785,495 $ (2,367,456) $ 5,418,039 $ 7,491,994 $ (1,697,557) $ 5,794,437 Manufacturing contracts — 11,828 (11,828) — 11,417 (11,417) — Trademarks — 2,886 (2,886) — 2,876 (2,876) — Total finite-lived intangible assets $ 7,800,209 $ (2,382,170) $ 5,418,039 $ 7,506,287 $ (1,711,850) $ 5,794,437 The increase in the gross carrying amount of intangible assets as of December 31, 2023 compared to December 31, 2022 primarily relates to the positive impact of foreign currency translation adjustments due to the strengthening of sterling against the U.S. dollar. The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines. Based on finite-lived intangible assets recorded as of December 31, 2023, and assuming the underlying assets will not be impaired and that we will not change the expected lives of any other assets, future amortization expenses were estimated as follows (in thousands): Year Ending December 31, Estimated Amortization Expense 2024 $ 624,651 2025 624,651 2026 624,651 2027 624,651 2028 623,319 Thereafter 2,296,116 Total $ 5,418,039

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consisted of the following (in thousands): December 31, 2023 2022 Rebates and other sales deductions $ 325,711 $ 313,176 Employee compensation and benefits 121,209 143,243 Accrued facilities expenses 55,455 25,864 Clinical trial accruals 44,757 31,338 Accrued interest 36,443 35,614 Accrued royalties 30,706 57,347 Sales return reserve 20,435 26,164 Consulting and professional services 19,538 22,278 Current portion of lease liabilities 19,447 15,938 Selling and marketing accruals 14,743 18,553 Inventory-related accruals 13,977 8,565 Accrued collaboration expenses 10,158 33,205 Accrued construction-in-progress 5,141 3,298 Derivative instrument liabilities 681 — Other 75,513 68,672 Total accrued liabilities $ 793,914 $ 803,255

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	Debt The following table summarizes the carrying amount of our indebtedness (in thousands): December 31, 2023 2022 2024 Notes $ 575,000 $ 575,000 Unamortized - debt issuance costs (1,046) (2,738) 2024 Notes, net 573,954 572,262 2026 Notes 1,000,000 1,000,000 Unamortized - debt issuance costs (6,400) (8,932) 2026 Notes, net 993,600 991,068 Secured Notes 1,480,214 1,476,938 Term Loan 2,665,174 2,684,073 Total debt 5,712,942 5,724,341 Less current portion (1) 604,954 31,000 Total long-term debt $ 5,107,988 $ 5,693,341 ______________________________ (1) Balance as of December 31, 2023 includes the 2024 Notes since they mature in August 2024. Credit Agreement On May 5, 2021, the Company, Jazz Financing Lux S.à.r.l., or Jazz Lux, and certain of our other subsidiaries, as borrowers, or collectively with the Company and Jazz Lux, the “Borrowers”, entered into the Credit Agreement by and among the Borrowers, the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee, or the Credit Agreement, that provided for (i) the Dollar Term Loan which was drawn by Jazz Lux on the Closing Date in U.S. dollars (ii) the Euro Term Loan which was drawn by Jazz Lux on the Closing Date in Euros and (iii) the Revolving Credit Facility. We used the proceeds from the Term Loan (i) to repay in full $575.9 million under that certain credit agreement, dated as of June 18, 2015 (as amended) among the Company, and certain of our other subsidiaries as borrowers, the lenders party thereto and Bank of America, N.A., as administrative agent and collateral agent, or the Existing Credit Agreement, (ii) to fund, in part, the cash consideration payable in connection with the GW Acquisition and (iii) to pay related fees and expenses. Upon the repayment in full of loans under the Existing Credit Agreement, it was terminated and all guarantees and liens thereunder were released. In 2021, we made voluntary prepayments on the Euro Term Loan totaling €416.7 million, or $502.0 million, and in March 2022 we repaid the remaining outstanding principal of €208.3 million, or $251.0 million. The Euro Term Loan bore interest at the Euro Inter-Bank Offered Rate, or EURIBOR, plus an applicable margin. The applicable margin for the Euro Term Loan was 3.50%. During the term of the Euro Term Loan, the interest rate and effective interest rate were 4.43% and 4.93%, respectively. In January 2024, Jazz Lux entered into an amendment, or Repricing Amendment, to the Credit Agreement. Upon entry into the Repricing Amendment, certain existing lenders converted outstanding Dollar Term Loans into a new tranche of U.S. dollar term loans, or the Tranche B-1 Dollar Term Loans, and Jazz Lux borrowed $201.9 million aggregate principal amount of additional Tranche B-1 Dollar Term Loans, the proceeds of which were used to repay the outstanding Dollar Term Loans that were not converted. The Tranche B-1 Dollar Term Loans are a separate class of term loans under the Credit Agreement with the same material terms (including with respect to maturity, prepayment, security, covenants and events of default) as the previously outstanding Dollar Term Loans, with the interest rate amended as described below. The principal amount of Dollar Term Loans outstanding immediately prior to the Repricing Amendment and the outstanding principal amount of Tranche B-1 Dollar Term Loans immediately following the Repricing Amendment, each totaled $2.723 billion. The Tranche B-1 Dollar Term Loans bear interest at a rate equal to either (a) Term SOFR or (b) the prime lending rate, in each case, plus an applicable margin. The applicable margin for the Tranche B-1 Dollar Term Loans is 3.00% (in the case of Term SOFR borrowings) and 2.00% (in the case of borrowings at the prime lending rate), a decrease of 50 basis points from the applicable margin on the Initial Dollar Term Loans. The Tranche B-1 Dollar Term Loans are subject to a Term SOFR floor of 0.50%. The applicable margin for the Revolving Credit Facility ranges from 3.25% to 2.75% (in the case of Term SOFR borrowings) and 2.25% to 1.75% (in the case of borrowings at the prime lending rate), depending on our first lien secured net leverage ratio level. The Tranche B-1 Dollar Term Loan is subject to a Term SOFR floor of 0.50% and loans under the Revolving Credit Facility are not subject to a floor. The Revolving Credit Facility has a commitment fee payable on the undrawn amount ranging from 0.50% to 0.40% per annum based upon our first lien secured net leverage ratio. As of December 31, 2023, the interest rate and effective interest rate on the Dollar Term Loan were 8.97% and 4.56%, respectively. Pursuant to the Repricing Amendment, the interest rate and effective interest rate on the Tranche B-1 Dollar Term Loans are 8.90% and 9.50%, respectively. As of December 31 ,2023, we had an undrawn Revolving Credit Facility totaling $500.0 million. We may make voluntary prepayments at any time without payment of a premium or penalty, subject to certain exceptions, and are required to make certain mandatory prepayments of outstanding indebtedness under the Credit Agreement in certain circumstances. Principal repayments of the Dollar Term Loan, which were due quarterly, began in September 2021 and were equal to 1.0% per annum of the original principal amount of $3.1 billion with any remaining balance payable on the maturity date. In September 2022, we made a voluntary repayment on the Dollar Term Loan totaling $300.0 million. The Tranche B-1 Dollar Term Loans will amortize in quarterly installments equal to 0.284664830% of the initial principal amount thereof, with the remaining balance payable on May 5, 2028. The Borrowers’ obligations under the Credit Agreement and any hedging or cash management obligations entered into with any lender thereunder are guaranteed by the Company, the other borrowers, and each of the Company’s other existing or subsequently acquired or organized direct and indirect subsidiaries (subject to certain exceptions), or the Guarantors. We refer to the Borrowers and the Guarantors collectively as the “Loan Parties.” The Loan Parties’ obligations under the Credit Agreement are secured, subject to customary permitted liens and other exceptions, by a security interest in (a) all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and (b) all of the equity interests of the subsidiaries of the Loan Parties held by the Loan Parties. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of junior indebtedness and dividends and other distributions. The Credit Agreement contains financial covenants that require the Company and its restricted subsidiaries to (a) not exceed a maximum first lien secured net leverage ratio and (b) not fall below a minimum interest coverage ratio, provided that such covenants apply only to the Revolving Credit Facility and are applicable only if amounts are drawn (or non-cash collateralized letters of credit in excess of $50 million are outstanding) under the Revolving Credit Facility. The Credit Agreement also contains customary events of default relating to, among other things, failure to make payments, breach of covenants and breach of representations. 2029 Senior Secured Notes On April 29, 2021, Jazz Securities Designated Activity Company, or Jazz Securities, a direct wholly owned subsidiary of the Company, closed the offering of the Secured Notes in a private placement. We used the proceeds from the Secured Notes to fund, in part, the cash consideration payable in connection with the GW Acquisition. Interest on the Secured Notes is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2022, at a rate of 4.375% per year. The Secured Notes mature on January 15, 2029. The Secured Notes are jointly and severally guaranteed by the Company and each of its restricted subsidiaries, other than Jazz Securities, that is a borrower, or a guarantor, under the Credit Agreement. The Secured Notes and related guarantees are secured by a first priority lien (subject to permitted liens and certain other exceptions), equally and ratably with the Credit Agreement, on the collateral securing the Credit Agreement. Except as described below, the Secured Notes may not be optionally redeemed before July 15, 2024. Thereafter, some or all of the Secured Notes, may be redeemed at any time and from time to time at a specified redemption prices, plus accrued and unpaid interest, if any, to, but excluding, to the redemption date. Jazz Securities may redeem all but not part of the Secured Notes at its option at any time in connection with certain tax-related events and may redeem some or all of the Secured Notes at any time and from time to time prior to July 15, 2024 at a price equal to 100% of the principal amount of the Secured Notes to be redeemed plus a “make whole” premium, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, Jazz Securities may redeem up to 40% of the aggregate principal amount of the Secured Notes at any time and from time to time prior to July 15, 2024, with the net proceeds of certain equity offerings at a price of 104.375% of the principal amount of such Secured Notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, during each of the three consecutive twelve-month periods commencing on the issue date of the Secured Notes, Jazz Securities may redeem up to 10% of the original aggregate initial principal amount of the Secured Notes at a redemption price of 103% of the principal amount of such Secured Notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If Jazz undergoes a change of control, Jazz Securities will be required to make an offer to purchase all of the Secured Notes at a purchase price in cash equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the date of repurchase, subject to certain exceptions. The indenture governing the Secured Notes contains customary affirmative covenants and negative covenants applicable to the Company and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of junior indebtedness and dividends and other distributions. If Jazz Securities or the Company’s restricted subsidiaries engage in certain asset sales, Jazz Securities will be required under certain circumstances to make an offer to purchase the Secured Notes at 100% of the principal amount, plus accrued and unpaid interest, if any, to, but excluding, the repurchase date. As of December 31, 2023, the interest rate and effective interest rate on the Secured Notes were 4.375% and 4.64%, respectively. Exchangeable Senior Notes Due 2026 In 2020 we completed a private placement of $1.0 billion principal amount of the 2026 Notes. We used a portion of the net proceeds from this offering to repurchase for cash $332.9 million aggregate principal amount of the 1.875% exchangeable senior notes due 2021, or 2021 Notes, through privately-negotiated transactions concurrently with the offering of the 2026 Notes. Interest on the 2026 Notes is payable semi-annually in cash in arrears on June 15 and December 15 of each year, beginning on December 15, 2020, at a rate of 2.00% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2026 Notes. The 2026 Notes mature on June 15, 2026, unless earlier exchanged, repurchased or redeemed. The holders of the 2026 Notes have the ability to require us to repurchase all or a portion of their 2026 Notes for cash in the event we undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2026 Notes include certain events of default after which the 2026 Notes may be due and payable immediately. Prior to June 15, 2026, we may redeem the 2026 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2026 Notes additional amounts as a result of certain tax-related events. We also may redeem the 2026 Notes on or after June 20, 2023 and prior to March 15, 2026, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption. The 2026 Notes are exchangeable at an initial exchange rate of 6.4182 ordinary shares per $1,000 principal amount of 2026 Notes, which is equivalent to an initial exchange price of approximately $155.81 per ordinary share. Upon exchange, the 2026 Notes may be settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal amount of the 2026 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2026 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2026 Notes who elect to exchange their 2026 Notes in connection with that make-whole fundamental change or during the related redemption period. Prior to March 15, 2026, the 2026 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. As of December 31, 2023, the “if converted value” did not exceed the principal amount of the 2026 Notes. As of December 31, 2022, the “if converted value” of the 2026 Notes exceeded the principal amount by $22.5 million. The total liability is reflected net of issuance costs of $15.3 million which will be amortized over the term of the 2026 Notes. We have determined the expected life of the 2026 Notes to be equal to the original six-year term. The effective interest rate of the 2026 Notes is 2.26%. Exchangeable Senior Notes Due 2024 In 2017, we completed a private placement of $575.0 million principal amount of 2024 Notes. We used the net proceeds from this offering to repay $500.0 million in outstanding loans under the revolving credit facility and to pay related fees and expenses. We used the remainder of the net proceeds for general corporate purposes. Interest on the 2024 Notes is payable semi-annually in cash in arrears on February 15 and August 15 of each year, beginning on February 15, 2018, at a rate of 1.50% per year. In certain circumstances, we may be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the 2024 Notes. The 2024 Notes mature on August 15, 2024, unless earlier exchanged, repurchased or redeemed. The holders of the 2024 Notes have the ability to require us to repurchase all or a portion of their 2024 Notes for cash in the event we undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our ordinary shares from The Nasdaq Global Select Market. Prior to August 15, 2024, we may redeem the 2024 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder of any 2024 Notes additional amounts as a result of certain tax-related events. We also may redeem the 2024 Notes on or after August 20, 2021, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the notice of redemption. The 2024 Notes are exchangeable at an initial exchange rate of 4.5659 ordinary shares per $1,000 principal amount of 2024 Notes, which is equivalent to an initial exchange price of approximately $219.02 per ordinary share. In August 2023, we made an irrevocable election to fix the settlement method for exchanges of the 2024 Notes to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the 2024 Notes of $1,000. The exchange rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of the 2024 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of the 2024 Notes who elect to exchange their 2024 Notes in connection with that make-whole fundamental change or during the related redemption period. Prior to May 15, 2024, the 2024 Notes will be exchangeable only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. As of December 31, 2023 and 2022, the “if-converted value” did not exceed the principal amount of the 2024 Notes. The total liability is reflected net of issuance costs of $11.4 million which will be amortized over the term of the 2024 Notes. We have determined the expected life of the 2024 Notes to be equal to the original seven-year term. The effective interest rate of the 2024 Notes is 1.79%. The Exchangeable Senior Notes were issued by Jazz Investments I Limited, or the Issuer, a 100%-owned finance subsidiary of Jazz Pharmaceuticals plc. The Exchangeable Senior Notes are senior unsecured obligations of the Issuer and are fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the Exchangeable Senior Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or Jazz Pharmaceuticals plc’s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or advances. There is no assurance that in the future such restrictions will not be adopted. For the years ended December 31, 2023 and 2022, we recognized $32.8 million, in interest expense, net, of which, $28.6 million related to the contractual coupon rate and $4.2 million related the amortization of the debt issuance costs on the Exchangeable Senior Notes. For the year ended December 31, 2021, we recognized $89.9 million in interest expense, net, of which, $31.2 million related to the contractual coupon rate, $4.4 million related to the debt issuance costs and $54.3 million related to the amortization of the debt discount costs. Scheduled maturities with respect to our long-term debt are as follows (in thousands): Year Ending December 31, Scheduled Long-Term Debt Maturities 2024 $ 606,000 2025 31,000 2026 1,031,000 2027 31,000 2028 2,598,500 Thereafter 1,500,000 Total $ 5,797,500

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	Leases We have noncancelable leases for our buildings and growing facilities and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force. The components of the lease expense for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands): Year Ended December 31, Lease Cost 2023 2022 2021 Operating lease cost $ 19,394 $ 19,670 $ 23,869 Short-term lease cost 6,290 5,088 5,540 Variable lease cost 81 5 10 Sublease income (22) — — Finance Lease Cost Amortization of leased asset 481 472 324 Interest on lease liabilities 377 429 295 Net lease cost $ 26,601 $ 25,664 $ 30,038 Supplemental balance sheet information related to operating and finance leases was as follows (in thousands): December 31, Leases Classification 2023 2022 Assets Operating lease assets Operating lease assets $ 65,340 $ 73,326 Finance lease assets Property, plant and equipment 4,450 4,671 Total lease assets $ 69,790 $ 77,997 Liabilities Current Operating lease liabilities Accrued liabilities $ 19,019 $ 15,557 Finance lease liabilities Accrued liabilities 428 381 Non-current Operating lease liabilities Operating lease liabilities, less current portion 59,225 71,838 Finance lease liabilities Other non-current liabilities 5,039 5,210 Total lease liabilities $ 83,711 $ 92,986 December 31, Lease Term and Discount Rate 2023 2022 Weighted-average remaining lease term (years) Operating leases 5.1 5.8 Finance leases 11.2 12.0 Weighted-average discount rate Operating leases 5.4 % 5.3 % Finance leases 7.5 % 7.4 % Supplemental cash flow information related to operating and finance leases was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 20,646 $ 20,544 $ 24,847 Operating cash outflows from finance leases 835 806 625 Financing cash outflows from finance leases 377 429 324 Non-cash operating activities: Operating lease assets obtained in exchange for new operating lease liabilities $ 9,953 $ 4,312 $ 8,188 Finance lease assets obtained in exchange for new finance lease liabilities — — 650 De-recognition of operating lease asset on lease assignment / termination 4,169 — 56,968 De-recognition of operating lease liability on lease assignment / termination 4,457 — 68,064 Maturities of operating and finance lease liabilities were as follows (in thousands): Year Ending December 31, Operating Leases Finance Leases 2024 $ 22,841 $ 823 2025 16,891 823 2026 14,184 823 2027 12,675 769 2028 12,008 610 Thereafter 11,819 4,382 Total lease payments 90,418 8,230 Less imputed interest (12,174) (2,763) Present value of lease liabilities $ 78,244 $ 5,467
Leases	Leases We have noncancelable leases for our buildings and growing facilities and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force. The components of the lease expense for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands): Year Ended December 31, Lease Cost 2023 2022 2021 Operating lease cost $ 19,394 $ 19,670 $ 23,869 Short-term lease cost 6,290 5,088 5,540 Variable lease cost 81 5 10 Sublease income (22) — — Finance Lease Cost Amortization of leased asset 481 472 324 Interest on lease liabilities 377 429 295 Net lease cost $ 26,601 $ 25,664 $ 30,038 Supplemental balance sheet information related to operating and finance leases was as follows (in thousands): December 31, Leases Classification 2023 2022 Assets Operating lease assets Operating lease assets $ 65,340 $ 73,326 Finance lease assets Property, plant and equipment 4,450 4,671 Total lease assets $ 69,790 $ 77,997 Liabilities Current Operating lease liabilities Accrued liabilities $ 19,019 $ 15,557 Finance lease liabilities Accrued liabilities 428 381 Non-current Operating lease liabilities Operating lease liabilities, less current portion 59,225 71,838 Finance lease liabilities Other non-current liabilities 5,039 5,210 Total lease liabilities $ 83,711 $ 92,986 December 31, Lease Term and Discount Rate 2023 2022 Weighted-average remaining lease term (years) Operating leases 5.1 5.8 Finance leases 11.2 12.0 Weighted-average discount rate Operating leases 5.4 % 5.3 % Finance leases 7.5 % 7.4 % Supplemental cash flow information related to operating and finance leases was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 20,646 $ 20,544 $ 24,847 Operating cash outflows from finance leases 835 806 625 Financing cash outflows from finance leases 377 429 324 Non-cash operating activities: Operating lease assets obtained in exchange for new operating lease liabilities $ 9,953 $ 4,312 $ 8,188 Finance lease assets obtained in exchange for new finance lease liabilities — — 650 De-recognition of operating lease asset on lease assignment / termination 4,169 — 56,968 De-recognition of operating lease liability on lease assignment / termination 4,457 — 68,064 Maturities of operating and finance lease liabilities were as follows (in thousands): Year Ending December 31, Operating Leases Finance Leases 2024 $ 22,841 $ 823 2025 16,891 823 2026 14,184 823 2027 12,675 769 2028 12,008 610 Thereafter 11,819 4,382 Total lease payments 90,418 8,230 Less imputed interest (12,174) (2,763) Present value of lease liabilities $ 78,244 $ 5,467

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations. We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of December 31, 2023 and December 31, 2022. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations. Other Commitments As of December 31, 2023, we had $56.6 million of noncancelable purchase commitments due within one year, primarily related to agreements with third party manufacturers. Legal Proceedings We are involved in legal proceedings, including the following matters: Xyrem Antitrust Litigation From June 2020 to May 2022, a number of lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement agreements we entered with generic drug manufacturers who had filed Abbreviated New Drug Applications, or ANDA, violate state and federal antitrust and consumer protection laws, as follows: On June 17, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by Blue Cross and Blue Shield Association, or BCBS, against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Limited, or, collectively, the Company Defendants (hereinafter referred to as the BCBS Lawsuit). The BCBS Lawsuit also names Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA), Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc., or, collectively, the BCBS Defendants. On June 18 and June 23, 2020, respectively, two additional class action lawsuits were filed against the Company Defendants and the BCBS Defendants: one by the New York State Teamsters Council Health and Hospital Fund in the United States District Court for the Northern District of California, and another by the Government Employees Health Association Inc. in the United States District Court for the Northern District of Illinois (hereinafter referred to as the GEHA Lawsuit). On June 18, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of California by the City of Providence, Rhode Island, on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc, and Roxane Laboratories, Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., and Hikma Pharmaceuticals plc, or, collectively, the City of Providence Defendants. On June 30, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by UFCW Local 1500 Welfare Fund on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals Ireland Ltd., Jazz Pharmaceuticals, Inc., Roxane Laboratories, Inc., Hikma Pharmaceuticals plc, Eurohealth (USA), Inc. and West-Ward Pharmaceuticals Corp., or collectively the UFCW Defendants (hereinafter referred to as the UFCW Lawsuit). On July 13, 2020, the plaintiffs in the BCBS Lawsuit and the GEHA Lawsuit dismissed their complaints in the United States District Court for the Northern District of Illinois and refiled their respective lawsuits in the United States District Court for the Northern District of California. On July 14, 2020, the plaintiffs in the UFCW Lawsuit dismissed their complaint in the United States District Court for the Northern District of Illinois and on July 15, 2020, refiled their lawsuit in the United States District Court for the Northern District of California. On July 31, 2020, a class action lawsuit was filed in the United States District Court for the Southern District of New York by the A.F. of L.-A.G.C. Building Trades Welfare Plan on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc (hereinafter referred to as the AFL Plan Lawsuit). The AFL Plan Lawsuit also names Roxane Laboratories Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc. On August 14, 2020, an additional class action lawsuit was filed in the United States District Court for the Southern District of New York by the Self-Insured Schools of California on behalf of itself and all others similarly situated, against the Company Defendants, as well as Hikma Pharmaceuticals plc, Eurohealth (USA) Inc., Hikma Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Roxane Laboratories, Inc., Amneal Pharmaceuticals LLC, Endo International, plc, Endo Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Lupin Inc., Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Holdings USA, Inc., Sun Pharmaceutical Industries, Inc., Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Watson Laboratories, Inc., Wockhardt Ltd., Morton Grove Pharmaceuticals, Inc., Wockhardt USA LLC, Mallinckrodt plc, and Mallinckrodt LLC (hereinafter referred to as the Self-Insured Schools Lawsuit). On September 16, 2020, an additional class action lawsuit was filed in the United States District Court for the Northern District of California, by Ruth Hollman on behalf of herself and all others similarly situated, against the same defendants named in the Self-Insured Schools Lawsuit. In December 2020, the above cases were centralized and transferred to the United States District Court for the Northern District of California, where the multidistrict litigation will proceed for the purpose of discovery and pre-trial proceedings. On March 18, 2021, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota against the Company Defendants, Hikma Pharmaceuticals plc, Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA) Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc., raising similar allegations, or the UHS Lawsuit. On March 24, 2021, the U.S. Judicial Panel on Multidistrict Litigation conditionally transferred the UHS Lawsuit to the United States District Court for the Northern District of California, where it was consolidated for discovery and pre-trial proceedings with the other cases. On August 13, 2021, the United States District Court for the Northern District of California granted in part and denied in part the Company Defendants' motion to dismiss the complaints in the cases referenced above. On October 8, 2021, Humana Inc. filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On October 8, 2021, Molina Healthcare Inc. filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On February 17, 2022, Health Care Service Corporation filed a lawsuit in the United States District Court for the Northern District of California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On April 19, 2023, the Court held a hearing on class certification in the consolidated multi-district litigation referenced above. On May 12, 2023, the Court granted the plaintiffs’ motion and preliminarily certified classes of Xyrem purchasers seeking monetary and injunctive relief. The Court excluded Xywav purchasers from the classes. Trial in this matter is scheduled for October 28, 2024. On January 13, 2023, Amneal Pharmaceuticals LLC, Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, notified the Court that they had reached a settlement-in-principle with the class action plaintiffs. On April 19, 2023, the Court held a hearing on a motion for preliminary approval of this proposed settlement. On May 12, 2023, the Court granted the motion for preliminary approval of the proposed settlement. On January 11, 2024, the Court held a hearing on the motion for final approval of the proposed settlement. The Court deferred ruling and scheduled a further hearing for final approval of the proposed settlement on April 17, 2024. On December 11, 2023, Blue Cross and Blue Shield of Florida, Inc. and Health Options, Inc. filed a lawsuit in the United States District Court for the Middle District of Florida against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., and Eurohealth (USA), Inc., raising similar allegations. On January 23 , 2024, the Blue Cross Florida case was transferred to the United States District Court for the Northern District of California and consolidated with the above referenced multidistrict litigation for pretrial purposes. On May 9, 2022, Aetna Inc., or Aetna, filed a lawsuit in the Superior Court of California for the County of Alameda against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations. On December 27, 2022, the Court granted in part and denied in part our motion to dismiss Aetna’s complaint. As a result of that ruling, the generic defendants have been dismissed from the case, and certain of Aetna’s claims against Jazz have been dismissed. On January 27, 2023, Aetna filed an amended complaint against Jazz. On March 22, 2023, we filed motions to dismiss and to strike portions of the amended complaint. On June 26, 2023, the Court granted our motions, and granted Aetna leave to further amend its complaint. On November 17, 2023, Aetna filed its second amended complaint. On February 2 , 2024, we filed our answer to the second amended complaint and Hikma filed a motion to quash service. That motion remains pending. The plaintiffs in certain of these lawsuits are seeking to represent a class of direct purchasers of Xyrem, and the plaintiffs in the remaining lawsuits are seeking to represent a class of indirect purchasers of Xyrem. Each of the lawsuits generally alleges violations of U.S. federal and state antitrust, consumer protection, and unfair competition laws in connection with the Company Defendants’ conduct related to Xyrem, including actions leading up to, and entering into, patent litigation settlement agreements with each of the other named defendants. Each of the lawsuits seeks monetary damages, exemplary damages, equitable relief against the alleged unlawful conduct, including disgorgement of profits and restitution, and injunctive relief. It is possible that additional lawsuits will be filed against the Company Defendants making similar or related allegations. If the plaintiffs were to be successful in their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. GW Acquisition Litigation On March 15, 2021, GW filed a definitive proxy statement, or Proxy Statement, with the Securities and Exchange Commission in connection with the GW Acquisition. Since the filing of the Proxy Statement, Jazz Pharmaceuticals plc has been named in two lawsuits filed in state and federal courts in New York on March 17, 2021 by purported GW shareholders in connection with the GW Acquisition. The first was filed in the United States District Court for the Southern District of New York by James Farrell (hereinafter referred to as the Farrell Lawsuit) and an additional suit was filed in New York state court by Brian Levy (hereinafter referred to as the Levy Lawsuit). In addition to Jazz Pharmaceuticals plc, Jazz Pharmaceuticals U.K. Holdings Ltd., GW Pharmaceuticals plc, and the GW board of directors are named as defendants in the Farrell Lawsuit. In the Levy Lawsuit, GW Pharmaceuticals plc, the GW board of directors, Centerview Partners LLC, and Goldman Sachs & Co. LLC are named as defendants. In addition to the Farrell Lawsuit and the Levy Lawsuit, ten additional suits have been filed in New York, California, and Pennsylvania federal courts by purported GW shareholders against GW Pharmaceuticals plc and its board of directors, but which do not name any Jazz Pharmaceuticals parties (hereinafter referred to as the GW Litigation, and collectively with the Farrell Lawsuit and the Levy Lawsuit, as the Transaction Litigation). In the Transaction Litigation, the plaintiffs allege that the Proxy Statement omitted material information and contained misrepresentations, and that the individual members of the GW board of directors breached their fiduciary duties, in violation of state and federal laws, including the Securities Exchange Act of 1934. The plaintiffs in the Transaction Litigation sought various remedies, including injunctive relief to prevent the consummation of the GW Acquisition unless certain allegedly material information was disclosed, or in the alternative, rescission or damages. On April 14, 2021, GW filed a Form 8-K containing supplemental disclosures related to the GW Acquisition. Pursuant to a memorandum of understanding between the parties, the Levy Lawsuit was dismissed on April 14, 2021. On May 27, 2021, a class action lawsuit was filed in the United States District Court for the Southern District of California by plaintiff Kurt Ziegler against GW and its former Directors asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, referred to as the Ziegler Lawsuit. The allegations in the Ziegler Lawsuit are similar to those in the previously dismissed Transaction Litigation. On June 3, 2022, we filed a motion to dismiss the Ziegler Lawsuit. While the motion to dismiss was pending, in December 2022, the parties participated in a mediation and reached a tentative settlement, which remains subject to court approval. On March 20, 2023, the plaintiffs in the Ziegler Lawsuit filed a motion for preliminary approval of the settlement. On July 28, 2023, the Court granted the motion for preliminary approval, which conditionally certified a class for settlement purposes. On December 11, 2023, the Court held a hearing regarding final approval of the proposed settlement and took the matter under advisement. The Court has yet to issue a final written order approving the settlement. Patent Infringement Litigation Avadel Patent Litigation On May 13, 2021, we filed a patent infringement suit against Avadel Pharmaceuticals plc, or Avadel, and several of its corporate affiliates in the United States District Court for the District of Delaware. The suit alleges that Avadel’s Lumryz will infringe five of our patents related to controlled release formulations of oxybate and the safe and effective distribution of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe these patents, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. Avadel filed a motion for partial judgment on the pleadings on its counterclaim that one of our patents should be delisted from the Orange Book. On November 18, 2022, the Court issued an order that we delist the patent from the Orange Book. On November 22, 2022, we filed a notice of appeal to the United States Court of Appeals for the Federal Circuit. The Federal Circuit temporarily stayed the District Court’s delisting order. On February 24, 2023, the Federal Circuit affirmed the District Court’s delisting order, lifted the temporary stay, and gave Jazz 14 days to request that FDA delist the patent from the Orange Book. Jazz complied with the Federal Circuit’s order and requested delisting on February 28, 2023. On March 3, 2023, we and Avadel stipulated to the dismissal without prejudice of the claims and counterclaims related to infringement and validity of the delisted patent in both this suit and a later-filed suit described below related to the same patent. On August 4, 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the District of Delaware. The second suit alleges that Avadel’s Lumryz will infringe a newly-issued patent related to sustained-release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. On November 10, 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the District of Delaware. The third suit alleges that Avadel’s Lumryz will infringe a newly-issued patent related to sustained-release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product will not infringe our patents. On April 14, 2022, Avadel sued us in the United States District Court for the District of Delaware. Avadel’s new suit alleges that we misappropriated trade secrets related to Avadel’s once-nightly sodium oxybate development program and breached certain contracts between the parties. Avadel seeks monetary damages, an injunction preventing us from using Avadel’s confidential information, and an order directing the United States Patent and Trademark Office to modify the inventorship of one of our oxybate patents. On July 8, 2022, we filed a motion for judgment on the pleadings, which the Court denied on July 18, 2023. The denial is not a ruling that Jazz misappropriated Avadel‘s trade secrets or breached any contract. The case will go forward in discovery and the Court instructed the parties to submit a proposed scheduling order. On June 7, 2022, we received notice from Avadel that it had filed a "paragraph IV certification" regarding one patent listed in the Orange Book for Xyrem. A paragraph IV certification is a certification by a generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product. On July 15, 2022, we filed an additional lawsuit against Avadel asserting infringement of that patent. The suit alleges that the filing of Avadel’s application for approval of FT218 is an act of infringement, and that Avadel’s product would infringe the patent if launched. The suit seeks an injunction to prevent Avadel from launching a product that would infringe the patent, and an award of damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patent is invalid, that its product would not infringe, and that by listing the patent in the Orange Book, we engaged in unlawful monopolization in violation of the Sherman Act. On December 9, 2022, we filed a motion to dismiss Avadel’s counterclaims. On June 29, 2023, we filed a motion seeking leave to supplement our motion to dismiss, as well as a motion to stay discovery pending resolution of the motion to dismiss. The Court has not yet ruled on these motions. As noted above, on March 3, 2023, we and Avadel stipulated to the dismissal without prejudice of the claims and counterclaims related to infringement and validity of the delisted patent. On November 1, 2023, the Court held a claim construction hearing relating to disputed terms in the asserted patents. On December 15, 2023, the Court issued a written opinion and order resolving the parties’ remaining claim construction disputes. On November 20, 2023, we and Avadel each filed motions for summary judgment. On February 14, 2024, the Court issued a written opinion and order denying both parties’ motions for summary judgment. Trial regarding our patent infringement claims against Avadel began on February 26, 2024, and the jury has not yet reached a verdict. The Court scheduled a trial regarding Avadel’s counterclaims for unlawful monopolization for November 3, 2025, and a trial regarding Avadel’s trade secret misappropriation claims for December 15, 2025. On July 21, 2022, Avadel filed a lawsuit against FDA in the United States District Court for the District of Columbia, challenging FDA’s determination that Avadel was required to file a paragraph IV certification regarding one of our Orange Book listed patents. Avadel filed a motion for preliminary injunction, or in the alternative, summary judgment, seeking relief including a declaration that FDA’s decision requiring patent certification was unlawful, an order setting aside that decision, an injunction prohibiting FDA from requiring such certification as a precondition to approval of its application for FT218, and an order requiring FDA to take final action on Avadel’s application for approval of FT218 within 14 days of the Court’s ruling. On July 27, 2022, we filed a motion to intervene in that case, which the Court granted. The Court held a hearing on the parties’ respective motions for summary judgment on October 7, 2022. On November 3, 2022, the Court granted our and FDA’s motions for summary judgment and denied Avadel’s motion. Xywav Patent Litigation In June 2021, we received notice from Lupin Inc., or Lupin, that it has filed with FDA an ANDA, for a generic version of Xywav. The notice from Lupin included a paragraph IV certification with respect to ten of our patents listed in FDA’s Orange Book for Xywav on the date of our receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of treatment when Xywav is administered concomitantly with certain other medications. In July 2021, we filed a patent infringement suit against Lupin in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Lupin has infringed ten of our Orange Book listed patents. We are seeking a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Lupin's ANDA. In June 2021, FDA recognized seven years of Orphan Drug Exclusivity for Xywav through July 21, 2027. On October 4, 2021, Lupin filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents. In April 2022, we received notice from Lupin that it had filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On May 11, 2022, we filed an additional lawsuit against Lupin in the United States District Court for the District of New Jersey alleging that by filing its ANDA, Lupin infringed the newly-issued patent related to a method of treatment when Xywav is administered concomitantly with certain other medications. The suit seeks a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patent. On June 22, 2022, the Court consolidated the two lawsuits we filed against Lupin. In November 2022, we received notice from Lupin that it had filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Xywav. On January 19, 2023, we filed an additional lawsuit against Lupin in the United States District Court for the District of New Jersey alleging that by filing its ANDA, Lupin infringed the newly-issued patent referenced in its November 2022 paragraph IV certification, as well as another patent that issued in January 2023. The suit seeks a permanent injunction to prevent Lupin from introducing a generic version of Xywav that would infringe the two patents in suit. On February 15, 2023, the Court consolidated the new lawsuit with the two suits we previously filed against Lupin. No trial date has been set in the consolidated case against Lupin. In February 2023, we received notice from Teva Pharmaceuticals, Inc., or Teva, that it had filed with FDA an ANDA for a generic version of Xywav. The notice from Teva included a paragraph IV certification with respect to thirteen of our patents listed in FDA’s Orange Book for Xywav on the date of the receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of treatment when Xywav is administered concomitantly with certain other medications. In March 2023, we filed a patent infringement suit against Teva in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Teva has infringed thirteen of our Orange Book listed patents. We are seeking a permanent injunction to prevent Teva from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Teva’s ANDA. On May 23, 2023, Teva filed an answer to the complaint and counterclaims asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents. On December 15, 2023, based on a stipulation between all parties, the Court consolidated the Lupin lawsuits and the Teva lawsuit for all purposes. No trial date has been set in the consolidated case. Alkem Patent Litigation In April 2023, we received notice from Alkem Laboratories Ltd., or Alkem, that it has filed with FDA an ANDA, for a generic version of Xyrem. The notice from Alkem included a paragraph IV certification with respect to six of our patents listed in FDA’s Orange Book for Xyrem on the date of our receipt of the notice. The asserted patents relate generally to methods of treatment when Xyrem is administered concomitantly with certain other medications. In June 2023, we filed a patent infringement suit against Alkem in the United States District Court for the District of New Jersey. The complaint alleges that by filing its ANDA, Alkem has infringed six of our Orange Book listed patents. We are seeking a permanent injunction to prevent Alkem from introducing a generic version of Xyrem that would infringe our patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on Alkem’s ANDA. On October 4, 2023, we entered into a settlement agreement with Alkem that resolves our patent litigation. Under the settlement agreement, we granted Alkem a license to manufacture, market, and sell its generic version of Xyrem on or after December 31, 2025, or earlier under certain circumstances, including circumstances where Hikma launches its own generic sodium oxybate product. Epidiolex Patent Litigation In November and December 2022, we received notices from Teva Pharmaceuticals, Inc.; Padagis US LLC; Apotex Inc.; API Pharma Tech LLC and InvaGen Pharmaceuticals, Inc.; Lupin Limited; Taro Pharmaceutical Industries Ltd.; Zenara Pharma Private Limited and Biophore Pharma, Inc.; MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc.; Alkem Laboratories Ltd.; and Ascent Pharmaceuticals, Inc. (hereinafter referred to as the “Epidiolex ANDA Filers”), that they have each filed with FDA an ANDA for a generic version of Epidiolex (cannabidiol) oral solution. As of the date of this filing, we are not aware of other ANDA filers. The notices from the Epidiolex ANDA Filers each included a “paragraph IV certification” with respect to certain of our patents listed in FDA’s Orange Book for Epidiolex on the date of the receipt of the notice. The listed patents relate generally to the composition and method of use of Epidiolex, and methods of treatment using Epidiolex. A paragraph IV certification is a certification by a generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product. On January 3, 2023, we filed a patent infringement suit against the Epidiolex ANDA Filers in the United States District Court for the District of New Jersey. The complaint alleges that by filing their ANDAs, the Epidiolex ANDA Filers have infringed certain of our Orange Book listed patents, and seeks an order that the effective date of FDA approval of the ANDAs shall be a date no earlier than the expiration of the last to expire of the asserted patents. As a result of this lawsuit, we expect that a stay of approval of up to 30 months will be imposed by FDA on the Epidiolex ANDA Filers’ ANDAs. From March 2023 through May 2023, we received the Epidiolex ANDA Filers’ answers to the complaint. The answers include defenses and counterclaims asserting that the Epidiolex ANDA Filers’ products, if launched would not infringe our patents, that our patents are invalid, and in one instance, counterclaims related to allegations of inequitable conduct and improper listing of patents in the Orange Book. On May 25, 2023, we filed a motion to dismiss certain of the counterclaims. On January 11, 2024, the Court issued an order granting in part and denying in part our motion to dismiss. The Court in the Epidiolex Patent Litigation scheduled trial for September 2025. In June and July 2023, we received notice from certain of the Epidiolex ANDA Filers that they had each filed a paragraph IV certification regarding a newly-issued patent listed in the Orange Book for Epidiolex. On July 21, 2023, we filed an additional lawsuit against all of the Epidiolex ANDA Filers in the United States District Court for the District of New Jersey alleging that, by filing its ANDA, each Epidiolex ANDA Filer infringed the newly-issued patent related to a method of treatment using Epidiolex. The suit seeks an order that the effective date of FDA approval of each Epidiolex ANDA Filer’s application shall be a date no earlier than the expiration of the newly-issued patent. On October 24, 2023, we entered into a settlement agreement with Padagis US LLC, or Padagis, that resolved our patent litigation with Padagis related to Epidiolex. Under the settlement agreement, we granted

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity Share Repurchase Program In November 2016, our board of directors authorized a share repurchase program and as of December 31, 2023, had authorized the repurchase of up to $1.5 billion, exclusive of any brokerage commissions. Under this program, which has no expiration date, we may repurchase ordinary shares from time to time on the open market. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the May 2021 credit agreement, corporate and regulatory requirements and market conditions. The share repurchase program may be modified, suspended or discontinued at any time without prior notice. In 2023, we spent a total of $269.8 million to purchase 2.1 million of our ordinary shares under the share repurchase program at an average total purchase price, including commissions, of $126.65 per share. In 2022, we spent a total of $0.1 million to repurchase 338 of our ordinary shares at a total purchase price, including brokerage commissions, of $160.70 per share. As of December 31, 2023, the remaining amount authorized under the share repurchase program was $161.4 million, exclusive of any brokerage commissions. Authorized But Unissued Ordinary Shares We had reserved the following shares of authorized but unissued ordinary shares (in thousands): December 31, 2023 2022 2011 Equity Incentive Plan 22,855 23,689 2007 Employee Stock Purchase Plan 3,913 4,069 GW Incentive Plans 1,570 1,707 Amended and Restated 2007 Non-Employee Directors Stock Award Plan 714 755 Total 29,052 30,220 Dividends

Comprehensive Income (Loss)

Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) includes net income (loss) and all changes in shareholders’ equity during a period, except for those changes resulting from investments by shareholders or distributions to shareholders. Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss as of December 31, 2023 and 2022 were as follows (in thousands): Net Unrealized Foreign Total Balance at December 31, 2022 $ — $ (1,125,509) $ (1,125,509) Other comprehensive income before reclassifications 3,658 283,127 286,785 Amounts reclassified from accumulated other comprehensive income (loss) (3,423) — (3,423) Other comprehensive income, net 235 283,127 283,362 Balance at December 31, 2023 $ 235 $ (842,382) $ (842,147) In 2023, other comprehensive income primarily reflects foreign currency translation adjustments due to the strengthening of the sterling and the euro against the U.S. dollar.

Net Income (Loss) per Ordinary

Net Income (Loss) per Ordinary Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Net Income (Loss) per Ordinary Share	Net Income (Loss) per Ordinary Share Basic net income (loss) per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income (loss) per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income (loss) per ordinary share were computed as follows (in thousands, except per share amounts): Year Ended December 31, 2023 2022 2021 Numerator: Net income (loss) $ 414,832 $ (224,060) $ (329,668) Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax 24,876 — — Net income (loss) for dilutive net income (loss) per ordinary share $ 439,708 $ (224,060) $ (329,668) Denominator: Weighted-average ordinary shares used in per share calculations - basic 63,291 62,539 59,694 Dilutive effect of Exchangeable Senior Notes 8,016 — — Dilutive effect of employee equity incentive and purchase plans 759 — — Weighted-average ordinary shares used in per share calculations - diluted 72,066 62,539 59,694 Net income (loss) per ordinary share: Basic $ 6.55 $ (3.58) $ (5.52) Diluted $ 6.10 $ (3.58) $ (5.52) Potentially dilutive ordinary shares from our employee equity incentive and purchase plans are determined by applying the treasury stock method to the assumed vesting of outstanding restricted stock units, or RSUs, and PRSUs, the assumed exercise of share options and the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP. On January 1, 2022, we adopted ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” on a modified retrospective basis, which requires the use of the if-converted method to calculate potentially dilutive ordinary shares for convertible instruments. In August 2023, we made an irrevocable election to fix the settlement method for exchanges of the 2024 Notes to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the 2024 Notes of $1,000. As a result, the assumed issuance of ordinary shares upon exchange of the 2024 Notes has only been included in the calculation of diluted net income per ordinary share in 2023 up to the date the irrevocable election was made. The potential issue of ordinary shares upon exchange of the Exchangeable Senior Notes was anti-dilutive and had no impact on diluted net loss per ordinary share for 2022. In 2021, potentially dilutive ordinary shares from the Exchangeable Senior Notes were determined by applying the treasury stock method to the assumed issuance of ordinary shares upon exchange of the Exchangeable Senior Notes. The average price of our ordinary shares in 2021 exceeded the effective exchange price per ordinary share of the 2026 Notes. However, the potential ordinary shares issuable upon exchange were excluded from the calculation of diluted net loss per ordinary shares because their effect would have been anti-dilutive. The average price of our ordinary shares in 2021 did not exceed the effective exchange price per ordinary share of the 2021 Notes and 2024 Notes. The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income (loss) per ordinary share for the years presented because including them would have an anti-dilutive effect (in thousands): Year Ended December 31, 2023 2022 2021 Employee equity incentive and purchase plans 2,973 2,751 3,927 Exchangeable Senior Notes — 9,044 9,725

Segment and Other Information

Segment and Other Information	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment and Other Information	Segment and Other Information Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs. The following table presents total long-lived assets by location (in thousands): December 31, 2023 2022 Ireland $ 68,201 $ 71,276 United Kingdom 80,293 143,870 United States 59,440 63,559 Italy 20,942 15,768 Other 6,110 6,904 Total long-lived assets (1) $ 234,986 $ 301,377 _________________________ (1) Long-lived assets consist of property, plant and equipment and operating lease assets.

Revenues

Revenues	12 Months Ended
	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenues	Revenues The following table presents a summary of total revenues (in thousands): Year Ended December 31, 2023 2022 2021 Xywav $ 1,272,977 $ 958,425 $ 535,297 Xyrem 569,730 1,020,453 1,265,830 Epidiolex/Epidyolex 845,468 736,398 463,645 Sativex 19,668 16,825 12,707 Sunosi 1 — 28,844 57,914 Total Neuroscience 2,707,843 2,760,945 2,335,393 Rylaze 394,226 281,659 85,629 Zepzelca 289,533 269,912 246,808 Defitelio/defibrotide 184,000 194,290 197,931 Vyxeos 147,495 127,980 134,060 Erwinaze/Erwinase — — 69,382 Total Oncology 1,015,254 873,841 733,810 Other 13,846 6,643 9,798 Product sales, net 3,736,943 3,641,429 3,079,001 High-sodium oxybate AG royalty revenue 75,918 — — Other royalty and contract revenues 21,343 17,945 15,237 Total revenues $ 3,834,204 $ 3,659,374 $ 3,094,238 ____________________________ (1) Divestiture of Sunosi U.S. was completed in May 2022. The following table presents a summary of total revenues attributed to geographic sources (in thousands): Year Ended December 31, 2023 2022 2021 United States $ 3,489,977 $ 3,370,379 $ 2,820,242 Europe 269,243 239,638 230,158 All other 74,984 49,357 43,838 Total revenues $ 3,834,204 $ 3,659,374 $ 3,094,238 The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Year Ended December 31, 2023 2022 2021 ESSDS 48 % 56 % 60 % McKesson 11 % 11 % 12 % Financing and payment Our payment terms vary by the type and location of our customer, but payment is generally required in a term ranging from 30 to 65 days.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation GW Incentive Plans On May 5, 2021, Jazz Pharmaceuticals plc acquired the entire issued share capital of GW Pharmaceuticals plc. In connection with the GW Acquisition, we assumed the GW Pharmaceuticals plc 2008 Long-Term Incentive Plan, GW Pharmaceuticals plc 2017 Long-Term Incentive Plan and GW Pharmaceuticals plc 2020 Long-Term Incentive Plan, each as amended from time to time, together referred to as the GW Incentive Plans. The terms of the GW Incentive Plans provide for the grant of stock options, stock appreciation rights, RSUs, other stock awards, and performance awards that may be settled in cash, shares, or other property. Ordinary shares granted to employees in exchange for GW ADS in connection with the GW Acquisition vest ratably over service periods of two years, while all post-acquisition grants vest ratably over service periods of four years and expire no more than 10 years after the date of grant. As of December 31, 2023, a total of 1,864,475 of our ordinary shares had been authorized for issuance under the GW Incentive Plans. 2011 Equity Incentive Plan On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction, or the Azur Merger. In connection with the Azur Merger, Jazz Pharmaceuticals, Inc.’s board of directors adopted the 2011 Equity Incentive Plan, or the 2011 Plan, in October 2011 and its stockholders approved the 2011 Plan at the special meeting of the stockholders held in December 2011 in connection with the Azur Merger. The 2011 Plan became effective immediately before the consummation of the Azur Merger and was assumed and adopted by us upon the consummation of the Azur Merger. The terms of the 2011 Plan provide for the grant of stock options, stock appreciation rights, RSUs, other stock awards, and performance awards that may be settled in cash, shares, or other property. All outstanding grants under the 2011 Plan were granted to employees and vest ratably over service periods of four years and expire no more than 10 years after the date of grant. As of December 31, 2023, a total of 34,836,988 of our ordinary shares had been authorized for issuance under the 2011 Plan. 2007 Employee Stock Purchase Plan In 2007, Jazz Pharmaceuticals, Inc.’s employees became eligible to participate in the ESPP. The ESPP was amended and restated by Jazz Pharmaceuticals, Inc.’s board of directors in October 2011 and approved by its stockholders in December 2011. The amended and restated ESPP became effective immediately prior to the effective time of the Azur Merger and was assumed by us upon the consummation of the Azur Merger. The amended and restated ESPP allows our eligible employee participants (including employees of any parent or subsidiary company if our board of directors designates such company as eligible to participate) to purchase our ordinary shares at a discount of 15% through payroll deductions. The ESPP consists of a fixed offering period of 24 months with four purchase periods within each offering period. The number of shares available for issuance under our ESPP during any six-month purchase period is 175,000 shares. As of December 31, 2023, a total of 7,029,250 of our ordinary shares had been authorized for issuance under the ESPP. Amended and Restated 2007 Non-Employee Directors Stock Award Plan The Amended and Restated 2007 Non-Employee Directors Stock Award Plan, or the 2007 Directors Award Plan, which was initially adopted by the Jazz Pharmaceuticals, Inc. board of directors and approved by the Jazz Pharmaceuticals, Inc. stockholders in connection with its initial public offering, was continued and assumed by us upon the consummation of the Azur Merger. Until October 2011, the 2007 Directors Award Plan provided for the automatic grant of stock options to purchase shares of Jazz Pharmaceuticals, Inc.’s common stock to its non-employee directors initially at the time any individual first became a non-employee director, which vest over three years, and then annually over their period of service on its board of directors, which vest over one year. On October 24, 2011, Jazz Pharmaceuticals, Inc.’s board of directors amended the 2007 Directors Award Plan to eliminate all future initial and annual automatic grants so that future automatic grants would not be made that would be subject to the excise tax imposed by Section 4985 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, in connection with the Azur Merger. Accordingly, all future stock option grants under the 2007 Directors Award Plan will be at the discretion of our board of directors. Since the Azur Merger, all of the new grants under the 2007 Directors Award Plan were granted to non-employee directors and vest ratably over service periods of one Share-Based Compensation Share-based compensation expense related to share options, RSUs, PRSUs and grants under our ESPP was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Selling, general and administrative $ 146,942 $ 151,986 $ 135,285 Research and development 64,847 57,522 43,758 Cost of product sales 15,052 12,488 9,963 Total share-based compensation expense, pre-tax 226,841 221,996 189,006 Income tax benefit from share-based compensation expense (40,015) (41,058) (33,958) Total share-based compensation expense, net of tax $ 186,826 $ 180,938 $ 155,048 We recognized income tax benefits related to share option exercises of $1.9 million, $8.0 million and $9.3 million in 2023, 2022 and 2021, respectively. Restricted Stock Units In 2023, 2022 and 2021, we granted RSUs covering an equal number of our ordinary shares to employees with a weighted-average grant date fair value of $144.65, $152.08 and $168.10, respectively. The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares as of that date. The fair value of the RSUs is recognized as an expense ratably over the vesting period of four years. In 2023, 2022 and 2021, 1,094,000, 910,000 and 692,000 RSUs were released, respectively, with 735,000, 610,000 and 465,000 ordinary shares issued, respectively, and 359,000, 300,000 and 227,000 ordinary shares withheld for tax purposes, respectively. The total fair value of shares vested was $155.5 million, $138.1 million and $109.2 million during 2023, 2022 and 2021, respectively. As of December 31, 2023, total compensation cost not yet recognized related to unvested RSUs was $307.7 million, which is expected to be recognized over a weighted-average period of 2.4 years. The following table summarizes information as of December 31, 2023 and activity during 2023 related to our RSUs: Number of RSUs (In thousands) Weighted- Weighted- Aggregate Outstanding at January 1, 2023 3,209 $ 151.11 RSUs granted 1,768 144.65 RSUs released (1,094) 148.68 RSUs forfeited (320) 149.54 Outstanding at December 31, 2023 3,563 $ 148.79 1.3 $ 438,224 Performance-Based Restricted Stock Units The Compensation & Management Development Committee of our board of directors, and in the case of our Chief Executive Officer, the independent members of our board of directors, approved awards of PRSUs to certain employees of the Company, subject to vesting on the achievement of certain commercial and pipeline performance criteria to be assessed over a performance period from the date of the grant to December 31, 2023, December 31, 2024 and December 31, 2025, respectively. Following the determination of the Company’s achievement with respect to the performance criteria, the amount of shares awarded will be subject to adjustment based on the application of a relative TSR modifier. The number of shares that may be earned ranges between 0% and 200% of the target number of PRSUs granted based on the degree of achievement of the applicable performance metric and the application of the relative TSR modifier. The following table summarizes information as of December 31, 2023 and activity during 2023 related to our PRSUs: Number of PRSUs (In thousands) Weighted- Weighted- Aggregate Outstanding at January 1, 2023 440 $ 183.68 PRSUs granted 271 156.91 PRSUs forfeited (47) 176.06 Outstanding at December 31, 2023 664 $ 173.30 1.5 $ 81,729 As of December 31, 2023, total compensation cost not yet recognized related to unvested PRSUs was $24.6 million, which is expected to be recognized over a weighted-average period of 1.5 years. As the PRSUs granted in each year are subject to a market condition, the grant date fair value for such PRSUs was based on a Monte Carlo simulation model. In 2023, 2022 and 2021, we granted PRSUs to employees with a weighted-average grant date fair value of $156.91, $178.78 and $190.81, respectively. The Company evaluated the performance targets in the context of its current long-range financial plan and its product candidate development pipeline and recognized compensation expense based on the probable number of awards that will ultimately vest. Share Options There were no share options granted in 2023 and 2022. The table below shows, for market strike price option grants, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of market strike price options granted in 2021: Year Ended Grant date fair value $ 51.39 Volatility 37 % Expected term (years) 4.5 Range of risk-free rates 0.4-0.8% Expected dividend yield — % We relied on a blend of the historical and implied volatilities of our own ordinary shares to determine expected volatility for share option grants. In addition, we used a single volatility estimate for each share option grant. The weighted-average volatility was determined by calculating the weighted average of volatilities for all share options granted in a given year. The expected term of share option grants represented the weighted-average period the awards were expected to remain outstanding and our estimates were based on historical exercise data. The risk-free interest rate assumption was based on zero coupon U.S. Treasury instruments whose term was consistent with the expected term of our share option grants. The expected dividend yield assumption was based on our history and expectation of dividend payouts. The following table summarizes information as of December 31, 2023 and activity during 2023 related to our share option plans: Shares Weighted- Weighted- Aggregate Outstanding at January 1, 2023 3,189 $ 140.64 Options exercised (251) 120.29 Options forfeited (16) 133.93 Options expired (206) 153.92 Outstanding at December 31, 2023 2,716 $ 141.55 4.1 $ 3,900 Vested and expected to vest at December 31, 2023 2,715 $ 141.55 4.1 $ 3,896 Exercisable at December 31, 2023 2,669 $ 141.69 4.1 $ 3,669 Aggregate intrinsic value shown in the table above is equal to the difference between the exercise price of the underlying share options and the fair value of our ordinary shares for share options that were in the money. The aggregate intrinsic value changes based on the fair market value of our ordinary shares. The aggregate intrinsic value of share options exercised was $6.3 million, $34.8 million and $51.8 million during 2023, 2022 and 2021, respectively. We issued new ordinary shares upon exercise of share options. As of December 31, 2023, total compensation cost not yet recognized related to unvested share options was $1.5 million, which is expected to be recognized over a weighted-average period of 0.5 years. As of December 31, 2023, total compensation cost not yet recognized related to grants under the ESPP was $11.3 million, which is expected to be recognized over a weighted-average period of 1.2 years. Nominal Strike Price Options During the second quarter of 2021, we issued nominal strike price options to replace certain unvested GW awards in connection with the GW Acquisition with a weighted-average grant date fair value of $170.82. The fair value of nominal strike price options was determined on the date of the grant based on the market price of our ordinary shares as of that date. The following table summarizes information as of December 31, 2023 and activity during 2023 related to our nominal strike price options: Shares Weighted- Weighted- Aggregate Outstanding at January 1, 2023 56 $ 0.02 Options exercised (29) 0.02 Outstanding at December 31, 2023 27 $ 0.02 6.4 $ 3,357 Vested and expected to vest at December 31, 2023 27 $ 0.02 6.4 $ 3,357 Exercisable at December 31, 2023 27 $ 0.02 6.4 $ 3,357 The aggregate intrinsic value of nominal strike price options exercised was $3.9 million, $8.4 million and $0.2 million during 2023, 2022 and 2021, respectively. We issued new ordinary shares upon exercise of nominal strike price options.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans We maintain a qualified 401(k) savings plan, in which all U.S. based employees are eligible to participate, provided they meet the requirements of the plan. We match certain employee contributions under the 401(k) savings plan and for the years ended December 31, 2023, 2022 and 2021 we recorded expense of $13.4 million, $10.6 million and $9.1 million, respectively, related to this plan. We also operate a number of defined contribution retirement plans for certain non-U.S. based employees. Expenses related to contributions to such plans for the years ended December 31, 2023, 2022 and 2021 were $14.0 million, $14.6 million and $11.4 million, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of income (loss) before income tax expense (benefit) and equity in loss of investees were as follows (in thousands): Year Ended December 31, 2023 2022 2021 Ireland $ 449,214 $ (50,311) $ 97,557 United Kingdom (643,096) (963,598) (681,291) United States (6,056) 224,453 221,185 Other 497,867 416,672 249,711 Total $ 297,929 $ (372,784) $ (112,838) The following table sets forth the details of income tax expense (benefit) (in thousands): Year Ended December 31, 2023 2022 2021 Current Ireland $ 77,343 $ 61,550 $ 25,770 United Kingdom 7,726 1,454 (924) United States 20,803 37,823 88,850 Other 34,433 32,779 33,222 Total current tax expense 140,305 133,606 146,918 Deferred, exclusive of other components below Ireland (10,919) (62,011) (5,388) United Kingdom (150,506) (193,219) (111,534) United States (89,246) (9,086) (46,531) Other (8,990) (11,144) (28,604) Total deferred, exclusive of other components (259,661) (275,460) (192,057) Deferred, change in tax rates United Kingdom 268 (16,990) 259,873 United States (824) 201 1,377 Other — (2) 5 Total deferred, change in tax rates (556) (16,791) 261,255 Total deferred tax expense (benefit) (260,217) (292,251) 69,198 Total income tax expense (benefit) $ (119,912) $ (158,645) $ 216,116 Our income tax benefit was $119.9 million and $158.6 million in 2023 and 2022, respectively, and our income tax expense was $216.1 million in 2021, relating to tax arising on income or losses in Ireland, the U.K., the U.S. and certain other foreign jurisdictions, offset by deductions on subsidiary equity, foreign derived intangible income benefits and originating tax credits. Our income tax benefit in 2023 decreased compared to 2022 primarily due to pretax losses from payments for acquired IPR&D made in 2022 and the 2022 impairment of our acquired IPR&D asset as a result of the decision to discontinue our nabiximols program partially offset by the change in income mix across jurisdictions. Our income tax expense in 2021 included an expense of $259.9 million arising on the remeasurement of our U.K. net deferred tax liability, which arose primarily in relation to the GW Acquisition, due to a change in the statutory tax rate in the U.K. following enactment of the U.K. Finance Act 2021. The reconciliation between income tax expense (benefit) at the Irish statutory trading income tax rate of 12.5 percent, the jurisdiction of tax domicile of Jazz Pharmaceuticals, applied to income before the income tax expense (benefit) and equity in loss of investees and our reported income tax expense (benefit) was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Income tax expense (benefit) at the statutory income tax rate $ 37,241 $ (46,598) $ (14,105) Deduction on subsidiary equity (153,655) (158,488) (116,438) Change in valuation allowance 75,081 95,051 81,280 Research and other tax credits (49,900) (27,976) (31,069) Foreign derived intangible income benefit (42,400) (29,541) (3,416) Non-deductible facility expense 16,618 8,093 — Non-deductible financing costs 15,705 4,504 14,418 Non-deductible compensation 14,092 13,505 19,914 Patent box incentive benefit (13,862) (6,203) — Change in unrecognized tax benefits (12,612) 5,029 (6,436) Foreign income tax rate differential (7,763) 5,863 (4,343) Change in estimates (5,472) (14,065) (2,653) Tax deficiencies/(excess tax benefits) from share-based compensation 3,959 (1,690) (5,555) Change in tax rate (605) (16,790) 261,663 Non-deductible royalty expense — 6,274 — Non-deductible acquisition-related costs — — 20,929 Other 3,661 4,387 1,927 Reported income tax expense (benefit) $ (119,912) $ (158,645) $ 216,116 Significant components of our net deferred tax assets (liabilities) were as follows (in thousands): December 31, 2023 2022 Deferred tax assets: Operating loss carryforwards $ 296,490 $ 263,235 Intangible assets 238,062 236,462 Deduction on subsidiary equity carryforwards 212,015 157,367 Capitalized research and development 201,186 88,009 Tax credit carryforwards 142,854 189,792 Accrued liabilities 128,948 109,257 Share-based compensation 48,403 42,795 Indirect effects of unrecognized tax benefits 40,811 47,224 Lease liabilities 13,415 14,081 Other 5,925 11,595 Total deferred tax assets 1,328,109 1,159,817 Valuation allowance (312,340) (234,732) Deferred tax assets, net of valuation allowance 1,015,769 925,085 Deferred tax liabilities: Intangible assets (1,290,425) (1,367,146) Inventories (81,995) (110,927) Operating lease assets (10,628) (10,978) Other (2,593) (4,124) Total deferred tax liabilities (1,385,641) (1,493,175) Net deferred tax liabilities $ (369,872) $ (568,090) The net change in valuation allowance was an increase of $77.6 million, $80.5 million and $76.9 million in 2023, 2022 and 2021, respectively. The following table summarizes the presentation of deferred tax assets and liabilities (in thousands): December 31, 2023 2022 Deferred tax assets $ 477,834 $ 376,247 Deferred tax liabilities (847,706) (944,337) Net deferred tax liabilities $ (369,872) $ (568,090) As of December 31, 2023, we had net operating losses, or NOL, carryforwards and tax credit carryforwards for U.S. federal income tax purposes of approximately $15.2 million and $47.2 million, respectively, available to reduce future income subject to income taxes. The U.S. federal NOL carryforwards will expire, if not utilized, in the tax years 2024 to 2033 and the U.S. federal tax credits will expire, if not utilized, in the tax years 2024 to 2043. In addition, we had approximately $13.5 million of NOL carryforwards and $6.4 million of tax credit carryforwards as of December 31, 2023 available to reduce future taxable income for U.S. state income tax purposes. The U.S. state NOL carryforwards will expire, if not utilized, in the tax years 2024 to 2034. As of December 31, 2023, there were NOL and other carryforwards for income tax purposes of approximately $1,017.5 million, $605.8 million and $295.5 million available to reduce future income subject to income taxes in the United Kingdom, Malta and Ireland respectively. The NOLs and other carryforwards generated in the United Kingdom, Malta and Ireland have no expiration date. We also had foreign tax credit carryforwards in Ireland, as of December 31, 2023, of $89.0 million, which may only be utilized against certain sources of income. The foreign tax credit carryforwards have no expiration date. Utilization of certain of our NOL and tax credit carryforwards in the U.S. is subject to an annual limitation due to the ownership change limitations provided by Sections 382 and 383 of the Internal Revenue Code and similar state provisions. Such an annual limitation may result in the expiration of certain NOLs and tax credits before future utilization. In addition, as a result of the Azur Merger, until 2022 we were subject to certain limitations under the Internal Revenue Code in relation to the utilization of U.S. NOLs to offset U.S. taxable income resulting from certain transactions. Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required by tax-paying component. Our valuation allowance was $312.3 million and $234.7 million as of December 31, 2023 and 2022, respectively, for certain Irish, U.S. (federal and state) and foreign deferred tax assets which we maintain until sufficient positive evidence exists to support reversal. As part of the overall change in valuation allowance, we recognized a net income tax expense of $76.2 million, $95.1 million and $81.3 million in 2023, 2022 and 2021, respectively, relating primarily to the creation of a valuation allowance against certain deferred tax assets primarily associated with temporary differences related to carryforwards in foreign subsidiaries and foreign tax credit carryforwards. We periodically evaluate the likelihood of the realization of deferred tax assets and will adjust such amounts in light of changing facts and circumstances including, but not limited to, future projections of taxable income, tax legislation, rulings by relevant taxing authorities, the progress of tax examinations and the regulatory approval of products currently under development. Realization of the deferred tax assets is dependent on future taxable income. The Company believes that it is more likely than not to generate sufficient taxable income to realize the deferred tax assets carried as of December 31, 2023 for which no valuation allowance has been recognized. No provision has been made for income tax on undistributed earnings of the Company’s foreign subsidiaries where such earnings are considered indefinitely reinvested in the foreign operations. Temporary differences related to such earnings totaled approximately $1.6 billion as of December 31, 2023. In the event of the distribution of those earnings in the form of dividends, a sale of the subsidiaries, or certain other transactions, we may be liable for income taxes, subject to an adjustment, if any, for foreign tax credits. The Company estimates that it would incur additional income taxes of up to approximately $79.8 million on repatriation of these unremitted earnings to Ireland. We only recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have recorded an unrecognized tax benefit for certain tax positions which we judge may not be sustained upon examination. A reconciliation of our unrecognized tax benefits follows (in thousands): December 31, 2023 2022 2021 Balance at the beginning of the year $ 143,976 $ 137,867 $ 146,557 Increases related to current year tax positions 15,004 25,128 26,675 Increases related to prior year tax positions 224 2,794 211 Decreases related to prior year tax positions (12,702) (164) (182) Increases recognized through purchase accounting — — 5,916 Decreases related to settlements with taxing authorities — (223) (14,744) Lapse of the applicable statute of limitations (23,808) (21,426) (26,566) Balance at the end of the year $ 122,694 $ 143,976 $ 137,867 The unrecognized tax benefits were included in income taxes payable, other non-current liabilities and deferred tax assets, net, in our consolidated balance sheets. Interest related to income taxes is recorded in the income tax expense (benefit) in our consolidated statements of income (loss). As of December 31, 2023 and 2022, our accrued interest related to income taxes was $8.4 million and $5.8 million, respectively. Interest related to income taxes recognized in the consolidated statements of income (loss) were not significant. Included in the balance of unrecognized tax benefits were potential benefits of $77.1 million and $91.7 million at December 31, 2023 and 2022, respectively, that, if recognized, would affect the effective tax rate on income. The Company believes that it is reasonably possible that approximately $26.5 million of its currently remaining unrecognized tax benefits may be recognized by the end of 2024 as a result of a lapse of the statute of limitations. We file income tax returns in multiple tax jurisdictions, the most significant of which are Ireland, the U.K. and the U.S. (both at the federal level and in various state jurisdictions). For Ireland we are no longer subject to income tax examinations by taxing authorities for the years prior to 2019. For the U.K. we are no longer subject to income tax examinations by taxing authorities for the years prior to 2016. The U.S. jurisdictions generally have statute of limitations three to four years from the later of the return due date or the date when the return was filed. However, in the U.S. (at the federal level and in most states), carryforwards that were generated in 2019 and earlier may still be adjusted upon examination by the taxing authorities. Certain of our Luxembourg subsidiaries are currently under examination by the Luxembourg taxing authorities for the years ended December 31, 2017, 2018 and 2019. In October 2022 and January 2023, we received tax assessment notices from the Luxembourg taxing authorities for all open tax years relating to certain transfer pricing and other adjustments. The notices propose additional Luxembourg income tax of approximately $24.7 million, translated at the foreign exchange rate as at December 31, 2023. We disagree with the proposed assessments and are contesting them vigorously.

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II Valuation and Qualifying Accounts	Schedule II Valuation and Qualifying Accounts (In thousands) Balance at Additions charged to costs and expenses Other Additions Deductions Balance at For the year ended December 31, 2023 Allowance for doubtful accounts (1) $ 242 $ — $ — $ — $ 242 Allowance for sales discounts (1) 2,980 22,334 — (19,352) 5,962 Allowance for chargebacks (1) 14,621 185,886 — (185,575) 14,932 Deferred tax asset valuation allowance (2)(4) 234,732 76,670 1,368 (430) 312,340 For the year ended December 31, 2022 Allowance for doubtful accounts (1) $ 298 $ — $ — $ (56) $ 242 Allowance for sales discounts (1) 2,126 20,133 — (19,279) 2,980 Allowance for chargebacks (1) 11,389 135,854 — (132,622) 14,621 Deferred tax asset valuation allowance (2)(4) 154,255 95,947 — (15,470) 234,732 For the year ended December 31, 2021 Allowance for doubtful accounts (1) $ 50 $ 127 $ 771 $ (650) $ 298 Allowance for sales discounts (1) 144 13,196 1,243 (12,457) 2,126 Allowance for chargebacks (1) 5,293 91,425 1,322 (86,651) 11,389 Deferred tax asset valuation allowance (2)(3)(4) 77,342 82,820 9 (5,916) 154,255 __________________________ (1) Shown as a reduction of accounts receivable. Charges related to sales discounts and chargebacks are reflected as a reduction of revenue. (2) Additions to the deferred tax asset valuation allowance charged to costs and expenses relate to movements on certain Irish, U.S. (federal and state) and other foreign deferred tax assets where we continue to maintain a valuation allowance until sufficient positive evidence exists to support reversal. (3) Other additions to the deferred tax asset valuation allowance in 2021 relate to currency translation adjustments recorded directly in other comprehensive income. (4)

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pay vs Performance Disclosure
Net (loss) income	$ 414,832	$ (224,060)	$ (329,668)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, and include the accounts of Jazz Pharmaceuticals plc and our subsidiaries. Intercompany transactions and balances have been eliminated. Our consolidated financial statements include the results of operations of businesses we have acquired from the date of each acquisition for the applicable reporting periods.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.
Adoption of New Accounting Standards and Recent Accounting Pronouncements	Adoption of New Accounting Standards In October 2021, the Financial Accounting Standards Board issued ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, or ASU 2021-08, which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 was effective for the Company from January 1, 2023 and adoption did not have a material impact on our consolidated financial statements. We will apply to future business combinations, if any. Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures”, which requires enhanced disclosures about significant segment expenses. The amendments are effective retrospectively to all prior periods presented in the financial statements, for fiscal years beginning after December 15, 2023. We are currently evaluating the impact of adopting this new accounting guidance. In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740) - Improvements to Income Tax Disclosures”, which requires additional enhanced tax disclosures. The amendments are effective on a prospective basis, with the option to apply it retrospectively, for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of adopting this new accounting guidance.
Significant Risks and Uncertainties	Significant Risks and Uncertainties Historically, our business was substantially dependent on Xyrem and while we expect that our business will continue to meaningfully depend on oxybate revenues from both Xywav and Xyrem, there is no guarantee that oxybate revenues will remain at current levels, or that oxybate revenues will otherwise grow in future periods. In this regard, our ability to maintain or increase oxybate revenues and realize the anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties including, without limitation, those related to the launch of Xywav for the treatment of IH in adults and adoption in that indication; competition from the recent introduction of two authorized generic, or AG, versions of high-sodium oxybate and new products, such as Avadel’s Lumryz, for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market, as well as potential future competition from additional AG versions of high-sodium oxybate and from generic versions of high-sodium oxybate and from other competitors; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for Xywav and Xyrem; increased rebates required to maintain access to our products; challenges to our intellectual property around Xywav and/or Xyrem, including from pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients . A significant decline in oxybate revenues could cause us to reduce our operating expenses or seek to raise additional funds, which would have a material adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license or develop new products to grow our business. In addition to risks related specifically to Xywav and Xyrem, we are subject to other challenges and risks related to successfully commercializing a portfolio of oncology products and other neuroscience products, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: ongoing clinical research activity and related outcomes, obtaining regulatory approval of our late-stage product candidates; effectively commercializing our approved or acquired products such as Epidiolex, Rylaze and Zepzelca; obtaining and maintaining adequate coverage and reimbursement for our products; contracting and rebates to pharmacy benefit managers and similar organizations that reduce our net revenue; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws and policy; market acceptance; regulatory concerns with controlled substances generally and the potential for abuse; future legislation, action by the U.S. Federal Government authorizing the sale, distribution, use, and insurance reimbursement of non-FDA approved cannabinoid products;
Concentrations of Risk	Concentrations of Risk Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet. We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.
Business Acquisitions	Business Acquisitions Our consolidated financial statements include the results of operations of an acquired business from the date of acquisition. We account for acquired businesses using the acquisition method of accounting. The acquisition method of accounting for acquired businesses requires, among other things, that assets acquired, liabilities assumed and any noncontrolling interests in the acquired business be recognized at their estimated fair values as of the acquisition date, with limited exceptions, and that the fair value of acquired in-process research and development, or IPR&D, be recorded on the balance sheet. Also, transaction costs are expensed as incurred. Any excess of the acquisition consideration over the assigned values of the net assets acquired is recorded as goodwill. Contingent consideration is included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized in earnings.
Cash Equivalents and Investments	Cash Equivalents and Investments We consider all highly liquid investments, readily convertible to cash, that mature within three months or less from date of purchase to be cash equivalents. Investments consist of time deposits with initial maturities of greater than three months. Collectively, cash equivalents and investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses, net of tax, are recorded in accumulated other comprehensive loss in shareholders’ equity. We use the specific-identification method for calculating realized gains and losses on securities sold. Realized gains and losses and declines in value judged to be other than temporary on investments are included in interest expense, net in the consolidated statements of income (loss).
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities We record the fair value of derivative instruments as either assets or liabilities on the consolidated balance sheets. Changes in the fair value of derivative instruments are recorded each period in current earnings or other comprehensive income (loss), depending on whether a derivative instrument is designated as part of a hedging transaction and, if it is, the type of hedging transaction. For a derivative to qualify as a hedge at inception and throughout the hedged period, we formally document the nature and relationships between the hedging instruments and hedged item. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Gains or losses on cash flow hedges are reclassified from other comprehensive income (loss) to earnings when the hedged transaction occurs. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting and any related unrealized gain or loss on the derivative instrument is recognized in current earnings. We designate cross-currency interest rate swaps as fair value hedges to hedge foreign currency risks related to our borrowings denominated in currencies other than the U.S. dollar. Fair value hedge amounts included in the assessment of hedge effectiveness are recognized in foreign exchange gain (loss) within the consolidated statements of income (loss), along with the offsetting gains and losses of the related hedged item. We have elected to exclude the total forward points or currency basis from the assessment of hedge effectiveness and account for them as excluded components. The initial fair value of the excluded component is amortized to foreign exchange gain (loss) and the difference between changes in fair value of the excluded component and the amount recorded in earnings is recorded in other comprehensive income (loss). Derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current e arnings.
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales. We capitalize inventory costs associated with our products prior to regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other impediments to obtaining regulatory approval. We had no pre-approval inventory on our consolidated balance sheet as of December 31, 2023 or 2022. Our inventory production process for our cannabinoid products includes the cultivation of botanical raw material. Because of the duration of the cultivation process, a portion of our inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are as follows: Buildings 40 years Manufacturing equipment and machinery 4-20 years Computer software and equipment 3-7 years Furniture and fixtures 5 years Leasehold improvements are amortized over the shorter of the noncancelable term of our leases or their economic useful lives. Maintenance and repairs are expensed as incurred.
Leases	Leases We determine if an arrangement is a lease at inception. Leases are classified at lease commencement as either operating leases or finance leases. Operating leases are included in operating lease assets, accrued liabilities, and operating lease liabilities on our consolidated balance sheets. Finance lease assets are included in property, plant and equipment, net, and finance lease liabilities are included in accrued liabilities and other non-current liabilities in our consolidated balance sheets. Lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. In determining the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The lease asset also includes any lease payments made, reduced by lease incentives and increased by initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease expense is recognized as depreciation expense of property, plant and equipment and interest expense on finance lease liabilities. We have lease agreements with lease and non-lease components, which are generally accounted for separately. For vehicle leases we account for the lease and non-lease components as a single lease component. We have elected the short-term lease exemption and, therefore, do not recognize a lease asset or corresponding liability for lease arrangements with an original term of 12 months or less. Rent expense under short-term leases is recognized on a straight-line basis over the lease term.
Goodwill, Acquired In-Process Research and Development, and Intangible Assets	Goodwill Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. We have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. In performing the annual impairment test, the fair value of the reporting unit is compared to its corresponding carrying value, including goodwill. If the carrying value exceeds the fair value of the reporting unit an impairment loss will be recognized for the amount by which the reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount of goodwill. We test goodwill for impairment annually in October and when events or changes in circumstances indicate that the carrying value may not be recoverable. Acquired In-Process Research and Development The initial costs of rights to IPR&D projects acquired in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a finite-lived intangible asset, or discontinued, at which point the intangible asset will be written off. Development costs incurred after an acquisition are expensed as incurred. Intangible Assets Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line basis over their estimated useful lives, which range from seven
Revenue Recognition and Cost of Product Sales	Revenue Recognition Our revenue comprises product sales, net and royalty and contract revenues. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Product Sales, Net Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient. Reserves for Variable Consideration Revenues from sales of products are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established and which relate to returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government rebates, government chargebacks, coupon programs and rebates under managed care plans and commercial payor contracts. Calculating certain of these reserves involves estimates and judgments and we determine their expected value based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in these programs’ regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and channel inventory data. These reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. We reassess our reserves for variable consideration at each reporting date. Historically, adjustments to estimates for these reserves have not been material. Reserves for returns, specialty distributor fees, wholesaler fees, government rebates, coupon programs and rebates under managed care plans and commercial payor contracts are included within current liabilities in our consolidated balance sheets. Reserves for government chargebacks and prompt payment discounts are shown as a reduction in accounts receivable. Royalties and Contract Revenues We enter into out-licensing agreements under which we license certain rights to our products or product candidates to third parties. If a licensing arrangement includes multiple goods or services, we consider whether the license is distinct. If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If the license to our intellectual property is determined not to be distinct, it is combined with other goods or services into a combined performance obligation. We consider whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting date and, if necessary, adjust the measure of performance and related revenue recognition. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or that of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. For arrangements that include sales-based royalties and milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties and sales-based milestones relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty or sales-based milestone has been allocated has been satisfied (or partially satisfied). Cost of Product Sales
Research and Development	Research and Development Research and development expenses consist primarily of costs related to clinical studies and outside services, personnel expenses, milestone expenses and other research and development costs, including milestone payments incurred prior to regulatory approval of products. Clinical study and outside services costs relate primarily to services performed by clinical research organizations, clinical studies performed at clinical sites, materials and supplies, and other third party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other research and development expenses primarily include overhead allocations consisting of various support and facilities-related costs. Research and development costs are expensed as incurred. For product candidates that have not been approved by FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the trial.
Advertising Expenses	Advertising Expenses
Income Taxes	Income Taxes We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amount and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to the amount that is more-likely-than-not to be realized. We recognize the benefits of a tax position if it is more-likely-than-not of being sustained. A recognized tax benefit is then measured as the largest amount of tax benefit that is greater than fifty percent likely of being realized upon settlement. Interest and penalties related to income taxes are included in the income tax expense and classified with the related liability on the consolidated balance sheets.
Foreign Currency	Foreign Currency Our functional and reporting currency is the U.S. dollar. The assets and liabilities of our subsidiaries that have a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date with the results of operations of subsidiaries translated at the weighted average exchange rate for the reporting period. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive income (loss) in shareholders’ equity. Transactions in foreign currencies are translated into the functional currency of the relevant subsidiary at the weighted average exchange rate for the reporting period. Any monetary assets and liabilities arising from these transactions are translated into the relevant functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange gain (loss) in our consolidated statements of income (loss).
Deferred Financing Costs	Deferred Financing Costs
Contingencies	Contingencies
Share-Based Compensation	Share-Based Compensation We account for compensation cost for all share-based awards at fair value on the date of grant. The fair value is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method. The estimation of share-based awards that will ultimately vest requires judgment, and, to the extent actual results or updated estimates differ from current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We primarily consider historical experience when estimating expected forfeitures. Performance-Based Restricted Stock Unit Awards Performance-based restricted stock units, or PRSUs, awarded to employees vest upon the achievement of certain performance criteria at the end of a specified performance period, subject to a relative total shareholder return, or TSR, modifier. The estimated fair value of these PRSUs is based on a Monte Carlo simulation model. Compensation expense for PRSUs is recognized from the date the Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the performance criteria until the date results are determined.
Variable Interest Entity	Variable Interest Entity

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Property, Plant and Equipment Estimated Useful Life	Estimated useful lives are as follows: Buildings 40 years Manufacturing equipment and machinery 4-20 years Computer software and equipment 3-7 years Furniture and fixtures 5 years Property, plant and equipment consisted of the following (in thousands): December 31, 2023 2022 Manufacturing equipment and machinery $ 82,897 $ 73,580 Land and buildings 70,912 68,935 Leasehold improvements 67,722 64,776 Computer software 38,134 34,116 Construction-in-progress 18,661 67,385 Computer equipment 15,398 16,424 Furniture and fixtures 9,273 10,481 Subtotal 302,997 335,697 Less accumulated depreciation and amortization (133,351) (107,647) Property, plant and equipment, net $ 169,646 $ 228,050

Collaborations, Disposition a_2

Collaborations, Disposition and Business Combination (Tables)	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Business Combination Consideration	The aggregate consideration for the GW Acquisition was $7.2 billion as follows (all amounts in thousands except American Depositary Shares, or ADS, and per GW ADS amounts): GW ADS outstanding May 5, 2021 31,556,200 Cash consideration per GW ADS $ 200 Total cash consideration to GW ADS holders $ 6,311,240 Cash consideration to GW share option holders (inclusive of payroll taxes) 267,450 Total cash consideration 6,578,690 Equity consideration to GW ADS holders (1) 608,456 Consideration related to replacement share option pre-combination service 3,555 Total equity consideration 612,011 Total purchase consideration $ 7,190,701 ________________________ (1) 3.8 million ordinary shares were issued to GW ADS holders. The closing price of the ordinary shares on May 4, 2021 ($160.20) was used to determine the fair value of this equity consideration because the closing of the transaction on May 5, 2021 occurred prior to the opening of regular trading.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of assets acquired and liabilities assumed at the Closing Date (in thousands): Fair Values of Assets Acquired and Liabilities Assumed Cash and cash equivalents $ 343,898 Accounts receivable 76,355 Inventory 1,206,290 Prepaid expenses and other current assets 72,758 Property, plant and equipment 154,407 Acquired developed technologies 5,480,000 In-process research and development 160,000 Total acquired identifiable intangible assets 5,640,000 Goodwill 933,234 Deferred tax liabilities, net (1,069,076) Accrued liabilities (131,971) Other assets/liabilities (35,194) Total purchase consideration $ 7,190,701

Cash and Available-for-Sale S_2

Cash and Available-for-Sale Securities (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments	Cash, cash equivalents and investments consisted of the following (in thousands): December 31, 2023 Amortized Gross Gross Estimated Cash and Investments Cash $ 437,724 $ — $ — $ 437,724 $ 437,724 $ — Time deposits 420,000 — — 420,000 300,000 120,000 Money market funds 768,586 — — 768,586 768,586 — Totals $ 1,626,310 $ — $ — $ 1,626,310 $ 1,506,310 $ 120,000 December 31, 2022 Amortized Gross Gross Estimated Cash and Investments Cash $ 334,018 $ — $ — $ 334,018 $ 334,018 $ — Time deposits 30,000 — — 30,000 30,000 — Money market funds 517,464 — — 517,464 517,464 — Totals $ 881,482 $ — $ — $ 881,482 $ 881,482 $ —

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes, by major security type, our available-for-sale securities and derivative contracts that were measured at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands): December 31, 2023 December 31, 2022 Quoted Significant Total Quoted Significant Total Assets: Available-for-sale securities: Time deposits $ — $ 420,000 $ 420,000 $ — $ 30,000 $ 30,000 Money market funds 768,586 — 768,586 517,464 — 517,464 Interest rate contracts — 3,784 3,784 — — — Foreign exchange forward contracts — 18,035 18,035 — 17,356 17,356 Totals $ 768,586 $ 441,819 $ 1,210,405 $ 517,464 $ 47,356 $ 564,820 Liabilities: Interest rate contracts $ — $ 3,410 $ 3,410 $ — $ — $ — Foreign exchange forward contracts — 681 681 — — — Totals $ — $ 4,091 $ 4,091 $ — $ — $ —

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Foreign Exchange Gain (Loss) of Outstanding Derivatives	The foreign exchange gain (loss) in our consolidated statements of income (loss) included the following gains and losses associated with foreign exchange contracts not designated as hedging instruments (in thousands): Year Ended December 31, Foreign Exchange Forward Contracts: 2023 2022 2021 Gain (loss) recognized in foreign exchange gain (loss) $ 13,543 $ (58,755) $ (19,585)
Schedule of Gains (Losses) on Derivative Instruments	The impact on accumulated other comprehensive income (loss) and earnings from derivative instruments that qualified as cash flow hedges was as follows (in thousands): Year Ended December 31, Interest Rate Contracts: 2023 2022 2021 Gain (loss) recognized in accumulated other comprehensive income (loss), net of tax $ 3,658 $ — $ (14) (Gain) loss reclassified from accumulated other comprehensive income (loss) to interest expense, net of tax (3,423) — 2,482
Schedule of Income (Losses) on Derivative Instruments	The impact on accumulated other comprehensive income (loss) and earnings from the cross-currency interest rate swap contract was as follows (in thousands): Year Ended December 31, Cross-Currency Interest Rate Contract: 2022 2021 Loss recognized in accumulated other comprehensive income (loss), net of tax $ — $ (375) Loss reclassified from accumulated other comprehensive income (loss) to foreign exchange loss, net of tax 128 246 Loss recognized in foreign exchange loss 2,646 35,885 The cash flow effects of our derivative contracts are included within net cash provided by operating activities in the consolidated statements of cash flows, except for the settlement of notional amounts of the cross-currency swap, which were included in net cash used in financing activities.
Schedule of the Fair Value of Outstanding Derivatives	The following tables summarize the fair value of outstanding derivatives (in thousands): December 31, 2023 Asset Derivatives Liability Derivatives Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives designated as hedging instruments: Interest rate contracts Other current assets $ 3,784 Accrued liabilities $ — Other non-current assets — Other non-current liabilities 3,410 Derivatives not designated as hedging instruments: Foreign exchange forward contracts Other current assets 18,035 Accrued liabilities 681 Total fair value of derivative instruments $ 21,819 $ 4,091 December 31, 2022 Asset Derivatives Liability Derivatives Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives not designated as hedging instruments: Foreign exchange forward contracts Other current assets $ 17,356 Accrued liabilities $ — Total fair value of derivative instruments $ 17,356 $ —
Schedule of Offsetting Assets	The following table summarizes the potential effect on our consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions as of December 31, 2023 (in thousands): December 31, 2023 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 21,819 $ — $ 21,819 $ (4,091) $ — $ 17,728 Derivative liabilities (4,091) — (4,091) 4,091 — —
Schedule of Offsetting Liabilities	The following table summarizes the potential effect on our consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions as of December 31, 2023 (in thousands): December 31, 2023 Gross Amounts of Recognized Assets/ Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet Gross Amounts Not Offset in the Consolidated Balance Sheet Description Derivative Financial Instruments Cash Collateral Received (Pledged) Net Amount Derivative assets $ 21,819 $ — $ 21,819 $ (4,091) $ — $ 17,728 Derivative liabilities (4,091) — (4,091) 4,091 — —

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following (in thousands): December 31, 2023 2022 Raw materials $ 25,595 $ 20,786 Work in process 431,732 517,670 Finished goods 139,712 175,605 Total inventories $ 597,039 $ 714,061

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Other Current Assets [Abstract]
Schedule of Other Current Assets	Other current assets consisted of the following (in thousands): December 31, 2023 2022 Deferred charge for income taxes on intercompany profit $ 171,507 $ 176,057 Other 149,302 91,135 Total other current assets $ 320,809 $ 267,192

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Estimated useful lives are as follows: Buildings 40 years Manufacturing equipment and machinery 4-20 years Computer software and equipment 3-7 years Furniture and fixtures 5 years Property, plant and equipment consisted of the following (in thousands): December 31, 2023 2022 Manufacturing equipment and machinery $ 82,897 $ 73,580 Land and buildings 70,912 68,935 Leasehold improvements 67,722 64,776 Computer software 38,134 34,116 Construction-in-progress 18,661 67,385 Computer equipment 15,398 16,424 Furniture and fixtures 9,273 10,481 Subtotal 302,997 335,697 Less accumulated depreciation and amortization (133,351) (107,647) Property, plant and equipment, net $ 169,646 $ 228,050

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Gross Carrying Amount of Goodwill	The gross carrying amount of goodwill was as follows (in thousands): Balance at December 31, 2022 $ 1,692,662 Foreign exchange 60,468 Balance at December 31, 2023 $ 1,753,130
Schedule of Gross Carrying Amounts and Net Book Values of Intangible Assets	The gross carrying amounts and net book values of our intangible assets were as follows (in thousands): December 31, 2023 December 31, 2022 Remaining Gross Accumulated Net Book Gross Accumulated Net Book Acquired developed technologies 8.8 $ 7,785,495 $ (2,367,456) $ 5,418,039 $ 7,491,994 $ (1,697,557) $ 5,794,437 Manufacturing contracts — 11,828 (11,828) — 11,417 (11,417) — Trademarks — 2,886 (2,886) — 2,876 (2,876) — Total finite-lived intangible assets $ 7,800,209 $ (2,382,170) $ 5,418,039 $ 7,506,287 $ (1,711,850) $ 5,794,437
Schedule of Estimated Future Amortization Costs	Based on finite-lived intangible assets recorded as of December 31, 2023, and assuming the underlying assets will not be impaired and that we will not change the expected lives of any other assets, future amortization expenses were estimated as follows (in thousands): Year Ending December 31, Estimated Amortization Expense 2024 $ 624,651 2025 624,651 2026 624,651 2027 624,651 2028 623,319 Thereafter 2,296,116 Total $ 5,418,039

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): December 31, 2023 2022 Rebates and other sales deductions $ 325,711 $ 313,176 Employee compensation and benefits 121,209 143,243 Accrued facilities expenses 55,455 25,864 Clinical trial accruals 44,757 31,338 Accrued interest 36,443 35,614 Accrued royalties 30,706 57,347 Sales return reserve 20,435 26,164 Consulting and professional services 19,538 22,278 Current portion of lease liabilities 19,447 15,938 Selling and marketing accruals 14,743 18,553 Inventory-related accruals 13,977 8,565 Accrued collaboration expenses 10,158 33,205 Accrued construction-in-progress 5,141 3,298 Derivative instrument liabilities 681 — Other 75,513 68,672 Total accrued liabilities $ 793,914 $ 803,255

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The following table summarizes the carrying amount of our indebtedness (in thousands): December 31, 2023 2022 2024 Notes $ 575,000 $ 575,000 Unamortized - debt issuance costs (1,046) (2,738) 2024 Notes, net 573,954 572,262 2026 Notes 1,000,000 1,000,000 Unamortized - debt issuance costs (6,400) (8,932) 2026 Notes, net 993,600 991,068 Secured Notes 1,480,214 1,476,938 Term Loan 2,665,174 2,684,073 Total debt 5,712,942 5,724,341 Less current portion (1) 604,954 31,000 Total long-term debt $ 5,107,988 $ 5,693,341 ______________________________
Schedule of Maturities of Long-term Debt	Scheduled maturities with respect to our long-term debt are as follows (in thousands): Year Ending December 31, Scheduled Long-Term Debt Maturities 2024 $ 606,000 2025 31,000 2026 1,031,000 2027 31,000 2028 2,598,500 Thereafter 1,500,000 Total $ 5,797,500

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of Lease Cost and Supplemental Cash Flow Information	The components of the lease expense for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands): Year Ended December 31, Lease Cost 2023 2022 2021 Operating lease cost $ 19,394 $ 19,670 $ 23,869 Short-term lease cost 6,290 5,088 5,540 Variable lease cost 81 5 10 Sublease income (22) — — Finance Lease Cost Amortization of leased asset 481 472 324 Interest on lease liabilities 377 429 295 Net lease cost $ 26,601 $ 25,664 $ 30,038 December 31, Lease Term and Discount Rate 2023 2022 Weighted-average remaining lease term (years) Operating leases 5.1 5.8 Finance leases 11.2 12.0 Weighted-average discount rate Operating leases 5.4 % 5.3 % Finance leases 7.5 % 7.4 % Supplemental cash flow information related to operating and finance leases was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 20,646 $ 20,544 $ 24,847 Operating cash outflows from finance leases 835 806 625 Financing cash outflows from finance leases 377 429 324 Non-cash operating activities: Operating lease assets obtained in exchange for new operating lease liabilities $ 9,953 $ 4,312 $ 8,188 Finance lease assets obtained in exchange for new finance lease liabilities — — 650 De-recognition of operating lease asset on lease assignment / termination 4,169 — 56,968 De-recognition of operating lease liability on lease assignment / termination 4,457 — 68,064
Schedule of Lease Supplemental Balance Sheet Information	Supplemental balance sheet information related to operating and finance leases was as follows (in thousands): December 31, Leases Classification 2023 2022 Assets Operating lease assets Operating lease assets $ 65,340 $ 73,326 Finance lease assets Property, plant and equipment 4,450 4,671 Total lease assets $ 69,790 $ 77,997 Liabilities Current Operating lease liabilities Accrued liabilities $ 19,019 $ 15,557 Finance lease liabilities Accrued liabilities 428 381 Non-current Operating lease liabilities Operating lease liabilities, less current portion 59,225 71,838 Finance lease liabilities Other non-current liabilities 5,039 5,210 Total lease liabilities $ 83,711 $ 92,986
Schedule of Operating Lease Liability Maturities	Maturities of operating and finance lease liabilities were as follows (in thousands): Year Ending December 31, Operating Leases Finance Leases 2024 $ 22,841 $ 823 2025 16,891 823 2026 14,184 823 2027 12,675 769 2028 12,008 610 Thereafter 11,819 4,382 Total lease payments 90,418 8,230 Less imputed interest (12,174) (2,763) Present value of lease liabilities $ 78,244 $ 5,467
Schedule of Finance Lease Liability Maturities	Maturities of operating and finance lease liabilities were as follows (in thousands): Year Ending December 31, Operating Leases Finance Leases 2024 $ 22,841 $ 823 2025 16,891 823 2026 14,184 823 2027 12,675 769 2028 12,008 610 Thereafter 11,819 4,382 Total lease payments 90,418 8,230 Less imputed interest (12,174) (2,763) Present value of lease liabilities $ 78,244 $ 5,467

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Authorized but Unissued Ordinary Shares	We had reserved the following shares of authorized but unissued ordinary shares (in thousands): December 31, 2023 2022 2011 Equity Incentive Plan 22,855 23,689 2007 Employee Stock Purchase Plan 3,913 4,069 GW Incentive Plans 1,570 1,707 Amended and Restated 2007 Non-Employee Directors Stock Award Plan 714 755 Total 29,052 30,220

Comprehensive Income (Loss) (Ta

Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss as of December 31, 2023 and 2022 were as follows (in thousands): Net Unrealized Foreign Total Balance at December 31, 2022 $ — $ (1,125,509) $ (1,125,509) Other comprehensive income before reclassifications 3,658 283,127 286,785 Amounts reclassified from accumulated other comprehensive income (loss) (3,423) — (3,423) Other comprehensive income, net 235 283,127 283,362 Balance at December 31, 2023 $ 235 $ (842,382) $ (842,147)

Net Income (Loss) per Ordinar_2

Net Income (Loss) per Ordinary Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Basic and Diluted Net Income (Loss) per Ordinary Share Computation	Basic and diluted net income (loss) per ordinary share were computed as follows (in thousands, except per share amounts): Year Ended December 31, 2023 2022 2021 Numerator: Net income (loss) $ 414,832 $ (224,060) $ (329,668) Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax 24,876 — — Net income (loss) for dilutive net income (loss) per ordinary share $ 439,708 $ (224,060) $ (329,668) Denominator: Weighted-average ordinary shares used in per share calculations - basic 63,291 62,539 59,694 Dilutive effect of Exchangeable Senior Notes 8,016 — — Dilutive effect of employee equity incentive and purchase plans 759 — — Weighted-average ordinary shares used in per share calculations - diluted 72,066 62,539 59,694 Net income (loss) per ordinary share: Basic $ 6.55 $ (3.58) $ (5.52) Diluted $ 6.10 $ (3.58) $ (5.52)
Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income (Loss) per Share	The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income (loss) per ordinary share for the years presented because including them would have an anti-dilutive effect (in thousands): Year Ended December 31, 2023 2022 2021 Employee equity incentive and purchase plans 2,973 2,751 3,927 Exchangeable Senior Notes — 9,044 9,725

Segment and Other Information (

Segment and Other Information (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Total Long-lived Assets by Location	The following table presents total long-lived assets by location (in thousands): December 31, 2023 2022 Ireland $ 68,201 $ 71,276 United Kingdom 80,293 143,870 United States 59,440 63,559 Italy 20,942 15,768 Other 6,110 6,904 Total long-lived assets (1) $ 234,986 $ 301,377 _________________________ (1) Long-lived assets consist of property, plant and equipment and operating lease assets.

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue	The following table presents a summary of total revenues (in thousands): Year Ended December 31, 2023 2022 2021 Xywav $ 1,272,977 $ 958,425 $ 535,297 Xyrem 569,730 1,020,453 1,265,830 Epidiolex/Epidyolex 845,468 736,398 463,645 Sativex 19,668 16,825 12,707 Sunosi 1 — 28,844 57,914 Total Neuroscience 2,707,843 2,760,945 2,335,393 Rylaze 394,226 281,659 85,629 Zepzelca 289,533 269,912 246,808 Defitelio/defibrotide 184,000 194,290 197,931 Vyxeos 147,495 127,980 134,060 Erwinaze/Erwinase — — 69,382 Total Oncology 1,015,254 873,841 733,810 Other 13,846 6,643 9,798 Product sales, net 3,736,943 3,641,429 3,079,001 High-sodium oxybate AG royalty revenue 75,918 — — Other royalty and contract revenues 21,343 17,945 15,237 Total revenues $ 3,834,204 $ 3,659,374 $ 3,094,238 ____________________________ (1) Divestiture of Sunosi U.S. was completed in May 2022. The following table presents a summary of total revenues attributed to geographic sources (in thousands): Year Ended December 31, 2023 2022 2021 United States $ 3,489,977 $ 3,370,379 $ 2,820,242 Europe 269,243 239,638 230,158 All other 74,984 49,357 43,838 Total revenues $ 3,834,204 $ 3,659,374 $ 3,094,238
Summary of Revenues from Customers Representing More Than 10% of Total Revenues	The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Year Ended December 31, 2023 2022 2021 ESSDS 48 % 56 % 60 % McKesson 11 % 11 % 12 %

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Share-based Compensation Expense Related to Share Options, RSUs, PSRUs and Grants Under ESPP	Share-based compensation expense related to share options, RSUs, PRSUs and grants under our ESPP was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Selling, general and administrative $ 146,942 $ 151,986 $ 135,285 Research and development 64,847 57,522 43,758 Cost of product sales 15,052 12,488 9,963 Total share-based compensation expense, pre-tax 226,841 221,996 189,006 Income tax benefit from share-based compensation expense (40,015) (41,058) (33,958) Total share-based compensation expense, net of tax $ 186,826 $ 180,938 $ 155,048
Schedule of RSU and PRSU Activity	The following table summarizes information as of December 31, 2023 and activity during 2023 related to our RSUs: Number of RSUs (In thousands) Weighted- Weighted- Aggregate Outstanding at January 1, 2023 3,209 $ 151.11 RSUs granted 1,768 144.65 RSUs released (1,094) 148.68 RSUs forfeited (320) 149.54 Outstanding at December 31, 2023 3,563 $ 148.79 1.3 $ 438,224 The following table summarizes information as of December 31, 2023 and activity during 2023 related to our PRSUs: Number of PRSUs (In thousands) Weighted- Weighted- Aggregate Outstanding at January 1, 2023 440 $ 183.68 PRSUs granted 271 156.91 PRSUs forfeited (47) 176.06 Outstanding at December 31, 2023 664 $ 173.30 1.5 $ 81,729
Schedule of Weighted-average Assumptions Used in Black-Scholes Option Pricing Model and Resulting Weighted-average Grant Date Fair Value of Share Options Granted	The table below shows, for market strike price option grants, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of market strike price options granted in 2021: Year Ended Grant date fair value $ 51.39 Volatility 37 % Expected term (years) 4.5 Range of risk-free rates 0.4-0.8% Expected dividend yield — %
Schedule of Information and Activity Related to Share Option Plans Activity	The following table summarizes information as of December 31, 2023 and activity during 2023 related to our share option plans: Shares Weighted- Weighted- Aggregate Outstanding at January 1, 2023 3,189 $ 140.64 Options exercised (251) 120.29 Options forfeited (16) 133.93 Options expired (206) 153.92 Outstanding at December 31, 2023 2,716 $ 141.55 4.1 $ 3,900 Vested and expected to vest at December 31, 2023 2,715 $ 141.55 4.1 $ 3,896 Exercisable at December 31, 2023 2,669 $ 141.69 4.1 $ 3,669 The following table summarizes information as of December 31, 2023 and activity during 2023 related to our nominal strike price options: Shares Weighted- Weighted- Aggregate Outstanding at January 1, 2023 56 $ 0.02 Options exercised (29) 0.02 Outstanding at December 31, 2023 27 $ 0.02 6.4 $ 3,357 Vested and expected to vest at December 31, 2023 27 $ 0.02 6.4 $ 3,357 Exercisable at December 31, 2023 27 $ 0.02 6.4 $ 3,357

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Components of Income (Loss) from Continuing Operations Before Income Tax Provision (Benefit)	The components of income (loss) before income tax expense (benefit) and equity in loss of investees were as follows (in thousands): Year Ended December 31, 2023 2022 2021 Ireland $ 449,214 $ (50,311) $ 97,557 United Kingdom (643,096) (963,598) (681,291) United States (6,056) 224,453 221,185 Other 497,867 416,672 249,711 Total $ 297,929 $ (372,784) $ (112,838)
Details of Income Tax Provision (Benefit)	The following table sets forth the details of income tax expense (benefit) (in thousands): Year Ended December 31, 2023 2022 2021 Current Ireland $ 77,343 $ 61,550 $ 25,770 United Kingdom 7,726 1,454 (924) United States 20,803 37,823 88,850 Other 34,433 32,779 33,222 Total current tax expense 140,305 133,606 146,918 Deferred, exclusive of other components below Ireland (10,919) (62,011) (5,388) United Kingdom (150,506) (193,219) (111,534) United States (89,246) (9,086) (46,531) Other (8,990) (11,144) (28,604) Total deferred, exclusive of other components (259,661) (275,460) (192,057) Deferred, change in tax rates United Kingdom 268 (16,990) 259,873 United States (824) 201 1,377 Other — (2) 5 Total deferred, change in tax rates (556) (16,791) 261,255 Total deferred tax expense (benefit) (260,217) (292,251) 69,198 Total income tax expense (benefit) $ (119,912) $ (158,645) $ 216,116
Reconciliation of Income Taxes at the Statutory Income Tax Rate to Effective Income Tax Rate	The reconciliation between income tax expense (benefit) at the Irish statutory trading income tax rate of 12.5 percent, the jurisdiction of tax domicile of Jazz Pharmaceuticals, applied to income before the income tax expense (benefit) and equity in loss of investees and our reported income tax expense (benefit) was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Income tax expense (benefit) at the statutory income tax rate $ 37,241 $ (46,598) $ (14,105) Deduction on subsidiary equity (153,655) (158,488) (116,438) Change in valuation allowance 75,081 95,051 81,280 Research and other tax credits (49,900) (27,976) (31,069) Foreign derived intangible income benefit (42,400) (29,541) (3,416) Non-deductible facility expense 16,618 8,093 — Non-deductible financing costs 15,705 4,504 14,418 Non-deductible compensation 14,092 13,505 19,914 Patent box incentive benefit (13,862) (6,203) — Change in unrecognized tax benefits (12,612) 5,029 (6,436) Foreign income tax rate differential (7,763) 5,863 (4,343) Change in estimates (5,472) (14,065) (2,653) Tax deficiencies/(excess tax benefits) from share-based compensation 3,959 (1,690) (5,555) Change in tax rate (605) (16,790) 261,663 Non-deductible royalty expense — 6,274 — Non-deductible acquisition-related costs — — 20,929 Other 3,661 4,387 1,927 Reported income tax expense (benefit) $ (119,912) $ (158,645) $ 216,116
Schedule of Net Deferred Tax Assets and (Liabilities)	Significant components of our net deferred tax assets (liabilities) were as follows (in thousands): December 31, 2023 2022 Deferred tax assets: Operating loss carryforwards $ 296,490 $ 263,235 Intangible assets 238,062 236,462 Deduction on subsidiary equity carryforwards 212,015 157,367 Capitalized research and development 201,186 88,009 Tax credit carryforwards 142,854 189,792 Accrued liabilities 128,948 109,257 Share-based compensation 48,403 42,795 Indirect effects of unrecognized tax benefits 40,811 47,224 Lease liabilities 13,415 14,081 Other 5,925 11,595 Total deferred tax assets 1,328,109 1,159,817 Valuation allowance (312,340) (234,732) Deferred tax assets, net of valuation allowance 1,015,769 925,085 Deferred tax liabilities: Intangible assets (1,290,425) (1,367,146) Inventories (81,995) (110,927) Operating lease assets (10,628) (10,978) Other (2,593) (4,124) Total deferred tax liabilities (1,385,641) (1,493,175) Net deferred tax liabilities $ (369,872) $ (568,090) The following table summarizes the presentation of deferred tax assets and liabilities (in thousands): December 31, 2023 2022 Deferred tax assets $ 477,834 $ 376,247 Deferred tax liabilities (847,706) (944,337) Net deferred tax liabilities $ (369,872) $ (568,090)
Reconciliation of Unrecognized Tax Benefits	A reconciliation of our unrecognized tax benefits follows (in thousands): December 31, 2023 2022 2021 Balance at the beginning of the year $ 143,976 $ 137,867 $ 146,557 Increases related to current year tax positions 15,004 25,128 26,675 Increases related to prior year tax positions 224 2,794 211 Decreases related to prior year tax positions (12,702) (164) (182) Increases recognized through purchase accounting — — 5,916 Decreases related to settlements with taxing authorities — (223) (14,744) Lapse of the applicable statute of limitations (23,808) (21,426) (26,566) Balance at the end of the year $ 122,694 $ 143,976 $ 137,867

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	May 05, 2021
Summary Of Significant Accounting Policies [Line Items]
Intangible asset amortization	$ 608,284,000	$ 599,169,000	$ 525,769,000
Advertising expenses	92,200,000	108,800,000	161,500,000
Acquired Developed Technologies
Summary Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life				12 years
Intangible asset amortization	$ 608,300,000	$ 599,200,000	$ 525,800,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life	7 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life	16 years
Customer concentration risk | Accounts Receivable | Five Customers
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	79%	87%
Customer concentration risk | Accounts Receivable | ESSDS
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	41%	55%
Customer concentration risk | Accounts Receivable | ASD Specialty Healthcare LLC
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	13%
Customer concentration risk | Accounts Receivable | Cardinal Health Inc
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		10%
Customer concentration risk | Accounts Receivable | McKesson
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	11%	9%
Foreign exchange forward contracts | Derivatives not designated as hedging instruments
Summary Of Significant Accounting Policies [Line Items]
Notional amount	$ 511,700,000	$ 505,000,000
Net asset fair value	17,400,000	$ 17,400,000
Interest Rate Swap | Derivatives designated as hedging instruments
Summary Of Significant Accounting Policies [Line Items]
Notional amount	500,000,000
Net asset fair value	$ 400,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Details)	Dec. 31, 2023
Buildings
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	40 years
Manufacturing equipment and machinery | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	4 years
Manufacturing equipment and machinery | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	20 years
Computer software and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	3 years
Computer software and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	7 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful life of property and equipment	5 years

Collaborations, Disposition a_3

Collaborations, Disposition and Business Combination - License Agreements (Details) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Nov. 30, 2023	Sep. 30, 2023	Oct. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Acquired in-process research and development				$ 19,000	$ 444,148	$ 0
Upfront and milestone payment values				7,800,209	7,506,287
Autifony Therapeutics | Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development	$ 18,000
Autifony Therapeutics | Potential Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values				$ 752,500
Zymeworks
Business Acquisition [Line Items]
Acquired in-process research and development					375,000
Tiered royalty fees percentage, minimum				10%
Tiered royalty fees percentage, maximum				20%
Zymeworks | Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development			$ 50,000
Zymeworks | Potential Milestone Payment
Business Acquisition [Line Items]
Total potential collaboration payments				$ 1,760,000
Zymeworks | One-Time Payments
Business Acquisition [Line Items]
Acquired in-process research and development			$ 325,000
Zymeworks | Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values				1,400,000
Sumitomo | Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development					50,000
Sumitomo | Potential Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values				1,090,000
Werewolf | Upfront Payment
Business Acquisition [Line Items]
Acquired in-process research and development					$ 15,000
Werewolf | Potential Milestone Payment
Business Acquisition [Line Items]
Upfront and milestone payment values				$ 1,260,000
Werewolf | Milestone Payment
Business Acquisition [Line Items]
Acquired in-process research and development		$ 5,000

Collaborations, Disposition a_4

Collaborations, Disposition and Business Combination - Narrative (Details) € in Millions		1 Months Ended	12 Months Ended
	May 05, 2021 USD ($)	May 31, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	May 31, 2022 USD ($)	Mar. 31, 2022	Sep. 30, 2021 USD ($)	May 31, 2021 EUR (€)	Apr. 30, 2021 USD ($)	Apr. 29, 2021
Business Acquisition [Line Items]
Disposal group, not discontinued operation, gain (loss) on disposal, statement of income or comprehensive income [Extensible Enumeration]				Selling, general and administrative
Impairment, intangible asset, finite-lived, statement of income or comprehensive income [Extensible Enumeration]			Intangible asset impairment charge
Intangible asset impairment charge			$ 0	$ 133,648,000	$ 0
Disposal Group, Held-for-sale, Not Discontinued Operations | Sunosi
Business Acquisition [Line Items]
Loss on disposal				$ 40,800,000
Axsome | Disposal Group, Held-for-sale, Not Discontinued Operations | Sunosi
Business Acquisition [Line Items]
Upfront payment received						$ 53,000,000
Acquired developed technologies
Business Acquisition [Line Items]
Finite-lived intangible asset, useful life	12 years
Acquired developed technologies | Measurement Input, Discount Rate | Valuation, Income Approach
Business Acquisition [Line Items]
Finite-lived intangible asset, measurement input	0.094
GW Pharmaceuticals plc
Business Acquisition [Line Items]
Total purchase consideration	$ 7,190,701,000
Transactions costs incurred during period					81,900,000
Revenue of acquiree since acquisition date, actual					476,400,000
Net loss of acquiree since acquisition date, actual					$ 704,600,000
Acquisition accounting inventory fair value step-up adjustment	1,062,600,000
Total acquired identifiable intangible assets	5,640,000,000
GW Pharmaceuticals plc | Acquired developed technologies
Business Acquisition [Line Items]
Total acquired identifiable intangible assets	$ 5,480,000,000
Secured Notes | Senior Secured Debt | Jazz Securities Designated Activity Company
Business Acquisition [Line Items]
Debt instrument, face amount										$ 1,500,000,000
Interest rate (as a percent)			4.375%							4.375%	4.375%
2021 Credit Agreement, Dollar Term Loan | Line of Credit
Business Acquisition [Line Items]
Debt instrument, face amount		$ 3,100,000,000						$ 3,100,000,000
Debt term (in years)		7 years
2021 Credit Agreement, Euro Term Loan | Line of Credit
Business Acquisition [Line Items]
Interest rate (as a percent)							4.43%
Debt term (in years)		7 years
2021 Credit Agreement, Euro Term Loan | Line of Credit | Foreign exchange forward contracts
Business Acquisition [Line Items]
Debt instrument, face amount | €									€ 625
2021 Credit Agreement, Revolving Credit Facility | Line of Credit | Borrowings under revolving credit facility
Business Acquisition [Line Items]
Debt term (in years)		5 years
Line of credit, maximum borrowing capacity		$ 500,000,000

Collaborations, Disposition a_5

Collaborations, Disposition and Business Combination - Schedule of Aggregate Consideration (Details) - GW Pharmaceuticals plc - USD ($) $ / shares in Units, $ in Thousands	May 05, 2021	May 04, 2021
Business Acquisition [Line Items]
GW ADS outstanding (in shares)	31,556,200
Cash consideration per GW ADS (USD per share)	$ 200
Total cash consideration	$ 6,578,690
Total equity consideration	612,011
Total purchase consideration	7,190,701
Share Options
Business Acquisition [Line Items]
Total cash consideration	267,450
Total equity consideration	3,555
ADR
Business Acquisition [Line Items]
Total cash consideration	6,311,240
Total equity consideration	$ 608,456
Ordinary Shares
Business Acquisition [Line Items]
Ordinary shares issued to GW ADS holders (in shares)	3,800,000
Closing price of ordinary shares (USD per share)		$ 160.20

Collaborations, Disposition a_6

Collaborations, Disposition and Business Combination - Schedule of Assets and Liabilities Acquired (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	May 05, 2021
Business Acquisition [Line Items]
Goodwill	$ 1,753,130	$ 1,692,662
GW Pharmaceuticals plc
Business Acquisition [Line Items]
Cash and cash equivalents			$ 343,898
Accounts receivable			76,355
Inventory			1,206,290
Prepaid expenses and other current assets			72,758
Property, plant and equipment			154,407
Total acquired identifiable intangible assets			5,640,000
Goodwill			933,234
Deferred tax liabilities, net			(1,069,076)
Accrued liabilities			(131,971)
Other assets/liabilities			(35,194)
Total purchase consideration			7,190,701
GW Pharmaceuticals plc | Acquired developed technologies
Business Acquisition [Line Items]
Total acquired identifiable intangible assets			5,480,000
GW Pharmaceuticals plc | Acquired IPR&D assets
Business Acquisition [Line Items]
Total acquired identifiable intangible assets			$ 160,000

Cash and Available-for-Sale S_3

Cash and Available-for-Sale Securities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 1,626,310	$ 881,482
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	1,626,310	881,482
Cash and Cash Equivalents	1,506,310	881,482
Investments	120,000	0
Interest income	65,100	11,500	$ 1,800
Cash
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	437,724	334,018
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	437,724	334,018
Cash and Cash Equivalents	437,724	334,018
Investments	0	0
Time deposits
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	420,000	30,000
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	420,000	30,000
Cash and Cash Equivalents	300,000	30,000
Investments	120,000	0
Money market funds
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	768,586	517,464
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	768,586	517,464
Cash and Cash Equivalents	768,586	517,464
Investments	$ 0	$ 0

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Available-for-sale securities:
Available-for-sale securities	$ 1,626,310	$ 881,482
Time deposits
Available-for-sale securities:
Available-for-sale securities	420,000	30,000
Money market funds
Available-for-sale securities:
Available-for-sale securities	768,586	517,464
Recurring
Available-for-sale securities:
Totals	1,210,405	564,820
Liabilities:
Totals	4,091	0
Recurring | Time deposits
Available-for-sale securities:
Available-for-sale securities	420,000	30,000
Recurring | Money market funds
Available-for-sale securities:
Available-for-sale securities	768,586	517,464
Recurring | Interest rate contracts
Available-for-sale securities:
Derivative asset	3,784	0
Liabilities:
Derivative Liability	3,410	0
Recurring | Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	18,035	17,356
Liabilities:
Derivative Liability	681	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Available-for-sale securities:
Totals	768,586	517,464
Liabilities:
Totals	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring | Time deposits
Available-for-sale securities:
Available-for-sale securities	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring | Money market funds
Available-for-sale securities:
Available-for-sale securities	768,586	517,464
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring | Interest rate contracts
Available-for-sale securities:
Derivative asset	0	0
Liabilities:
Derivative Liability	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring | Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	0	0
Liabilities:
Derivative Liability	0	0
Significant Other Observable Inputs (Level 2) | Recurring
Available-for-sale securities:
Totals	441,819	47,356
Liabilities:
Totals	4,091	0
Significant Other Observable Inputs (Level 2) | Recurring | Time deposits
Available-for-sale securities:
Available-for-sale securities	420,000	30,000
Significant Other Observable Inputs (Level 2) | Recurring | Money market funds
Available-for-sale securities:
Available-for-sale securities	0	0
Significant Other Observable Inputs (Level 2) | Recurring | Interest rate contracts
Available-for-sale securities:
Derivative asset	3,784	0
Liabilities:
Derivative Liability	3,410	0
Significant Other Observable Inputs (Level 2) | Recurring | Foreign exchange forward contracts
Available-for-sale securities:
Derivative asset	18,035	17,356
Liabilities:
Derivative Liability	$ 681	$ 0

Fair Value Measurement - Narrat

Fair Value Measurement - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Apr. 30, 2021	Apr. 29, 2021	Dec. 31, 2020	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity securities without readily determinable value, fair value	$ 4.7	$ 5.5
Convertible Debt | 2024 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate (as a percent)	1.50%					1.50%
Convertible Debt | 2026 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate (as a percent)	2%				2%
Senior Secured Debt | Secured Notes | Jazz Securities Designated Activity Company
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate (as a percent)	4.375%		4.375%	4.375%
Significant Other Observable Inputs (Level 2) | Convertible Debt | 2024 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of exchangeable senior notes	$ 559
Significant Other Observable Inputs (Level 2) | Convertible Debt | 2026 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of exchangeable senior notes	1,000
Significant Other Observable Inputs (Level 2) | Senior Secured Debt | Secured Notes | Jazz Securities Designated Activity Company
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of secured debt	1,400
Significant Other Observable Inputs (Level 2) | Line of Credit | 2021 Credit Agreement, Dollar Term Loan | Borrowings under revolving credit facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of lines of credit	$ 2,700

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Gain recognized in AOCI to be reclassified over the next 12 months	$ 2,800,000
Term Loan
Derivative [Line Items]
Interest rate (as a percent)	3.9086%
Foreign exchange forward contracts | Derivatives not designated as hedging instruments
Derivative [Line Items]
Notional amount	$ 511,700,000	$ 505,000,000

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Foreign Exchange Gain (Loss) Derivative Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivatives not designated as hedging instruments | Foreign exchange forward contracts
Derivative [Line Items]
Gain (loss) recognized in foreign exchange gain (loss)	$ 13,543	$ (58,755)	$ (19,585)

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Gains and Losses on Derivative Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in accumulated other comprehensive income (loss), net of tax	$ 3,658	$ 0	$ (14)
(Gain) loss reclassified from accumulated other comprehensive income (loss) to interest expense, net of tax	(3,423)	0	2,482
Interest rate contracts | Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in accumulated other comprehensive income (loss), net of tax	3,658	0	(14)
(Gain) loss reclassified from accumulated other comprehensive income (loss) to interest expense, net of tax	$ (3,423)	$ 0	$ 2,482

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Cross-Currency Loss Derivative Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Loss reclassified from accumulated other comprehensive income (loss) to foreign exchange loss, net of tax	$ 283,127	$ (725,277)	$ (268,347)
Cross-currency interest rate contracts | Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Loss recognized in accumulated other comprehensive income (loss), net of tax		0	(375)
Loss reclassified from accumulated other comprehensive income (loss) to foreign exchange loss, net of tax		128	246
Loss recognized in foreign exchange loss		$ 2,646	$ 35,885

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities - Fair Value of Outstanding Derivatives (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 21,819	$ 17,356
Liability Derivatives	4,091	0
Derivatives designated as hedging instruments | Interest rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	3,784
Derivatives designated as hedging instruments | Interest rate contracts | Accrued liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	0
Derivatives designated as hedging instruments | Interest rate contracts | Other non-current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	0
Derivatives designated as hedging instruments | Interest rate contracts | Other non-current liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	3,410
Derivatives not designated as hedging instruments | Foreign exchange forward contracts | Other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives	18,035	17,356
Derivatives not designated as hedging instruments | Foreign exchange forward contracts | Accrued liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 681	$ 0

Derivative Instruments and He_8

Derivative Instruments and Hedging Activities - Offsetting Assets and Liabilities (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative asset, statement of financial position [Extensible Enumeration]	Other non-current assets
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative liability, statement of financial position [Extensible Enumeration]	Other non-current liabilities
Pro Forma
Derivative assets
Gross Amounts of Recognized Assets/ Liabilities	$ 21,819
Gross Amounts Offset in the Consolidated Balance Sheet	0
Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet	21,819
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative Financial Instruments	(4,091)
Cash Collateral Received (Pledged)	0
Net Amount	17,728
Derivative liabilities
Gross Amounts of Recognized Assets/ Liabilities	(4,091)
Gross Amounts Offset in the Consolidated Balance Sheet	0
Net Amounts of Assets/ Liabilities Presented in the Consolidated Balance Sheet	(4,091)
Gross Amounts Not Offset in the Consolidated Balance Sheet
Derivative Financial Instruments	4,091
Cash Collateral Received (Pledged)	0
Net Amount	$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory [Line Items]
Raw materials	$ 25,595	$ 20,786
Work in process	431,732	517,670
Finished goods	139,712	175,605
Total inventories	597,039	714,061
GW Pharmaceuticals plc
Inventory [Line Items]
Inventory, step-up value	$ 328,000	$ 457,600

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other Current Assets [Abstract]
Deferred charge for income taxes on intercompany profit	$ 171,507	$ 176,057
Other	149,302	91,135
Total other current assets	$ 320,809	$ 267,192

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 302,997	$ 335,697
Less accumulated depreciation and amortization	(133,351)	(107,647)
Property, plant and equipment, net	169,646	228,050
Depreciation and amortization expense	30,400	30,300	$ 26,700
Manufacturing equipment and machinery
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	82,897	73,580
Land and buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	70,912	68,935
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	67,722	64,776
Computer software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	38,134	34,116
Construction-in-progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	18,661	67,385
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	15,398	16,424
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 9,273	$ 10,481

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Gross Carrying Amount of Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 1,692,662
Foreign exchange	60,468
Goodwill, end of period	$ 1,753,130

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Gross Carrying Amounts and Net Book Values (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 7,800,209	$ 7,506,287
Accumulated Amortization	(2,382,170)	(1,711,850)
Total	$ 5,418,039	5,794,437
Acquired developed technologies
Finite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	8 years 9 months 18 days
Gross Carrying Amount	$ 7,785,495	7,491,994
Accumulated Amortization	(2,367,456)	(1,697,557)
Total	$ 5,418,039	5,794,437
Manufacturing contracts
Finite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount	$ 11,828	11,417
Accumulated Amortization	(11,828)	(11,417)
Total	$ 0	0
Trademarks
Finite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	0 years
Gross Carrying Amount	$ 2,886	2,876
Accumulated Amortization	(2,886)	(2,876)
Total	$ 0	$ 0

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 624,651
2025	624,651
2026	624,651
2027	624,651
2028	623,319
Thereafter	2,296,116
Total	$ 5,418,039	$ 5,794,437

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Rebates and other sales deductions	$ 325,711	$ 313,176
Employee compensation and benefits	121,209	143,243
Accrued royalties	30,706	57,347
Accrued interest	36,443	35,614
Accrued collaboration expenses	10,158	33,205
Clinical trial accruals	44,757	31,338
Sales return reserve	20,435	26,164
Accrued facilities expenses	55,455	25,864
Consulting and professional services	19,538	22,278
Selling and marketing accruals	14,743	18,553
Current portion of lease liabilities	19,447	15,938
Inventory-related accruals	13,977	8,565
Accrued construction-in-progress	5,141	3,298
Derivative instrument liabilities	681	0
Other	75,513	68,672
Total accrued liabilities	$ 793,914	$ 803,255

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Long term debt outstanding	$ 5,797,500
Total debt	5,712,942	$ 5,724,341
Less current portion	604,954	31,000
Total long-term debt	5,107,988	5,693,341
Convertible Debt | 2024 Notes
Debt Instrument [Line Items]
Long term debt outstanding	575,000	575,000
Unamortized - debt issuance costs	(1,046)	(2,738)
Total debt	573,954	572,262
Convertible Debt | 2026 Notes
Debt Instrument [Line Items]
Long term debt outstanding	1,000,000	1,000,000
Unamortized - debt issuance costs	(6,400)	(8,932)
Total debt	993,600	991,068
Convertible Debt | Secured Notes
Debt Instrument [Line Items]
Total debt	1,480,214	1,476,938
Term Loan
Debt Instrument [Line Items]
Total debt	$ 2,665,174	$ 2,684,073

Debt - Credit Agreement Narrati

Debt - Credit Agreement Narrative (Details) € in Millions		1 Months Ended					3 Months Ended	12 Months Ended
	May 05, 2021 USD ($)	Jan. 31, 2024 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€)	Sep. 30, 2021 USD ($)	Mar. 31, 2022	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2023 USD ($) Rate	May 31, 2021 USD ($)
Tranche B-1 Dollar Term Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		(0.50%)
Term Loan
Debt Instrument [Line Items]
Interest rate (as a percent) | Rate										3.9086%
Term Loan | Credit Agreement June 2015
Debt Instrument [Line Items]
Repayment of debt	$ 575,900,000
Line of Credit | Subsequent Event
Debt Instrument [Line Items]
Remaining borrowing capacity		$ 2,723,000,000
Line of Credit | 2021 Credit Agreement, Euro Term Loan
Debt Instrument [Line Items]
Repayment of debt				$ 251,000,000	€ 208.3			$ 502,000,000	€ 416.7
Basis spread on variable rate							3.50%
Interest rate (as a percent)				4.43%	4.43%		4.43%
Effective interest rate (as a percent)				4.93%	4.93%		4.93%
Line of Credit | Tranche B-1 Dollar Term Loan
Debt Instrument [Line Items]
Interest rate (as a percent)										8.97%
Effective interest rate (as a percent)										4.56%
Line of Credit | Tranche B-1 Dollar Term Loan | Subsequent Event
Debt Instrument [Line Items]
Interest rate (as a percent)		8.90%
Effective interest rate (as a percent)		9.50%
Debt instrument, face amount		$ 201,900,000
Line of Credit | Tranche B-1 Dollar Term Loan | Prime Rate | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		2%
Line of Credit | Tranche B-1 Dollar Term Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		3%
Line of Credit | Tranche B-1 Dollar Term Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Line of Credit | 2021 Credit Agreement, Dollar Term Loan
Debt Instrument [Line Items]
Repayment of debt			$ 300,000,000
Debt instrument, face amount						$ 3,100,000,000					$ 3,100,000,000
Debt instrument, redemption price, percentage of principal amount redeemed (as a percent)						1%
Quarterly amortization rate, percentage										0.28466%
Line of Credit | Borrowings under revolving credit facility | Tranche B-1 Dollar Term Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Line of Credit | Borrowings under revolving credit facility | 2021 Credit Agreement, Revolving Credit Facility
Debt Instrument [Line Items]
Remaining borrowing capacity										$ 500,000,000
Debt covenant, revolving credit facility, outstanding amount threshold										$ 50,000,000
Line of Credit | Borrowings under revolving credit facility | 2021 Credit Agreement, Revolving Credit Facility | Maximum | Subsequent Event
Debt Instrument [Line Items]
Line of credit facility, commitment fee percentage (as a percentage)		0.50%
Line of Credit | Borrowings under revolving credit facility | 2021 Credit Agreement, Revolving Credit Facility | Minimum | Subsequent Event
Debt Instrument [Line Items]
Line of credit facility, commitment fee percentage (as a percentage)		0.40%
Line of Credit | Borrowings under revolving credit facility | 2021 Credit Agreement, Revolving Credit Facility | Prime Rate | Maximum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		2.25%
Line of Credit | Borrowings under revolving credit facility | 2021 Credit Agreement, Revolving Credit Facility | Prime Rate | Minimum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		1.75%
Line of Credit | Borrowings under revolving credit facility | 2021 Credit Agreement, Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		3.25%
Line of Credit | Borrowings under revolving credit facility | 2021 Credit Agreement, Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Minimum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate		2.75%

Debt - 2029 Senior Secured Note

Debt - 2029 Senior Secured Notes Narrative (Details) - Secured Notes - Senior Secured Debt - Jazz Securities Designated Activity Company	Apr. 29, 2021	Dec. 31, 2023	Apr. 30, 2021
Debt Instrument [Line Items]
Interest rate (as a percent)	4.375%	4.375%	4.375%
Effective interest rate (as a percent)		4.64%
Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Redemption price, percentage	100%
Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Redemption price, percentage	104.375%
Percentage of principal subject to redemption	40%
Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Redemption price, percentage	103%
Percentage of principal subject to redemption	10%
Debt Instrument, Redemption, Period Four
Debt Instrument [Line Items]
Redemption price, percentage	101%

Debt - Exchangeable Senior Note

Debt - Exchangeable Senior Notes Due 2026 Narrative (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2020 USD ($) d $ / shares	Dec. 31, 2023
2026 Notes
Debt Instrument [Line Items]
If-converted value in excess of principal	$ 22,500,000
2026 Notes | Convertible Debt
Debt Instrument [Line Items]
Debt instrument, face amount		$ 1,000,000,000
Interest rate (as a percent)		2%	2%
Percentage of conversion price		130%
Number of trading days | d		20
Number of consecutive days in trading period | d		30
Conversion rate of shares (in shares per dollar)		0.0064182
Debt conversion price (in dollars per share) | $ / shares		$ 155.81
Debt issuance cost		$ 15,300,000
Debt term (in years)		6 years
Effective interest rate (as a percent)		2.26%
2021 Notes | Convertible Debt
Debt Instrument [Line Items]
Debt repurchased amount		$ 332,900,000
2021 Notes | Senior Secured Debt
Debt Instrument [Line Items]
Interest rate (as a percent)		1.875%

Debt - Exchangeable Senior No_2

Debt - Exchangeable Senior Notes Due 2024 Narrative (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2017 USD ($) d $ / shares
Debt Instrument [Line Items]
Interest expense, net	$ 32,800,000	$ 32,800,000	$ 89,900,000
Contractual coupon rate interest expense	28,600,000	28,600,000	31,200,000
Amortization of debt issuance costs	$ 4,200,000	$ 4,200,000	4,400,000
Amortization of debt discount			$ 54,300,000
Jazz Investments I Limited
Debt Instrument [Line Items]
Ownership percentage (as a percent)	100%
Borrowings under revolving credit facility
Debt Instrument [Line Items]
Repayments under revolving credit facility				$ 500,000,000
2024 Notes | Convertible Debt
Debt Instrument [Line Items]
Debt instrument, face amount				$ 575,000,000
Interest rate (as a percent)	1.50%			1.50%
Percentage of conversion price				130%
Number of trading days | d				20
Number of consecutive days in trading period | d				30
Conversion rate of shares (in shares per dollar)				0.0045659
Debt conversion price (in dollars per share) | $ / shares				$ 219.02
Debt issuance cost				$ 11,400,000
Debt term (in years)				7 years
Effective interest rate (as a percent)				1.79%

Debt - Schedule of Debt Maturit

Debt - Schedule of Debt Maturities (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2024	$ 606,000
2025	31,000
2026	1,031,000
2027	31,000
2028	2,598,500
Thereafter	1,500,000
Total	$ 5,797,500

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lease Cost
Operating lease cost	$ 19,394	$ 19,670	$ 23,869
Short-term lease cost	6,290	5,088	5,540
Variable lease cost	81	5	10
Sublease income	(22)	0	0
Finance Lease Cost
Amortization of leased asset	481	472	324
Interest on lease liabilities	377	429	295
Net lease cost	$ 26,601	$ 25,664	$ 30,038

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets
Operating lease assets	$ 65,340	$ 73,326
Finance lease assets	4,450	4,671
Total lease assets	$ 69,790	$ 77,997
Finance lease, right-of-use asset, statement of financial position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Liabilities
Operating lease liabilities	$ 19,019	$ 15,557
Finance lease liabilities	$ 428	$ 381
Operating lease, liability, current, statement of financial position [Extensible List]	Accrued liabilities	Accrued liabilities
Finance lease, liability, current, statement of financial position [Extensible Enumeration]	Accrued liabilities	Accrued liabilities
Operating lease liabilities, less current portion	$ 59,225	$ 71,838
Finance lease liabilities	5,039	5,210
Total lease liabilities	$ 83,711	$ 92,986
Finance lease, liability, noncurrent, statement of financial position [Extensible Enumeration]	Other non-current liabilities	Other non-current liabilities

Leases - Weighted Average Terms

Leases - Weighted Average Terms and Discount Rates (Details)	Dec. 31, 2023	Dec. 31, 2022
Weighted-average remaining lease term (years)
Operating leases	5 years 1 month 6 days	5 years 9 months 18 days
Finance leases	11 years 2 months 12 days	12 years
Weighted-average discount rate
Operating leases	5.40%	5.30%
Finance leases	7.50%	7.40%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows from operating leases	$ 20,646	$ 20,544	$ 24,847
Operating cash outflows from finance leases	835	806	625
Financing cash outflows from finance leases	377	429	324
Non-cash operating activities:
Operating lease assets obtained in exchange for new operating lease liabilities	9,953	4,312	8,188
Finance lease assets obtained in exchange for new finance lease liabilities	0	0	650
De-recognition of operating lease asset on lease assignment / termination	4,169	0	56,968
De-recognition of operating lease liability on lease assignment / termination	$ 4,457	$ 0	$ 68,064

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Operating Leases
2024	$ 22,841
2025	16,891
2026	14,184
2027	12,675
2028	12,008
Thereafter	11,819
Total lease payments	90,418
Less imputed interest	(12,174)
Present value of lease liabilities	78,244
Finance Leases
2024	823
2025	823
2026	823
2027	769
2028	610
Thereafter	4,382
Total lease payments	8,230
Less imputed interest	(2,763)
Present value of lease liabilities	$ 5,467

Commitment and Contingencies (D

Commitment and Contingencies (Details) $ in Millions

1 Months Ended

Feb. 24, 2023

Jan. 03, 2023

Jul. 21, 2022

Jun. 22, 2022 litigationCase

May 13, 2021 patent

Mar. 17, 2021 litigationCase

Jun. 23, 2020 litigationCase

Jun. 30, 2023 patent

Mar. 31, 2023

Feb. 28, 2023 patent

Jul. 31, 2021 patent

Jun. 30, 2021

Dec. 31, 2023 USD ($)

Nov. 18, 2022 patent

Long-Term Purchase Commitment [Line Items]

Noncancelable purchase commitments due within one year | $

$ 56.6

Teamsters And GEHA Lawsuits

Long-Term Purchase Commitment [Line Items]

Class action lawsuits filed | litigationCase

2

Farrell Lawsuit And Levy Lawsuit

Long-Term Purchase Commitment [Line Items]

Class action lawsuits filed | litigationCase

2

GW Litigation

Long-Term Purchase Commitment [Line Items]

Class action lawsuits filed | litigationCase

10

Avadel Pharmaceuticals plc Lawsuit

Long-Term Purchase Commitment [Line Items]

Infringed patents suit, number of patents

5

Infringed patents suit, other party counterclaim, number of patents requested to be delisted

1

Number of days provided to delist patent

14 days

Number o days requested for FDA to take action

14 days

Lupin Lawsuit

Long-Term Purchase Commitment [Line Items]

Class action lawsuits filed | litigationCase

2

Infringed patents suit, number of patents

10

FDA stay of approval period

30 months

Lupin Lawsuit | Xywav

Long-Term Purchase Commitment [Line Items]

FDA recognition of orphan drug exclusivity, period

7 years

Teva Lawsuit

Long-Term Purchase Commitment [Line Items]

Infringed patents suit, number of patents

13

Infringed patents suit, number of patents

13

FDA stay of approval period

30 months

Alkem Patent Litigation

Long-Term Purchase Commitment [Line Items]

Infringed patents suit, number of patents

6

FDA stay of approval period

30 months

Epidiolex Patent Litigation

Long-Term Purchase Commitment [Line Items]

FDA stay of approval period

30 months

Shareholders' Equity - Narrativ

Shareholders' Equity - Narrative (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares
Stockholders' Equity Note [Line Items]
Cash dividends declared or paid	$ 0	$ 0
Maximum allowable dividend and restricted payments	30,000,000
Maximum allowable restricted payments	$ 100,000,000
Maximum secured leverage ratio, for restricted payments to be allowed	3
Minimum total leverage ratio, allowable restricted payments	2
Ordinary Shares | November 2016 Share Repurchase Program
Stockholders' Equity Note [Line Items]
Total amount authorized for repurchase of shares under share repurchase program	$ 1,500,000,000
Stock repurchased	$ 269,800,000	$ 100,000
Stock repurchased (in shares) | shares	2,100,000	338
Average price of shares repurchased (in dollars per share) | $ / shares	$ 126.65	$ 160.70
Remaining amount authorized for repurchase of shares	$ 161,400,000

Shareholders' Equity - Authoriz

Shareholders' Equity - Authorized But Unissued Ordinary Shares (Details) - shares shares in Thousands	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	29,052	30,220
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	22,855	23,689
2007 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	3,913	4,069
GW Incentive Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	1,570	1,707
Amended and Restated 2007 Non-Employee Directors Stock Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized but unissued ordinary shares reserved (in shares)	714	755

Comprehensive Income (Loss) (De

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ 3,085,734	$ 3,965,191	$ 3,659,745
Other comprehensive income before reclassifications	286,785
Amounts reclassified from accumulated other comprehensive income (loss)	(3,423)
Other comprehensive income, net	283,362	(725,149)	(266,008)
Ending balance	3,736,997	3,085,734	3,965,191
Total Accumulated Other Comprehensive Loss
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(1,125,509)	(400,360)	(134,352)
Other comprehensive income, net	283,362	(725,149)	(266,008)
Ending balance	(842,147)	(1,125,509)	$ (400,360)
Net Unrealized Gain From Hedging Activities
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	0
Other comprehensive income before reclassifications	3,658
Amounts reclassified from accumulated other comprehensive income (loss)	(3,423)
Other comprehensive income, net	235
Ending balance	235	0
Foreign Currency Translation Adjustments
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(1,125,509)
Other comprehensive income before reclassifications	283,127
Amounts reclassified from accumulated other comprehensive income (loss)	0
Other comprehensive income, net	283,127
Ending balance	$ (842,382)	$ (1,125,509)

Net Income (Loss) per Ordinar_3

Net Income (Loss) per Ordinary Share - Basic and Diluted Net Income (Loss) per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net income (loss)	$ 414,832	$ (224,060)	$ (329,668)
Effect of interest on assumed conversions of Exchangeable Senior Notes, net of tax	24,876	0	0
Net income (loss) for dilutive net income (loss) per ordinary share	$ 439,708	$ (224,060)	$ (329,668)
Denominator:
Weighted-average ordinary shares used in per share calculations - basic (in shares)	63,291	62,539	59,694
Dilutive effect of exchangeable senior notes (in shares)	8,016	0	0
Dilutive effect of employee equity incentive and purchase plans (in shares)	759	0	0
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	72,066	62,539	59,694
Net income (loss) per ordinary share:
Basic (in dollars per share)	$ 6.55	$ (3.58)	$ (5.52)
Diluted (in dollars per share)	$ 6.10	$ (3.58)	$ (5.52)

Net Income (Loss) per Ordinar_4

Net Income (Loss) per Ordinary Share - Anti-dilutive Effect (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee equity incentive and purchase plans
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares (in shares)	2,973	2,751	3,927
Exchangeable Senior Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary shares (in shares)	0	9,044	9,725

Segment and Other Information -

Segment and Other Information - Narrative (Details)	12 Months Ended
	Dec. 31, 2023 segment
Segment Reporting [Abstract]
Number of operating business segments	1

Segment and Other Information_2

Segment and Other Information - Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 234,986	$ 301,377
Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	68,201	71,276
United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	80,293	143,870
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	59,440	63,559
Italy
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	20,942	15,768
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 6,110	$ 6,904

Revenues - Summary of Disaggreg

Revenues - Summary of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenues	$ 3,834,204	$ 3,659,374	$ 3,094,238
United States
Disaggregation of Revenue [Line Items]
Total revenues	3,489,977	3,370,379	2,820,242
Europe
Disaggregation of Revenue [Line Items]
Total revenues	269,243	239,638	230,158
All other
Disaggregation of Revenue [Line Items]
Total revenues	74,984	49,357	43,838
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues	3,736,943	3,641,429	3,079,001
Total Neuroscience
Disaggregation of Revenue [Line Items]
Total revenues	2,707,843	2,760,945	2,335,393
Xywav
Disaggregation of Revenue [Line Items]
Total revenues	1,272,977	958,425	535,297
Xyrem
Disaggregation of Revenue [Line Items]
Total revenues	569,730	1,020,453	1,265,830
Epidiolex/Epidyolex
Disaggregation of Revenue [Line Items]
Total revenues	845,468	736,398	463,645
Sativex
Disaggregation of Revenue [Line Items]
Total revenues	19,668	16,825	12,707
Sunosi
Disaggregation of Revenue [Line Items]
Total revenues	0	28,844	57,914
Total Oncology
Disaggregation of Revenue [Line Items]
Total revenues	1,015,254	873,841	733,810
Rylaze
Disaggregation of Revenue [Line Items]
Total revenues	394,226	281,659	85,629
Zepzelca
Disaggregation of Revenue [Line Items]
Total revenues	289,533	269,912	246,808
Defitelio/defibrotide
Disaggregation of Revenue [Line Items]
Total revenues	184,000	194,290	197,931
Vyxeos
Disaggregation of Revenue [Line Items]
Total revenues	147,495	127,980	134,060
Erwinaze/Erwinase
Disaggregation of Revenue [Line Items]
Total revenues	0	0	69,382
Other
Disaggregation of Revenue [Line Items]
Total revenues	13,846	6,643	9,798
High-sodium oxybate AG royalty revenue
Disaggregation of Revenue [Line Items]
Total revenues	75,918	0	0
Other royalty and contract revenues
Disaggregation of Revenue [Line Items]
Total revenues	$ 21,343	$ 17,945	$ 15,237

Revenues - Summary of the Perce

Revenues - Summary of the Percentage of Total Revenues from Customers (Details) - Total Revenues - Customer concentration risk	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
ESSDS
Concentration Risk [Line Items]
Concentration risk, percentage	48%	56%	60%
McKesson
Concentration Risk [Line Items]
Concentration risk, percentage	11%	11%	12%

Revenues - Narrative (Details)

Revenues - Narrative (Details)	12 Months Ended
	Dec. 31, 2023
Minimum
Summary Of Deferred Revenue [Line Items]
Payment terms, range	30 days
Maximum
Summary Of Deferred Revenue [Line Items]
Payment terms, range	65 days

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) $ / shares in Units, $ in Millions			1 Months Ended		3 Months Ended	12 Months Ended
	May 05, 2021	Oct. 24, 2011	Jul. 31, 2020 shares	Dec. 31, 2011 period shares	Jun. 30, 2021 $ / shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized tax benefits related to share options exercised | $						$ 1.9	$ 8	$ 9.3
Aggregate intrinsic value of share options exercised | $						$ 6.3	$ 34.8	$ 51.8
Share Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, weighted-average period of recognition (in years)						6 months
Options granted (in shares)						0	0
Unrecognized compensation cost related to unvested stock options | $						$ 1.5
Grant date fair value (in dollars per share) | $ / shares								$ 51.39
Nominal Strike Price Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of share options exercised | $						$ 3.9	$ 8.4	$ 0.2
Grant date fair value (in dollars per share) | $ / shares					$ 170.82
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)						4 years
Weighted-average grant-date fair value, RSUs and PRSUs granted (in dollars per share) | $ / shares						$ 144.65	$ 152.08	$ 168.10
Number of RSUs released (in shares)						1,094,000	910,000	692,000
Shares issued (in shares)						735,000	610,000	465,000
Shares withheld for tax purposes (in shares)						359,000	300,000	227,000
Total fair value of shares vested | $						$ 155.5	$ 138.1	$ 109.2
Unrecognized compensation cost related to unvested RSUs | $						$ 307.7
Unrecognized compensation cost, weighted-average period of recognition (in years)						2 years 4 months 24 days
GW Incentive Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)	2 years
Grants expiration period (in years)	10 years
Shares authorized for issuance (in shares)						1,864,475
GW Incentive Plans, Post Acquisition Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)	4 years
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)				4 years
Shares authorized for issuance (in shares)						34,836,988
2011 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants expiration period (in years)				10 years
2007 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)						7,029,250
ESPP discount rate (as a percent)				15%
ESPP offering period (in months)				24 months
Number of purchase periods within each ESPP offering period | period				4
Number of shares available for issuance (in shares)				175,000
Unrecognized compensation cost, weighted-average period of recognition (in years)						1 year 2 months 12 days
Unrecognized compensation cost related to grants under the ESPP | $						$ 11.3
2007 Directors Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares authorized for issuance under deferred compensation plan (in shares)			500,000
Shares authorized for issuance under deferred compensation plan (in shares)						1,403,938
2007 Directors Award Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)		1 year
2007 Directors Award Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service periods (in years)		3 years
Grants expiration period (in years)		10 years
Initial Grant | 2007 Directors Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		3 years
Annual Automatic Grant | 2007 Directors Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		1 year

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	$ 226,841	$ 221,996	$ 189,006
Income tax benefit from share-based compensation expense	(40,015)	(41,058)	(33,958)
Total share-based compensation expense, net of tax	186,826	180,938	155,048
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	146,942	151,986	135,285
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	64,847	57,522	43,758
Cost of product sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense, pre-tax	$ 15,052	$ 12,488	$ 9,963

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of RSUs and PRSUs Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restricted Stock Units (RSUs)
Number of RSUs and PRSUs [Roll Forward]
Number of RSUs and PRSUs, outstanding, beginning balance (in shares)	3,209
Number of RSUs and PRSUs granted (in shares)	1,768
Number of RSUs and PRSUs released (in shares)	(1,094)	(910)	(692)
Number of RSUs and PRSUs forfeited (in shares)	(320)
Number of RSUs and PRSUs, outstanding, ending balance (in shares)	3,563	3,209
Weighted- Average Grant-Date Fair Value
Weighted-average grant-date fair value, outstanding, beginning balance (in dollars per share)	$ 151.11
Weighted-average grant-date fair value, RSUs and PRSUs granted (in dollars per share)	144.65	$ 152.08	$ 168.10
Weighted-average grant-date fair value, RSUs and PRSUs released (in dollars per share)	148.68
Weighted-average grant-date fair value, RSUs and PRSUs forfeited (in dollars per share)	149.54
Weighted-average grant-date fair value, outstanding, ending balance (in dollars per share)	$ 148.79	$ 151.11
Weighted-average remaining contractual term, outstanding	1 year 3 months 18 days
Aggregate intrinsic value, outstanding	$ 438,224
Performance-Based Restricted Stock Units (PRSUs)
Number of RSUs and PRSUs [Roll Forward]
Number of RSUs and PRSUs, outstanding, beginning balance (in shares)	440
Number of RSUs and PRSUs granted (in shares)	271
Number of RSUs and PRSUs forfeited (in shares)	(47)
Number of RSUs and PRSUs, outstanding, ending balance (in shares)	664	440
Weighted- Average Grant-Date Fair Value
Weighted-average grant-date fair value, outstanding, beginning balance (in dollars per share)	$ 183.68
Weighted-average grant-date fair value, RSUs and PRSUs granted (in dollars per share)	156.91	$ 178.78	$ 190.81
Weighted-average grant-date fair value, RSUs and PRSUs forfeited (in dollars per share)	176.06
Weighted-average grant-date fair value, outstanding, ending balance (in dollars per share)	$ 173.30	$ 183.68
Weighted-average remaining contractual term, outstanding	1 year 6 months
Aggregate intrinsic value, outstanding	$ 81,729

Share-Based Compensation - Perf

Share-Based Compensation - Performance-based RSU's Narrative (Details) - Performance-Based Restricted Stock Units (PRSUs) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to grants under the PRSUs	$ 24.6
Unrecognized compensation cost, weighted-average period of recognition (in years)	1 year 6 months
Weighted-average grant-date fair value, RSUs and PRSUs granted (in dollars per share)	$ 156.91	$ 178.78	$ 190.81
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Achievement target, percentage of awards granted	0%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Achievement target, percentage of awards granted	200%

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model and Resulting Weighted-Average Grant Date Fair Value of Share Options Granted (Details) - Share Options	12 Months Ended
	Dec. 31, 2021 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value (in dollars per share)	$ 51.39
Volatility (as a percent)	37%
Expected term (in years)	4 years 6 months
Range of risk-free rates, minimum (as a percent)	0.40%
Range of risk-free rates, maximum (as a percent)	0.80%
Expected dividend yield (as a percent)	0%

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of Share Option Plans Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Shares Subject to Outstanding Options
Outstanding, beginning balance (in shares) | shares	3,189
Options exercised (in shares) | shares	(251)
Options forfeited (in shares) | shares	(16)
Options expired (in shares) | shares	(206)
Outstanding, ending balance (in shares) | shares	2,716
Vested and expected to vest (in shares) | shares	2,715
Exercisable, balance (in shares) | shares	2,669
Weighted- Average Exercise Price
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 140.64
Options exercised (in dollars per share) | $ / shares	120.29
Options forfeited (in dollars per share) | $ / shares	133.93
Options expired (in dollars per share) | $ / shares	153.92
Outstanding, ending balance (in dollars per share) | $ / shares	141.55
Vested and expected to vest (in dollars per share) | $ / shares	141.55
Exercisable (in dollars per share) | $ / shares	$ 141.69
Weighted- Average Remaining Contractual Term (Years)
Weighted-average remaining contractual term, outstanding (in years)	4 years 1 month 6 days
Weighted-average remaining contractual term, vested and expected to vest, exercisable (in years)	4 years 1 month 6 days
Weighted-average remaining contractual term, exercisable (in years)	4 years 1 month 6 days
Aggregate Intrinsic Value
Aggregate intrinsic value, outstanding | $	$ 3,900
Aggregate intrinsic value, vested and expected to vest | $	3,896
Aggregate intrinsic value, exercisable | $	$ 3,669
Nominal Strike Price Options
Shares Subject to Outstanding Options
Outstanding, beginning balance (in shares) | shares	56
Options exercised (in shares) | shares	(29)
Outstanding, ending balance (in shares) | shares	27
Vested and expected to vest (in shares) | shares	27
Exercisable, balance (in shares) | shares	27
Weighted- Average Exercise Price
Outstanding, beginning balance (in dollars per share) | $ / shares	$ 0.02
Options exercised (in dollars per share) | $ / shares	0.02
Outstanding, ending balance (in dollars per share) | $ / shares	0.02
Vested and expected to vest (in dollars per share) | $ / shares	0.02
Exercisable (in dollars per share) | $ / shares	$ 0.02
Weighted- Average Remaining Contractual Term (Years)
Weighted-average remaining contractual term, outstanding (in years)	6 years 4 months 24 days
Weighted-average remaining contractual term, vested and expected to vest, exercisable (in years)	6 years 4 months 24 days
Weighted-average remaining contractual term, exercisable (in years)	6 years 4 months 24 days
Aggregate Intrinsic Value
Aggregate intrinsic value, outstanding | $	$ 3,357
Aggregate intrinsic value, vested and expected to vest | $	3,357
Aggregate intrinsic value, exercisable | $	$ 3,357

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
United States
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	$ 13.4	$ 10.6	$ 9.1
Outside United States
Defined Contribution Plan Disclosure [Line Items]
Expenses related to defined contribution plans	$ 14	$ 14.6	$ 11.4

Income Taxes - Components of In

Income Taxes - Components of Income Before Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Taxes - Components of Income Before Income Tax Provision (Benefit) [Line Items]
Ireland	$ 449,214	$ (50,311)	$ 97,557
Other	497,867	416,672	249,711
Income (loss) before income tax expense (benefit) and equity in loss of investees	297,929	(372,784)	(112,838)
United Kingdom
Income Taxes - Components of Income Before Income Tax Provision (Benefit) [Line Items]
United kingdom and united states	(643,096)	(963,598)	(681,291)
United States
Income Taxes - Components of Income Before Income Tax Provision (Benefit) [Line Items]
United kingdom and united states	$ (6,056)	$ 224,453	$ 221,185

Income Taxes - Details of Incom

Income Taxes - Details of Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current
Ireland	$ 77,343	$ 61,550	$ 25,770
Other	34,433	32,779	33,222
Total current tax expense	140,305	133,606	146,918
Deferred, exclusive of other components below
Ireland	(10,919)	(62,011)	(5,388)
Other	(8,990)	(11,144)	(28,604)
Total deferred, exclusive of other components	(259,661)	(275,460)	(192,057)
Deferred, change in tax rates
Other	0	(2)	5
Total deferred, change in tax rates	(556)	(16,791)	261,255
Total deferred tax expense (benefit)	(260,217)	(292,251)	69,198
Total income tax expense (benefit)	(119,912)	(158,645)	216,116
United Kingdom
Current
United kingdom and united states	7,726	1,454	(924)
Deferred, exclusive of other components below
United kingdom and united states	(150,506)	(193,219)	(111,534)
Deferred, change in tax rates
United kingdom and united states	268	(16,990)	259,873
United States
Current
United kingdom and united states	20,803	37,823	88,850
Deferred, exclusive of other components below
United kingdom and united states	(89,246)	(9,086)	(46,531)
Deferred, change in tax rates
United kingdom and united states	$ (824)	$ 201	$ 1,377

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Income tax expense (benefit)	$ (119,912)	$ (158,645)	$ 216,116
Increase in valuation allowance	77,600	80,500	76,900
Deferred tax assets, valuation allowance	312,340	234,732
Cumulated unremitted earnings of overseas subsidiaries	1,600,000
Additional expected tax expense if foreign earnings repatriated	79,800
Unrecognized tax benefits, accrued interest	8,400	5,800
Unrecognized tax benefits that would impact the effective tax rate	77,100	91,700
Decrease in unrecognized tax benefits is reasonably possible	26,500
GW Pharmaceuticals plc
Operating Loss Carryforwards [Line Items]
Income tax expense (benefit)			259,900
U.S. Federal
Operating Loss Carryforwards [Line Items]
NOL carryforwards	15,200
Tax credit carryforwards	47,200
U.S. State
Operating Loss Carryforwards [Line Items]
NOL carryforwards	13,500
Tax credit carryforwards	6,400
Foreign Tax Authorities
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	89,000
Foreign Tax Authorities | Luxembourg Inland Revenue
Operating Loss Carryforwards [Line Items]
Proposed additional tax including interest and penalties	24,700
Foreign Tax Authorities | United Kingdom
Operating Loss Carryforwards [Line Items]
NOL carryforwards	1,017,500
Foreign Tax Authorities | Malta
Operating Loss Carryforwards [Line Items]
NOL carryforwards	605,800
Ireland | Ireland
Operating Loss Carryforwards [Line Items]
NOL carryforwards	295,500
Valuation Allowance, Operating Loss Carryforwards
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance	$ 76,200	$ 95,100	$ 81,300

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Effective Income Tax Rate Reconciliation [Abstract]
Income tax expense (benefit) at the statutory income tax rate	$ 37,241	$ (46,598)	$ (14,105)
Deduction on subsidiary equity	(153,655)	(158,488)	(116,438)
Change in valuation allowance	75,081	95,051	81,280
Research and other tax credits	(49,900)	(27,976)	(31,069)
Foreign derived intangible income benefit	(42,400)	(29,541)	(3,416)
Non-deductible facility expense	16,618	8,093	0
Non-deductible financing costs	15,705	4,504	14,418
Non-deductible compensation	14,092	13,505	19,914
Patent box incentive benefit	(13,862)	(6,203)	0
Change in unrecognized tax benefits	(12,612)	5,029	(6,436)
Foreign income tax rate differential	(7,763)	5,863	(4,343)
Change in estimates	(5,472)	(14,065)	(2,653)
Tax deficiencies/(excess tax benefits) from share-based compensation	3,959	(1,690)	(5,555)
Change in tax rate	(605)	(16,790)	261,663
Non-deductible royalty expense	0	6,274	0
Non-deductible acquisition-related costs	0	0	20,929
Other	3,661	4,387	1,927
Total income tax expense (benefit)	$ (119,912)	$ (158,645)	$ 216,116

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Operating loss carryforwards	$ 296,490	$ 263,235
Intangible assets	238,062	236,462
Deduction on subsidiary equity carryforwards	212,015	157,367
Capitalized research and development	201,186	88,009
Tax credit carryforwards	142,854	189,792
Accrued liabilities	128,948	109,257
Share-based compensation	48,403	42,795
Indirect effects of unrecognized tax benefits	40,811	47,224
Lease liabilities	13,415	14,081
Other	5,925	11,595
Total deferred tax assets	1,328,109	1,159,817
Valuation allowance	(312,340)	(234,732)
Deferred tax assets, net of valuation allowance	1,015,769	925,085
Deferred tax liabilities:
Intangible assets	(1,290,425)	(1,367,146)
Inventories	(81,995)	(110,927)
Operating lease assets	(10,628)	(10,978)
Other	(2,593)	(4,124)
Total deferred tax liabilities	(1,385,641)	(1,493,175)
Net deferred tax liabilities	$ (369,872)	$ (568,090)

Income Taxes - Current and Non-

Income Taxes - Current and Non-current Deferred Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Deferred tax assets	$ 477,834	$ 376,247
Deferred tax liabilities	(847,706)	(944,337)
Net deferred tax liabilities	$ (369,872)	$ (568,090)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits
Balance at the beginning of the year	$ 143,976	$ 137,867	$ 146,557
Increases related to current year tax positions	15,004	25,128	26,675
Increases related to prior year tax positions	224	2,794	211
Decreases related to prior year tax positions	(12,702)	(164)	(182)
Increases recognized through purchase accounting	0	0	5,916
Decreases related to settlements with taxing authorities	0	(223)	(14,744)
Lapse of the applicable statute of limitations	(23,808)	(21,426)	(26,566)
Balance at the end of the year	$ 122,694	$ 143,976	$ 137,867

Schedule II Valuation and Qua_2

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 242	$ 298	$ 50
Additions charged to costs and expenses	0	0	127
Other Additions	0	0	771
Deductions	0	(56)	(650)
Balance at end of period	242	242	298
Allowance for sales discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	2,980	2,126	144
Additions charged to costs and expenses	22,334	20,133	13,196
Other Additions	0	0	1,243
Deductions	(19,352)	(19,279)	(12,457)
Balance at end of period	5,962	2,980	2,126
Allowance for chargebacks
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	14,621	11,389	5,293
Additions charged to costs and expenses	185,886	135,854	91,425
Other Additions	0	0	1,322
Deductions	(185,575)	(132,622)	(86,651)
Balance at end of period	14,932	14,621	11,389
Deferred tax asset valuation allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	234,732	154,255	77,342
Additions charged to costs and expenses	76,670	95,947	82,820
Other Additions	1,368	0	9
Deductions	(430)	(15,470)	(5,916)
Balance at end of period	$ 312,340	$ 234,732	$ 154,255